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BACKGROUND: Acute pancreatitis (AP) is a sterile initiator of systemic 
inflammation that can trigger multiple organ dysfunction syndrome (MODS). In 
the acute phase of AP, the kynurenine pathway of tryptophan metabolism 
plays an important role in the genesis of AP-MODS in experimental animal 
models, but it is unknown whether the pathway is activated in human AP. 
Human data are required to support the rationale for kynurenine 3-
monooxygenase (KMO) inhibition as a treatment for AP-MODS and reinforce 
the translational potential. Additionally, as respiratory dysfunction is frequent 
in severe AP, the role of lung ultrasonography in severity stratification 
deserves investigation. Furthermore, the effect of AP-MODS on long-term 
survival is unknown. 
 
OBJECTIVES: My objectives were to: 1) Define the temporal and quantitative 
relationship of kynurenine metabolites with the onset and severity of AP-
MODS, 2) Investigate the value of lung ultrasonography in the early diagnosis 
of respiratory dysfunction in human AP-MODS, and 3) Examine whether early 
AP-MODS impacts on long-term survival. 
 
METHODS: 1) A prospective, observational, clinical experimental medicine 
study titled “Inflammation, Metabolism, and Organ Failure in Acute 
Pancreatitis” (IMOFAP) was performed. For 90 days, consecutive patients with 
a potential diagnosis of AP were recruited and venous blood was sampled at 
0, 3, 6, 12, 24, 48, 72 and 168 hours post-recruitment. Kynurenine metabolite 
concentrations were measured by liquid chromatography–tandem mass 
spectrometry (LC-MS/MS) and analysed in the context of clinical data, disease 
severity indices, and cytokine profiles. 2) In a nested cohort within IMOFAP, 
41 participants underwent lung ultrasonography to evaluate whether this 
imaging modality can detect respiratory dysfunction in AP. 3) Survival data for 
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a prospectively maintained database of patients with AP was analysed after 
accounting for in-hospital deaths. 
 
RESULTS: 1) During the IMOFAP study, 79 patients were recruited with an 
elevated serum amylase, of which 57 patients met the diagnostic criteria for 
AP; 9 had severe disease. Temporal profiling revealed early tryptophan 
depletion and contemporaneous elevation of plasma concentrations of 3-
hydroxykynurenine, which paralleled systemic inflammation and AP severity. 
2) Lung ultrasonography findings correlated with respiratory dysfunction. 3) 
694 patients were followed up for a median of 8.8 years. AP-MODS conferred 
a deleterious effect on overall survival which persisted after the exclusion of 
inhospital deaths (10.0 years, 95% C.I. = 9.4-10.6 years) compared to AP 
without MODS (11.6 years, 95% C.I. = 11.2-11.9 years; P = 0.001). This effect 
was independent of age. 
 
CONCLUSIONS: In the acute phase of AP, metabolic flux through KMO is 
elevated and proportionate to AP severity. Lung ultrasonography may be a 
useful technique for evaluating AP-MODS. AP-MODS is an independent 
predictor of long-term mortality. Together, this work reinforces the rationale for 





The pancreas is an abdominal organ that is responsible for digestion. If 
the pancreas becomes acutely inflamed after drinking too much alcohol, or 
with an attack of gallstones, this leads to acute pancreatitis (AP). AP can be 
very serious and some people with AP need to be treated in intensive care. 1 
in 5 people with AP who go to intensive care will die during that illness, and 
there is no specific treatment. AP may also have a lasting harmful effect on life 
expectancy for many years after the acute illness. 
Recently, we have been measuring how the breakdown of the amino 
acid tryptophan may contribute to poor organ function in AP, and using 
laboratory experiments to see if medicines that block that metabolism may be 
a treatment for AP. I wanted to do research to see whether the metabolism of 
tryptophan is important during AP in humans. As part of this work, I measured 
tryptophan metabolism in patients who were admitted to hospital with AP, and 
researched life expectancy after AP. 
I discovered that during AP, tryptophan metabolism increased, and 
these changes were more obvious when the disease was more severe. 
Additionally, I discovered that we could detect poor lung function during AP 
using ultrasound. Lastly, I found that in the long term, patients with severe AP 
died earlier than those with mild AP, irrespective of their age. 
In conclusion, tryptophan metabolism is increased in severe AP. 
Furthermore, lung ultrasound scans can help to detect which patients with AP 
will become sicker. When patients’ organs stop working properly because of 
AP, they not only have a serious risk of death during that attack, but also live 
less in the long-term. I hope that my research supports our overall strategy of 
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1.1 OUTLINE OF THESIS 
 
The present thesis addresses previously unknown areas of knowledge 
in human acute pancreatitis (AP). An intensive, high resolution, prospective 
observational clinical study was undertaken to elucidate changes of the 
kynurenine pathway of tryptophan (TRP) metabolism in human AP. The aim 
was to acquire novel data which will inform the design of future trials of 
inhibitors in patients with AP. Next, the use of lung ultrasonography as a novel 
approach to the objective quantification of respiratory dysfunction in patients 
with AP was examined. Lastly, the long-term effects of AP-associated early 
organ dysfunction were examined under the hypothesis that life-expectancy of 
patients that survive an attack of AP with MODS is reduced. 
 
1.2 ACUTE PANCREATITIS 
 
Acute pancreatitis (AP) is defined as an inflammatory disorder of the 
pancreas, usually triggered by the passage of gallstones or excessive alcohol 
consumption (Goldacre and Roberts, 2004; Lankisch et al., 2015; Steinberg 
and Tenner, 1994). It is one of the common causes for emergency hospital 
admission in Scotland, with an incidence of 33.1 per 100000 per year (Mole et 
al., 2016a), and elsewhere (Appelros and Borgstrom, 1999; Halvorsen and 
Ritland, 1996), and as such it constitutes the leading gastrointestinal cause of 
hospital admission in many countries (Lankisch et al., 2015). Furthermore, the 
incidence of AP is rising steadily (Goldacre and Roberts, 2004; Yadav and 
Lowenfels, 2006). The reasons are unclear, but this fact is partly attributable 
to the increasing incidence of obesity, which promotes gallstone formation, and 
of alcohol misuse, although both explanations are speculative (Steinberg and 
Tenner, 1994; Yadav and Lowenfels, 2013). 
AP has a highly variable course with a potential outcome that ranges 
from complete resolution to death (Johnson and Abu-Hilal, 2004; Lerch, 2013). 
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The overall reported mortality rate in the United Kingdom ranges between 
5.0% and 9.1% (Johnson and Abu-Hilal, 2004; McKay et al., 1999; Mofidi et 
al., 2006; Mole et al., 2016a; Toh et al., 2000). 
In up to 82% of patients, AP has a self-limiting course and resolves 
rapidly with simple measures that rarely include anything more than simple 
analgesia and a short period of fluid resuscitation (McKay et al., 2014; Mole et 
al., 2016a). For these patients, identification and treatment of the underlying 
cause is the main goal (McKay and Carter, 2012). However, approximately 
20% of patients with AP will suffer a severe attack (Mitchell et al., 2003), with 
associated mortality rate that can exceed 30% (Lankisch et al., 2015). 
Importantly, up to 60% of all deaths occur during the first 7 days of hospital 
admission, as a result of progressive organ failure (McKay et al., 1999; Mole 
et al., 2009). Survivors who develop persistent extrapancreatic organ 
dysfunction will require critical care support and potentially a prolonged 
hospital stay, with substantial associated costs for the healthcare service 




In the U.K., gallstones are identified in approximately 40% of patients 
who develop AP, whereas the proportion cases linked to alcohol consumption 
varies from approximately 30% in Scotland, to much higher figures in other 
parts of the world (McKay and Carter, 2012). The causes of AP (McKay and 
Carter, 2012; McKay et al., 2014) can be categorised as shown on TABLE 1.1. 
 
1.2.2 CLINICAL FEATURES 
 
AP usually manifests with constant, severe upper abdominal pain of 
sudden onset. The pain is usually severe, and accompanying symptoms 
include nausea, vomiting, and fever or diaphoresis (Banks et al., 2006; Wu and 
Banks, 2013). Physical examination usually reveals upper abdominal 
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tenderness which may be associated with guarding, as well as tachycardia, 
tachypnoea and hypotension, depending on the severity of the attack (Banks 
et al., 2006; McKay et al., 2014). The differential diagnosis is broad and 
includes mesenteric ischaemia, perforated viscus, acute cholecystitis, 
dissecting aortic aneurysm, intestinal obstruction, and myocardial infarction 
(Banks et al., 2006; Wu and Banks, 2013). 
 
Class Specific cause 
Obstructive factors Biliary disease 
Benign pancreatic duct stricture (choledochal cyst, duodenal 
duplication, anomalous pancreaticobiliary junction, pancreas 
divisum) 
Tumours of the ampulla or pancreas 
Infective (parasites, worms) 
Duodenal obstruction (duodenal diverticulum, afferent limb 
obstruction) 
Toxic factors Alcohol 
Viral infections (mumps, coxsackie B, viral hepatitis) 
Drugs (valproic acid, mesalazine, simvastatin, azathioprine, 
corticosteroids) 
Metabolic factors Hyperlipidaemia (Familial hypertriglyceridaemia) 
Hypercalcaemia (Hyperparathyroidism) 
Genetic defects Cystic fibrosis 
Hereditary pancreatitis (cationic trypsinogen gene mutation) 
SPINK1 mutation 
Trauma Blunt trauma 
Iatrogenic causes Endoscopic retrograde cholangiopancreatography (ERCP) 
Inflammatory Autoimmune pancreatitis 
Physiological Type 1 pancreatic sphincter dysfunction 
 




According to the revised Atlanta classification of 2012 (Banks et al., 
2013), the diagnosis of AP requires two of the following three features: 1) 
abdominal pain characteristic for AP, as described on section 1.2.2, 2) serum 
concentration of amylase and/or lipase at least three times greater than the 
upper limit of normal, and 3) characteristic findings of AP on contrast enhanced 
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computerised tomography (CECT), and less commonly on magnetic 
resonance imaging (MRI) or transabdominal ultrasonography (AUSS) 
(Arvanitakis et al., 2004; Banks et al., 2006; Bollen et al., 2007; Uhl et al., 2002; 
UK Working Party on Acute Pancreatitis, 2005). 
In general, both serum amylase and lipase are elevated during the 
course of the disease, although it is usually not necessary to measure both. 
Serum amylase levels rise sharply within the first 24 hours of an attack and 
decline steadily to a normal range over the subsequent few days, with a 
dramatic loss of diagnostic sensitivity over the first 48 hours. Consequently, 
the diagnostic accuracy of serum amylase may be influenced by the time 
interval between the onset of AP and presentation to hospital. In the study of 
Clavien et al, normal amylase activity was reported in 19% of 352 AP attacks 
diagnosed by computerized tomography (CT) or autopsy, and repeating serum 
amylase at 4-6 hours has been suggested as a helpful measure to establish 
the diagnosis in suspected cases (Clavien et al., 1989). Furthermore, the 
magnitude of elevation of serum amylase and lipase does not correlate with 
severity (Winslet et al., 1992). 
Serum lipase is considered marginally more accurate than amylase in 
the diagnosis of AP, and may remain elevated for slightly longer. It remains 
normal in non-pancreatic conditions that may cause an increase in serum 
amylase, such as macroamylasemia, parotitis, and some types of carcinomata 
(Winslet et al., 1992). However, it is not commonly available in many hospital 
laboratories (McKay et al., 2014). 
Where uncertainty exists, as for example in patients with delayed 
presentation and/or a non-diagnostic level of serum amylase, a CT scan can 
confirm the diagnosis of AP (Banks et al., 2006). The use of intravenous 
contrast can help to establish the diagnosis and extent of pancreatic necrosis, 
and may be valuable in identifying the aetiology of AP (Banks et al., 2006). CT 
is also used to identify local complications of AP, with thin section multidetector 
row contrast-enhanced CT (CECT) scan being the gold standard modality 
(Balthazar, 2002; Balthazar and Fisher, 2001; Balthazar et al., 1994). CT 
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findings that support the diagnosis include pancreatic enlargement with diffuse 
oedema, heterogeneity of the pancreatic parenchyma, peripancreatic 
stranding, and peripancreatic fluid collections. 
AUSS should be performed in all patients with AP to investigate for the 
presence of gallstones as the aetiologic factor. In patients where the cause 
remains unidentified, endoscopic ultrasound (EUS) may detect microlithiasis 
or small pancreatic neoplasms. Additionally, EUS has emerged as an 
important tool for guided drainage of peripancreatic collections (McKay and 
Carter, 2012; McKay et al., 2014). The role of magnetic resonance imaging 
(MRI) and magnetic resonance cholangiopancreatography (MRCP) in the 
diagnosis of AP and establishment of severity remains incompletely defined 
(Banks et al., 2006). 
 
1.2.4 ASSESSMENT OF SEVERITY 
 
The development of extrapancreatic organ dysfunction that persists 
beyond 48 hours is central to the definition of severe AP, and is associated 
with increased overall mortality (Johnson, 2015; McKay and Buter, 2003). 
Consequently, early identification of patients at risk of developing persistent 
organ dysfunction is critical, and has been the focus of extensive research over 
the last three decades (Forsmark et al., 2007; Mounzer et al., 2012). The aim 
has been to improve the triage of patients, to ensure prompt and 
comprehensive management in an appropriate critical care environment, to 
obtain timely specialist input and support, and to facilitate the design of clinical 
studies (Banks et al., 2013; McKay and Carter, 2012). Importantly, the majority 
of patients who eventually develop severe AP have evidence of early organ 
dysfunction, which is present upon admission to hospital or develops shortly 
afterwards. As a consequence of this, up to 60% of all AP deaths occur during 
the first 7 days of hospital admission (Buter et al., 2002; Johnson and Abu-
Hilal, 2004; McKay et al., 1999; Mofidi et al., 2006; Mole et al., 2009; Renner 
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et al., 1985). Therefore, the group of patients who suffer from early organ 
dysfunction are at higher risk and merit close observation (McKay et al., 2014). 
To achieve accurate severity stratification, multiple approaches have 
been proposed, such as using laboratory tests, clinical and radiographic 
features, as well as multifactorial scoring systems. The Glasgow Prognostic 
Score (Blamey et al., 1984), the APACHE II score (Wilson et al., 1990) and C-
reactive protein (CRP) (Wilson et al., 1989) have been most widely studied. 
However, none of these have proved sufficiently accurate to influence clinical 
decision-making, particularly in the crucial initial 24-hour period after hospital 
admission (McKay and Carter, 2012). The composite multifactorial scoring 
systems identify established multisystem organ dysfunction more accurately, 
rather than predicting the subsequent development of organ failure, (Buter et 
al., 2002; Chauhan and Forsmark, 2010; Johnson, 2015; McKay et al., 2014). 
They have also been used extensively as methods of stratifying patients within 
clinical studies. Of these scores, APACHE II has been considered as the most 
accurate in prediction of mortality, however it is cumbersome for routine clinical 
use and suffers from its complexity (Chauhan and Forsmark, 2010). The 
mainstay of assessment remains repeated and thorough clinical evaluation 
(Gravante et al., 2009). 
The original Atlanta classification of 1992 (Bradley, 1993) was deemed 
suboptimal as it failed to discriminate with accuracy between patient 
subgroups with different outcomes (Bollen et al., 2008). This realisation led to 
the revised Atlanta classification in 2012 (Banks et al., 2013), according to 
which three levels of severity are defined, based primarily on the presence and 
duration of organ dysfunction: mild, moderately severe, and severe AP (TABLE 
1.2). Organ failure is classified as transient when present for less than 48 
hours, or persistent when present for more than 48 hours. Local complications 
include peripancreatic fluid collections and acute necrotic collections, while 




Mortality in mild AP is very rare, and in moderately severe AP is far less 
common than that of severe AP. Conversely, severe AP patients who develop 
early persistent organ failure are at increased risk of death, with a reported 
mortality rate as great as 36-50% (Banks et al., 2013). Based on a 
retrospective cohort, Choi et al further proposed to examine severe AP 
patients with infected necrosis separately in order to more accurately assess 
clinical outcomes (Choi et al., 2014). 
Additionally, the Determinant Based Classification has been developed, 
with similar insights (Dellinger et al., 2012). Comparison of the performance of 
the two systems has shown few differences (Acevedo-Piedra et al., 2014), with 
the revised Atlanta classification of 2012 being more relevant to the day-to-day 
clinical setting (Yadav, 2014), although the co-existence of two parallel 
classification systems seems conflicting and may limit their widespread 
implementation (Bakker et al., 2014). 
 
Degrees of AP severity 
Mild AP 
No organ failure and no local or systemic complications 
Moderately severe AP 
Organ failure that resolves within 48 hours (transient organ failure), and/or 
Local or systemic complications without persistent organ failure 
Severe AP 
Persistent organ failure (>48 hours) involving a single or multiple organ systems 
 
TABLE 1.2 – Degrees of severity of acute pancreatitis according to the revised Atlanta 
classification of 2012.  
 
In recent years, it has become apparent that the existing composite 
severity scoring systems may have reached their maximal prognostic efficacy. 
Combinations of prognostic rules only provide marginally greater accuracy, 
and are even more cumbersome and therefore of limited clinical applicability. 
As stated by Mounzer et al, our ability to predict AP severity is not expected to 
improve further unless new approaches are developed (Mounzer et al., 2012). 
This realisation has initially led to the development of simpler models of 
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outcome prediction, such as the BISAP score (Papachristou et al., 2010; Singh 
et al., 2009; Wu et al., 2008), with similar prognostic performance (Bollen et 
al., 2012; Cho et al., 2015). Moreover, individual parameters such as CRP, 
blood urea nitrogen, serum creatinine, blood glucose and chest radiographs 
have been highlighted as potential alternatives for the risk stratification and 
outcome prediction of patients with AP (Blum et al., 2001; Muddana et al., 
2009; Talamini et al., 1999; Wu et al., 2011). More recently, novel approaches 
with the use of biomarkers, genetic polymorphisms and mutations, proteomic 
and metabolomic analyses, and new methods of analysis, such as artificial 
neural networks (Mofidi et al., 2007a) have been suggested as potential means 
to develop more accurate models of early prediction (Chauhan and Forsmark, 
2010). 
 




Tryptophan (TRP) (FIGURE 1.1) is an essential amino acid with a 
principal role in protein synthesis. Its effects range widely, and it constitutes a 
critical component of multiple essential metabolic functions. (Richard et al., 
2009). A clear association between TRP catabolism and inflammatory 
reactions has been observed in recent years, in a vast array of conditions. The 
exact roles of TRP and its metabolites in the immune system are as yet not 
fully known, and the biological significance of inflammation-related TRP 
breakdown remains incompletely understood (Moffett and Namboodiri, 2003). 
TRP is primarily produced by bacteria, fungi and plants, which maintain 
TRP flux into the food chain. Animals and humans are unable to synthesize 
TRP from simpler molecules; hence it must be ingested in the form of proteins. 
These are hydrolysed and the resultant TRP – as a constituent amino acid – 
is delivered to the liver for protein synthesis, where it can play a rate-limiting 
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role, possibly because its concentration is the lowest of the 20 amino acids 
(Moffett and Namboodiri, 2003; Richard et al., 2009; Sainio et al., 1996). TRP 
is primarily transported bound to albumin (90%) or in free form (10%), and the 




FIGURE 1.1 –  L-Tryptophan. 
 
As for all amino acids, only the L-isomer is used in protein synthesis, 
and unused TRP can be degraded in the liver through the kynurenine pathway, 
which accounts for approximately 90% of TRP catabolism (Moffett and 
Namboodiri, 2003; Sainio et al., 1996) (FIGURE 1.2). Ultimately, through the 
kynurenine pathway, TRP can act as the sole source for de novo synthesis of 
nicotinamide adenine dinucleotide (NAD+) and NAD phosphate (NADP+) – the 
cellular co-enzymes essential for electron transfer reactions – when dietary 
niacin is insufficient (Kurnasov et al., 2003; Richard et al., 2009; Sainio et al., 
1996). NAD+ synthesis in particular, has long been thought to take place 
exclusively in the liver (Moffett and Namboodiri, 2003). Additionally, TRP can 
also act as a substrate for niacin synthesis (Sainio et al., 1996). 
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The initial and rate-limiting step of the kynurenine pathway during which 
TRP is degraded to N-formylkynurenine is catalysed by three enzymes: 
indoleamine 2,3-dioxygenase (IDO), tryptophan 2,3-dioxygenase (TDO), and 
the recently discovered indoleamine 2,3-dioxygenase-2 enzyme (IDO2) (Ball 
et al., 2007; Ball et al., 2009; Salter and Pogson, 1985; Takikawa et al., 1986). 
TDO initiates TRP catalysis predominantly in the liver, and is induced by TRP 
and general regulators of metabolism, such as corticosteroids and insulin 




FIGURE 1.2 – The kynurenine pathway. 
 
Conversely, IDO – the main extra-hepatic enzyme – and IDO-2 are 
expressed in a variety of cells. IDO is primarily induced by interferon-γ (IFN-γ) 
in response to inflammation, as well as by tumour necrosis factor alpha (TNF-
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α), and other cytokines and lipopolysaccharides (LPS) (Sainio et al., 1996; 
Taylor and Feng, 1991; Werner et al., 1987). IFN-γ stimulates IDO activity 
potently by inducing its gene expression (Dai and Gupta, 1990; Hayaishi and 
Yoshida, 1978; Werner-Felmayer et al., 1989; Yasui et al., 1986). Increased 
IDO activity inhibits T cell function and proliferation (Boasso et al., 2007; 
Fallarino et al., 2006; Munn et al., 1999; Munn et al., 2002), contributes to T 
cell apoptosis (Fallarino et al., 2002), and inhibits nitric oxide (NO) synthase 
(Chiarugi et al., 2003; Samelson-Jones and Yeh, 2006; Sekkai et al., 1997). 
The resultant TRP depletion may be an important factor in the 
suppression of lymphocyte proliferation, since TRP is essential for cell 
replication (Munn et al., 1999). As a consequence, a TRP-deficient state has 
been considered as a predisposing factor to poor clinical outcomes in critical 
illness, by altering host-immunity (Pellegrin et al., 2005). Furthermore, the 
increased production of L-kynurenine and other downstream metabolites, such 
as quinolinic acid (QA) and 3-hydroxykynurenine (3-HK), has been shown to 





The first stable intermediate metabolite of the kynurenine pathway is L-
kynurenine (KYN) (Chen et al., 2010). KYN is derived from N-formylkynurenine 
by the enzymatic activity of arylformamidase. KYN is the substrate for several 
enzymes, and is a key precursor of a number of metabolites, most importantly 
kynurenic acid (KYNA) and QA (Kolodziej et al., 2011). 
KYN metabolism may occur in the liver, kidneys or other tissues where 
the required enzymes are expressed and the substrate can access the 
relevant compartment. Due to the fact that KYN and its downstream 
metabolites are biologically active, its synthesis and metabolism must be 
tightly controlled (Kolodziej et al., 2011; Mehler and Knox, 1950; Oxenkrug, 




3-HK is generated from KYN by the action of the flavin adenine 
dinucleotide (FAD)-dependent kynurenine 3-monooxygenase (KMO). 3-HK 
exhibits significant cellular toxicity primarily through production of endogenous 
free radicals and reactive oxygen species (ROS) which induce apoptotic cell 
death (Eastman and Guilarte, 1990; Grohmann et al., 2003; Okuda et al., 1998; 
Stone et al., 2013; Wang et al., 2014). Furthermore, the quinonimine product 
of 3-HK oxidation is highly reactive with the thiol- and amine- proteins groups 
(Giles et al., 2003). The destructive properties of 3-HK can also partly be 
attributed to its metabolism to 3-hydroxyanthranilic acid (3-HAA), which can 
undergo auto-oxidation and form superoxide anions (Stone and Darlington, 
2002). According to Stone et al, this toxicity is probably produced at an 
intracellular site (Stone et al., 2013).  
Fluctuations in 3-HK or 3-HAA concentrations play a potentially 
significant role in the regulation of tissue oxidative status, by showing pro- or 
anti-oxidant activity, depending on the local oxidative environment (Stone et 
al., 2013). Importantly, it has been demonstrated that 3-HK can inhibit T cell 
proliferation even in micromolar concentrations (Frumento et al., 2002; 
Terness et al., 2002). 
 
1.3.4 KYNURENIC ACID 
 
Kynurenic acid (KYNA) is the product of metabolism of KYN by 
kynurenine aminotransferases I and II. KYNA inhibits LPS-induced TNF-α 
release from human peripheral blood mononuclear cells by activating the 
orphan G protein–coupled receptor GP35 (Wang et al., 2006). It is also an 
agonist of the aryl hydrocarbon receptor, a nuclear protein involved in the 




The resultant elevation of KYNA plasma levels following KMO inhibition 
could be protective or harmful in the context of AP. It may contribute to the 
benefit seen in KMOnull mice with AP and GSK180-treated rats with AP by 
exerting an anti-inflammatory effect on innate immune cells (Mole et al., 
2016b). In high concentrations KYNA is known to possess anti-convulsant and 
neuroprotective properties by potent antagonism at the glycine allosteric site 
of the N-methyl-D-aspartate (NMDA) receptor complex, therefore KMO 
inhibition may carry sedative effects (Foster et al., 1984a; Foster et al., 1984b; 
Mole et al., 2016b; Wang et al., 2006). 
 
1.3.5 QUINOLINIC ACID 
 
QA is another toxic intermediate metabolite along the synthetic route of 
nicotinic acid and NAD+ (Wang et al., 2015). Its harmful effects can be 
attributed to producing mitochondrial dysfunction (Baran et al., 2001; Bordelon 
et al., 1997) or increasing generation of free radicals (Behan et al., 1999; 
Santamaria et al., 2001). Furthermore, it can selectively target immune cells 
undergoing activation, thus suppressing T cell proliferation, an ability shared 
with other metabolites of the pathway (Chen and Guillemin, 2009; Frumento et 
al., 2002). 
 
1.3.6 3-HYDROXYANTHRANILIC ACID 
 
3-hydroxyanthranilic acid (3-HAA) is the product of 3-HK metabolism by 
kynureninase. 3-HAA is a free-radical generator (Goldstein et al., 2000). It can 
act in concert with QA to produce an additive effect in suppressing T cell 
proliferation (Terness et al., 2002). 3-HAA also carries abilities which could 
compromise the biological functions of NO (Stone et al., 2013), as it inhibits 
NO synthase in macrophages (Sekkai et al., 1997), and can be readily 
nitrosylated to oxadiazole compounds, a property shared with 3-HK (Backhaus 
et al., 2008). 
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1.3.7 KYNURENINE 3-MONOOXYGENASE 
 
Kynurenine 3-monooxygenase (KMO) is an outer mitochondrial 
membrane protein with a pivotal  role in kynurenine metabolism (Uemura and 
Hirai, 1998; Zwilling et al., 2011). KMO converts KYN to 3-HK in the presence 
of the co-factor FAD. Under both physiological and pathological conditions, 
KMO possesses a high affinity for its substrate, suggesting that KMO 
metabolizes most of the available KYN to 3-HK (Lowe et al., 2014). It is 
expressed at high levels in human macrophages, and its expression increases 
in inflammatory conditions or following immune stimulation (Connor et al., 
2008; Heyes et al., 1992). 
Our group has shown that both lack of KMO activity in genetically-
altered mice, and the use highly specific KMO inhibitors in rats result in the 
accumulation of KYN, and shift TRP metabolism toward increased KYNA 
production (Mole et al., 2016a), advancing the concept previously noted by 
others (Guidetti et al., 2007; Guidetti et al., 2004; Thevandavakkam, 2011; 
Uemura and Hirai, 1998; Zwilling et al., 2011). 
 
1.4 EXISTING KNOWLEDGE AND CHALLENGES 
 
1.4.1 THE ROLE OF 3-HK IN NEURODEGENERATIVE 
DISEASES 
 
Numerous studies over the last few decades have confirmed the role of 
neuroactive metabolites of the kynurenine pathway in brain physiology and the 
pathogenesis of affective disorders, neuroinflammatory conditions and 
neurodegeneration (Beaumont et al., 2016; Maddison and Giorgini, 2015; 
Schwarcz et al., 2012). 3-HK has been identified as a biomarker in the 
cerebrospinal fluid of patients with Parkinson’s and Alzheimer’s disease, and 
has been found in high levels in various brain regions of patients with 
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Parkinson’s and Huntington’s disease (Lewitt et al., 2013; Ogawa et al., 1992; 
Pearson and Reynolds, 1992). In Alzheimer’s disease, the oxidative stress 
caused by 3-HK and 3-HAA damages neuronal tissue and may potentially 
contribute to neurodegeneration (Gulaj et al., 2010). 
The pharmacological manipulation of the pathway in experimental 
settings has proven beneficial, and constitutes a possible gateway for the 
treatment of such diseases (Maddison and Giorgini, 2015). In specific, KMO is 
considered a promising candidate for inhibition, aiming to achieve a pathway 
shift towards enhanced formation of KYNA, with a concurrent reduction of the 
synthesis of neurotoxic kynurenines (Majláth et al., 2015). Ro 61-8048, a 
widely used KMO inhibitor, demonstrated pronounced neuroprotective and 
antidyskinetic effects in animal models of focal or global ischaemia and L-
dopa-induced dyskinesia (Cozzi et al., 1999; Gregoire et al., 2008; Schwarcz 
et al., 2012). Similarly, in a yeast model of Huntington’s disease, KMO 
inhibition by a structural analog of Ro 61-8048 reduced toxicity (Giorgini et al., 
2005), whereas in a Drosophila model, KMO inhibition diminished 
neurodegeneration (Campesan et al., 2011). In a mouse model of Alzheimer’s 
disease, KMO inhibition with the small molecule JM6 – a pro-drug of Ro 61-
8048 – prevented spatial memory deficits, anxiety-related behaviour and 
synaptic loss, whereas in Huntington’s disease it prevented synaptic loss and 
CNS inflammation, resulting in significantly improved survival (Zwilling et al., 
2011). More recently, the inhibitor CHDI-340246 was shown to restore several 
electrophysiological alterations in mouse models of Huntington’s disease 
(Beaumont et al., 2016). 
 
1.4.2 KYNURENINE METABOLISM IN CRITICAL ILLNESS 
 
The hypothesis that TRP and its downstream metabolites along the 
kynurenine pathway are implicated in the pathophysiology of systemic 
inflammation and critical illness irrespective of aetiology is supported by the 
findings of several studies. The studies of Pellegrin et al and Logters et al 
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discovered a marked depression of plasma TRP in major trauma patients 
(Logters et al., 2009; Pellegrin et al., 2005). KYN and KYN/TRP ratio levels 
were significantly increased in the blood of major trauma patients who later 
developed sepsis and organ failure (Logters et al., 2009; Ploder et al., 2010). 
Furthermore, TRP depletion and/or elevated concentrations of kynurenine 
metabolites have been detected in patients following cardiac bypass surgery. 
(Forrest et al., 2011). 
Implications in cardiovascular disease are also evident. Elevated 
KYN/TRP ratio was found in the blood (Wirleitner et al., 2003) and urine 
(Pedersen et al., 2013) of patients suffering from coronary artery disease and, 
in the latter study, this was found to be a strong predictor of major coronary 
events, acute myocardial infraction and mortality. Results from a Finnish 
prospective multicentre study showed that early activation of the kynurenine 
pathway predicts early death and poor long-term outcome in patients 
resuscitated from out-of-hospital cardiac arrest (Ristagno et al., 2014). 
In recent years, TRP metabolism via the kynurenine pathway has also 
been the focus of research in human sepsis. In this context, IDO-mediated 
TRP catabolism has been associated with dysregulated immune responses 
and impaired microvascular reactivity (Darcy et al., 2011). Increased levels of 
plasma KYN and KYN/TRP ratio were associated with severe sepsis, and an 
increased activity of IDO was associated with higher mortality rates (Girgin et 
al., 2011; Tattevin et al., 2010). Excessive degradation of TRP was proposed 
as a potential risk factor for critically ill sepsis patients, with plasma 
concentrations of QA and QA/TRP ratio showing the best predictive value in 
the study of Zeden et al (Zeden et al., 2010).  
In infected rodents, Wang et al showed that in systemic inflammation, 
TRP metabolism to KYN via the action of IDO – which is primarily expressed 
in vascular endothelial cells (Ball et al., 2002; Hansen et al., 2000) – 
contributes to vascular relaxation and blood pressure regulation (Wang et al., 
2010). More recently TRP metabolism to KYN was confirmed as an important 
contributor to the regulation of vascular tone in human septic shock, as IDO 
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activity was found to change in parallel to inotrope requirements in septic shock 
patients (Changsirivathanathamrong et al., 2011). In addition, the lack of 
reduction of KYNA was presented as a potential predictor of fatal outcomes in 
septic shock patients with acute kidney injury (AKI), managed with continuous 
veno-venous haemofiltration (Dabrowski et al., 2014). IDO activity was found 
to be markedly increased in bacteraemic patients and has been established 
as an independent predictor of severe disease and mortality (Huttunen et al., 
2010). In progressive HIV infection, IDO-dependent TRP catabolism was 
proposed as a potentially important link between immune activation and the 
observed gradual decline of immune function, and 3-HAA has been shown to 
invert the ratio of CD4+ T helper17 (Th17) and T regulatory (Treg) cells (Favre 
et al., 2010). 
From a slightly different perspective, plasma TRP has been identified 
as an independent risk factor for delirium in critically ill patients 
(Pandharipande et al., 2009a). The association of the kynurenine pathway with 
delirium was more recently supported by the findings of the prospective cohort 
study of Adams Wilson et al, who showed that increased baseline plasma KYN 
concentrations and KYN/TRP ratios were independently associated with acute 
brain dysfunction and fewer days free from delirium and coma in mechanically 
ventilated ITU patients (Adams Wilson et al., 2012). 
In an inflammatory context, TRP metabolism through the kynurenine 
pathway is dramatically increased through induction of IDO expression by pro-
inflammatory cytokines, particularly IFN-γ (Murakami and Saito, 2013). IDO 
upregulation increases substrate flux through downstream enzymes, in 
particular KMO, thereby generating biologically active metabolites that 
participate in multiple physiological and pathological processes (Bellac et al., 
2010; Grohmann et al., 2002; Moffett and Namboodiri, 2003; Pellegrin et al., 
2005; Schwarcz, 2004; Wang et al., 2010). Metabolites in the kynurenine 
pathway have been postulated to mediate immunological tolerance dependent 
on signalling via the aryl hydrocarbon receptor, whilst KYN specifically may 
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contribute to Th17 and T-reg lymphocyte differentiation (Mezrich et al., 2010; 
Nguyen et al., 2010). 
The exact pathological mechanisms that drive AP-MODS remain 
incompletely understood, however the kynurenine pathway of TRP metabolism 
is emerging as a potentially important contributory mechanism. To date, the 
only human data of TRP catabolism in AP come from the study of Mole et al, 
who showed a greater increase of plasma KYN concentrations in AP patients 
with higher APACHE II or MODS score (Mole et al., 2008). In rodent models 
of AP, therapeutic blockade of KMO by genetic deletion in mice or 
pharmacological inhibition of KMO in rats reduced 3-HK formation and 
protected against lung and kidney injury in experimental models of AP (Mole 
et al., 2016b). 
KMO inhibition may therefore offer a potential therapeutic strategy for 
reducing the incidence and severity of AP-MODS in humans, and although the 
exact effects of 3-HK activity in human AP are unclear, a translational study of 
KMO inhibition would be highly anticipated to support this novel concept (Mole 
et al., 2016b). As such, it is important to establish the precise timing and 
magnitude of activation of the kynurenine pathway in human patients with AP, 
in relation to the onset of the disease and the development of AP-MODS, the 
inflammatory burden and overall AP severity. 
 
1.4.3 SPECIFIC THERAPIES FOR ACUTE PANCREATITIS 
 
Effective specific therapies for AP and AP-associated organ dysfunction 
do not yet exist, with only few interventions offering benefit to patients. Despite 
several clinical trials, there is no licenced drug therapy available, and no 
treatment exists to prevent progression of AP to moderately severe and severe 
disease (Afghani et al., 2015). Management relies almost entirely on general 
supportive measures, and current optimal management may include fluid 
resuscitation, analgesia, nutritional support, prompt identification of severe 
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disease, support of organ function, and management of local and/or systemic 
complications (Wu and Banks, 2013). 
The mechanisms that drive systemic inflammation and organ failure in 
severe AP share characteristics with those encountered in conditions such as 
sepsis, major surgery, trauma, or severe burns, thus research results from 
these conditions may be relevant (Kylanpaa et al., 2012; Wilson et al., 1998). 
Nevertheless, our understanding of AP pathophysiology remains limited, and 
we still lack the necessary knowledge into the mechanisms of inflammation 
and how to manipulate them. The inflammatory pathways involved in the 
genesis and evolution of AP-associated organ dysfunction are complex, 
therefore, it is thought that the development of effective treatments may require 
targeting multiple pathways, either with a versatile agent which will be potent 
against multiple receptors, or by combinations of agents active at different sites 
(Johnson, 2015). Notably, the window of opportunity for anti-inflammatory 
therapy to suppress excessive activation of the inflammatory response is 
thought to be very narrow due to the rapid progress of AP, making matters 
even more challenging (Kylanpaa et al., 2012). 
An additional hurdle in the development of therapies for AP-associated 
organ failure is the relative lack of effective molecules to be tested in clinical 
trials. Several drugs tested in previous randomized controlled trials (RCT) 
failed to show a significant benefit (Afghani et al., 2015), including glucagon 
(Debas et al., 1980; Durr et al., 1978), gabexate mesilate (Buchler et al., 1993; 
Harada et al., 1991; Pezzilli and Miglioli, 2001; Valderrama et al., 1992; Yang 
et al., 1987), octreotide (Uhl et al., 1999; Wang et al., 2013), lexipafant 
(Johnson et al., 2001; Kingsnorth et al., 1995; McKay et al., 1997), and 
protease inhibitors (Piascik et al., 2010). Other agents recently reported to be 
effective in experimental AP models, have not been translated to the bedside 
due to the aforementioned inherent difficulties of clinical trials of investigational 




1.4.4 ACUTE CLINICAL RESEARCH IN ACUTE PANCREATITIS  
 
The design of acute clinical research studies in AP is associated with 
challenges which relate to the rapid evolution of the disease. It is established 
that the majority of patients who eventually develop severe AP have evidence 
of early organ dysfunction upon presentation (McKay et al., 2014), a fact which 
necessitates rapid enrolment of participants in trials and clinical studies. In the 
multicentre study on lexipafant by Johnson et al (Johnson et al., 2001), over 
40% of patients recruited within 72 hours had organ failure at the time of 
enrolment, and only a further 7% developed new organ failure during the first 
week, offering a valuable lesson in support of early recruitment (Johnson, 
2015). Additionally, a paucity of early time-series data in human AP exists. 
It would therefore be reasonable to focus enrolment of AP patients as 
early as their presentation to the Emergency Department (ED), or soon 
thereafter. This resource-intensive recruitment goal comes in addition to other 
well-known existing challenges encountered in single- and multi-center clinical 
research, as proven by acute research studies performed in different fields. 
These include difficulties pertaining to the timing of patient presentation, ED 
crowding, cooperation between clinical and research teams, patient 
acceptance, the method/strategy of obtaining consent, as well as the 
availability of infrastructure for early identification of participants, and ad-hoc 
intervention or sample and data collection, amongst others (Cofield et al., 
2010; Johnson et al., 2016; Kendrick et al., 2007). 
 
1.4.5 LUNG ULTRASONOGRAPY IN RESPIRATORY 
DYSFUNCTION 
 
The respiratory system is the most frequent extra-pancreatic organ 
system to be affected in AP (Johnson and Abu-Hilal, 2004; Mole et al., 2009; 
Renner et al., 1985). Respiratory dysfunction often precedes renal, 
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cardiovascular and hepatic dysfunction and constitutes a major determinant of 
mortality in severe AP (Bhatia et al., 2000; Buter et al., 2002; Johnson and 
Abu-Hilal, 2004). Several hypotheses have been explored and several 
inflammatory mediators and signalling pathways have been implicated in the 
pathophysiology of AP-associated respiratory dysfunction, however the exact 
mechanisms remain incompletely understood (Chooklin, 2009; Shields et al., 
2002; Zhou et al., 2010). 
The sequelae of AP-associated respiratory dysfunction range from 
subclinical hypoxaemia to severe Acute Respiratory Distress Syndrome 
(ARDS) (Imrie et al., 1978; Johnson and Abu-Hilal, 2004; Pastor et al., 2003; 
Ranson et al., 1974b; Zhou et al., 2010). Radiologically evident complications 
such as atelectasis, pleural effusions, pulmonary infiltrates and/or oedema 
may frequently be present (Basran et al., 1987; Raghu et al., 2007). Notably, 
hypoxaemia has been described as an early indicator of pathological changes 
in the pulmonary parenchyma and may precede radiological findings 
(Polyzogopoulou et al., 2004). Consequently, a timely and accurate detection 
of evolving respiratory dysfunction may aid in the identification of patients at 
risk and may expedite the implementation of appropriate management. 
Pulmonary conditions with diffuse involvement of the interstitium and 
impairment of the alveolo-capillary exchange capacity can be classified under 
the term Alveolar-Interstitial Syndrome (AIS) and are common in the critically 
ill (Stefanidis et al., 2012). This syndrome includes ARDS, acute pulmonary 
oedema, interstitial pneumonia, exacerbation of chronic interstitial lung 
disease, and miscellaneous other conditions (Lichtenstein et al., 1997; Pastor 
et al., 2003; Soldati et al., 2009; Volpicelli et al., 2006). ARDS in specific is 
defined as a type of acute diffuse inflammatory lung injury, characterised by 
increased permeability of the alveolo-capillary membrane with oedema, loss 
of aerated lung tissue, increased work of breathing and impaired gas exchange 
(Ferguson et al., 2012; Zompatori et al., 2014). 
There has been an increasing interest in the application of lung 
ultrasonography (LUSS) in critical care, following the rapid improvement of its 
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diagnostic potential in recent years (Soldati et al., 2009). LUSS has been 
proposed as a useful non-invasive modality for diagnosing AIS in the critically 
ill, based on the detection and quantification of comet-tail artefacts, generated 
by the reverberation of the ultrasound beam (Lichtenstein et al., 1997; 
Stefanidis et al., 2012; Volpicelli et al., 2006). These are described as vertical 
artefacts fanning out from the lung-wall interface and spreading up to the edge 
of the screen, resulting from thickened interlobular septa and extravascular 
lung fluid (Lichtenstein et al., 1997). Several studies confirmed the value of 
LUSS in the diagnosis of AIS (Bouhemad et al., 2007; Lichtenstein et al., 1997; 
Stefanidis et al., 2012; Via et al., 2012; Volpicelli et al., 2006), and its high 
sensitivity and specificity (Lichtenstein et al., 2004; Lichtenstein et al., 1997; 
Stefanidis et al., 2012). 
LUSS is a fast, economic, portable, radiation-free, highly reproducible 
modality with a short learning curve (Gardelli et al., 2012; Zompatori et al., 
2014), and has advantages over other imaging modalities; bedside X-rays 
frequently pose diagnostic challenges (Bouhemad et al., 2007; Lichtenstein et 
al., 1997), whereas CT can be time-consuming and hazardous for critically ill 
patients (Beckmann et al., 2004; Stefanidis et al., 2012), and is associated with 
radiation exposure (Kalra et al., 2004). 
The revised Atlanta classification of 2012 – similar to previous 
classification systems (Harrison et al., 2007; Imrie et al., 1978; Knaus et al., 
1985; Ranson et al., 1974a) – use the long established PaO2/FiO2 ratio as a 
measure of respiratory dysfunction, which although undoubtedly invaluable, 
constitutes a relatively non-specific prognostic marker, a fact already noted by 
Ranson et al four decades ago (Ranson et al., 1973). The introduction of LUSS 
as a method supplementary to PaO2/FiO2 would aim to increase prognostic 
efficiency in AP. The hope is that it may potentially provide a valid and accurate 
measure of respiratory dysfunction and severity early in the course of the 
disease, by differentiating between established pathological pulmonary 
changes and transient physiological impairment. If validated, this non-invasive, 
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easily repeatable bedside method would allow for a more timely patient 
stratification in comparison to and/or complementary to existing scores. 
 
1.4.6 LONG-TERM SURVIVAL FOLLOWING ACUTE 
PANCREATITIS 
 
It is recognized that many survivors of critical illness have significantly 
higher long-term mortality compared to the general population. In the literature 
review of Brinkman et al which included 24 studies with more than 48 000 
Intensive Therapy Unit (ITU) patients discharged alive between 2007 and 
2011, the median mortality rate 1 year after ITU admission ranged between 
16% and 44% (Brinkman et al., 2013). More recently, organ failure was 
amongst the important determinants of 1-year outcome in ITU survivors in the 
study of Ranzani et al, in which 1-year mortality was shown to be as high as 
27% (Ranzani et al., 2015). Timmers et al achieved longer follow-up and 
demonstrated a mortality rate of 51% 11 years following discharge from 
surgical ITU (Timmers et al., 2011). 
Lone and Walsh established that a higher burden of cardiovascular, 
respiratory and hepatic organ system failure during critical illness is strongly 
associated with higher 5-year mortality, and that this association remains 
strong even in patients who are alive 1 year after their episode of critical illness, 
suggesting an important residual effect of acute illness on long-term health and 
life-expectancy (Lone and Walsh, 2012).  
Similarly, deleterious long-term outcomes have been documented 
following acute renal failure in several studies. Gallagher et al reported that the 
long-term mortality for patients that survived to 90 days following acute kidney 
injury requiring acute renal replacement therapy, was 31.9% in the 3.5 years 
of follow-up (Gallagher et al., 2014). Van Berendoncks et al stated that 
mortality during the 1st and 2nd year following discharge in a similar cohort was 
23.0% and 7.6%, which was not related to disease severity or exact treatment 
modality (Van Berendoncks et al., 2010). 
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Although it is increasingly appreciated that long-term outcomes should 
be investigated following an episode of critical illness (Angus et al., 2003), the 
available data on the long-term survival of patients following an episode of AP 
are sparse. Few contemporary studies that have investigated long-term 
survival and the relevant prognostic factors in AP exist, and have for the most 
part examined morbidity outcomes, for example progression to chronic 
pancreatitis, or have focused upon a severe AP subgroup (Lankisch et al., 
2009; Nøjgaard, 2010). Those that do report on survival suggest that hospital 
survivors after severe AP may exhibit reduced life expectancy (Halonen et al., 
2003). After excluding inpatient mortality, death rates have been reported to 
be in the order of one death for every 4 to 8 AP patients , over 5 to 8 years 
(Halonen et al., 2003; Lankisch et al., 1996). Late deaths seem to be most 
commonly attributed to cardiovascular disease or malignancy (Lankisch et al., 
2009; Nøjgaard, 2010), but the factors that reduce long-term survival are likely 




The following hypotheses have been investigated in the respective 
chapters of the present thesis: 
• Hypothesis 1: Peripheral plasma concentrations of kynurenine 
pathway metabolites are altered in AP in humans. 
• Hypothesis 2: Transthoracic lung ultrasonography can detect 
respiratory dysfunction in AP-MODS. 
• Hypothesis 3: AP-MODS confers a long-term survival disadvantage 













2.1 SUMMARY OF CHAPTER 
 
Therapeutic inhibition of KMO, a key enzyme in the kynurenine pathway 
of TRP metabolism, protects against MODS in experimental AP . In order to 
inform clinical trial design and assist the translation of KMO inhibitors into 
clinical practice, I undertook the “Inflammation, Metabolism, and Organ Failure 
in Acute Pancreatitis” (IMOFAP) study to define the activation state of the 
kynurenine pathway in relation to AP and AP-MODS in humans. This study 
comprises the major part of the thesis. 
IMOFAP was a prospective, high-resolution, observational clinical study 
of all persons presenting to hospital with a potential diagnosis of AP at any 
time of day or night for 90 days. Clinical data and physiological measurements 
were recorded and peripheral venous blood was sampled at 0, 3, 6, 12, 24, 
48, 72 and 168 hours post-recruitment. KYN metabolite concentrations were 
measured and analysed in the context of clinical disease severity indices, 
cytokine profiles and CRP concentrations. 
Seventy-nine individuals were recruited (median age: 59.6 years; 47 
males, 59.5%). Fifty-seven met the revised Atlanta definition of AP, and of 
those 25 suffered from mild, 23 from moderate, and 9 from severe AP. Median 
time to recruitment was 5.6 hours (95% C.I.: 4.1-6.7 hours). Plasma 3-HK 
concentrations correlated with contemporaneous APACHE II scores (R2 = 
0.273; Spearman rho = 0.581; P < 0.001) and CRP (R2 = 0.132; Spearman rho 
= 0.455, P < 0.001). Temporal profiling showed early TRP depletion and 
contemporaneous 3-HK elevation. The magnitude of exposure to elevated 3-
HK paralleled AP severity. 
In conclusion, metabolic flux through KMO in human AP, and in 
particular 3-HK plasma concentrations, parallel systemic inflammation, MODS 
and overall disease severity. These findings reinforce the rationale for 
investigating early phase KMO inhibition as a therapeutic strategy to protect 





The University of Edinburgh (UoE) is presently involved in a 
collaboration with GSK aiming to develop novel inhibitors of KMO through the 
DPAc initiative. The aim of the prospective, observational clinical research 
study titled “Inflammation, Metabolism, and Organ Failure in Acute 
Pancreatitis” (IMOFAP) was to define the precise temporal and quantitative 
relationship between the kynurenine pathway metabolism and the onset and 
severity of AP-MODS, in order to improve our understanding of the role of KYN 
metabolism in human AP. Ultimately, the IMOFAP study will inform the design 
of future studies aiming to address efficacy of KMO inhibition in AP-MODS 




2.3.1 ETHICAL AND REGULATORY APPROVALS 
 
The IMOFAP study received ethical approval by the Scotland A 
Research Ethics Committee (REC reference number: 13/SS/0136, dated 4th 
September 2013; amended REC REF AM01, dated 27th October 2013) and 
regulatory approval by the NHS Lothian Research & Development committee 
(Lothian R&D Project No: 2013/0098, dated 13th September 2013; SA1, dated 
27th October 2013), as a non-CTIMP study. The study sponsor was the 
Academic and Clinical Central Office for Research and Development 
(ACCORD), a collaboration between UoE and NHS Lothian. Permission to 
access confidential medical records was granted by the NHS Lothian Caldicott 
Guardian. 
Written informed consent was obtained from all participants or their 
legal representatives. Appropriate information sheets were provided to each 
participant or surrogate (APPENDIX). The General Practitioners (GPs) of 
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participants were informed in writing. Prior to commencing the study, a 
summary of the study protocol was registered in the public domain on the UK 
Clinical Trials Gateway (former UK Clinical Research Network – registration 
number: 16116). The study was conducted in accordance with the principles 
of the Declaration of Helsinki (World Medical Association, 2013). 
 
2.3.2 RESEARCH SITES 
 
Recruitment of participants was undertaken in the ED, and the General 
Surgery wards of the Royal Infirmary of Edinburgh (RIE). Patients who had 
originally presented to the ED of St. John’s Hospital – a smaller District General 
Hospital within NHS Lothian serving a West Lothian community – and were 
transferred to the RIE for definitive management in accordance with the 
existing regional protocol, were also considered eligible for recruitment. In 
those circumstances, patients were enrolled and interventions were performed 
following their arrival at the RIE. 
 
2.3.3 INCLUSION CRITERIA 
 
All patients over the age of 16 years presenting to the ED of the RIE 
with a potential or confirmed new diagnosis of AP over the 90-day period 
between the 17th of September, and 16th of December 2013 were identified 
potential participants. For the diagnosis of AP, two of the following three criteria 
were required: 
i. A clinical history of symptoms compatible with AP (i.e. abdominal 
pain, nausea, and/or vomiting); 
ii. Serum amylase concentration greater than the upper limit of the 
reference range (> 100 IU/L). This threshold was decided upon in 
order to capture potential participants with an amylase level below 
the threshold of the revised Atlanta definition for AP, due to late or 
54 
atypical presentation. A serum amylase concentration in excess of 
300 IU/L was required for the diagnosis of ‘true’ AP (tAP). 
iii. Evidence of AP on CT and/or AUSS. 
Furthermore, patients with AP transferred from other centres or existing 
inpatients with a new finding of elevated serum amylase and/or a radiological 
suspicion of AP were considered eligible for recruitment. Adults without the 
capacity to give informed consent were recruited in accordance with the Adults 
with Incapacity (AWI) (Scotland) Act 2000, Part 5 (Scotland, 2000). Informed 
consent was sought at a later stage for those who regained capacity after initial 
recruitment under the AWI act. 
 
2.3.4 EXCLUSION CRITERIA 
 
Patients from the following vulnerable groups were excluded: 
i. Patients under the age of 16 years, and 




The recruitment phase of the study lasted 90 calendar days – from 17th 
September to 16th December 2013 – and was carried out 24 hours per day, 7 
days per week. The Wellcome Trust Clinical Research Facility (WTCRF) 
provided support for recruitment and consent, data collection, sample handling 
and storage, by staffing a 12-hour shift rota, with 30 research nurses, 
supported by two clinical support workers and one clinical technician. All 
participating research nurses and supporting staff attended two pre-
recruitment meetings, led by the author and were given access to preparatory 
study material and to relevant study documents. Debriefing handover meetings 
of the on-call nurses, led by the author, were held between consecutive shifts 
and pending actions were highlighted. The author provided 24/7 on-call 
support whenever necessary. 
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A short time interval between each patient’s presentation to hospital and 
recruitment to IMOFAP was of particular importance to ensure that participant 
capture and acquisition of samples were performed as early as possible in the 
course of AP. This point was quintessential in the design of IMOFAP, which 
was structured to maximize recruitment efficiency, a goal previously identified 
as challenging and resource-intensive in the context of clinical studies 
(Hunninghake et al., 1987). 
To this effect, an automated alert was initiated by the biochemistry 
laboratory of the RIE and was transmitted to the on-call WTCRF research 
nurse on a dedicated study mobile telephone, for any patient with elevated 
serum amylase concentration (serum amylase > 100 IU/L). The dedicated 
study telephone number was also distributed to all ED and surgical team 
members. Upon each alert, the WTCRF nurse would review the clinical history 
of each potential participant via his or her electronic records on InterSystems® 
TrakCare®. If the clinical presentation was compatible with AP, the patient was 
visited and suitability for recruitment was confirmed. A member of the direct 
clinical care team made the initial approach to each potential participant prior 




Upon identification of each potential participant – following a laboratory 
alert and review of the electronic clinical history – the on-call research nurse 
would liaise with a member of the direct clinical care team in order to obtain 
permission from the potential participant to be approached by a member of the 
research team. Each potential participant received a full explanation of the 
nature and purpose of the IMOFAP study, with the opportunity to ask 
questions. In addition, an information sheet and a consent form (APPENDIX) 
were provided. Recruitment was performed and informed consent was 
obtained by the on-call WTCRF nurse or the author. During the recruitment 
process, patients were being informed that they could withdraw from the study 
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at any point without justification and with no consequence to their care. 
Additionally, consent was being obtained to inform each participant’s GP. The 
established procedures for consent agreed by the Lothian Ethics Committee, 
UoE and NHS Lothian have been adhered to at all times. 
Patients willing to participate would sign and date the consent form, 
which would then be countersigned by the WTCRF nurse or the author. The 
signed form was photocopied; one copy was filed in the participant’s case 
notes, and one was handed to the patient (or welfare guardian), while the 
original signed form was filed in a dedicated secure storage in the WTCRF at 
the RIE. The respective direct clinical care team was informed of each patient’s 
participation in IMOFAP. 
AWI were considered for participation in the study in accordance with 
the set of principles outlined in the relevant subsections of Part 5 of the AWI 
(Scotland) Act 2000 (Scotland, 2000). AWI consent was obtained from any 
guardian or welfare attorney with power to consent to participation in research, 
or from the nearest relative where no such guardian or welfare attorney 
existed. 
Every effort was made to take into account prior wishes of the individual 
with incapacity about whom to consult, and to act in accordance with any 
relevant previous statement or wishes, however made, including non-verbal 
forms of communication. Adherence to the principles of the Act was ensured 
by applying the following measures, amongst others: advice was sought from 
the nursing staff caring for the patient regarding evidence or indications of 
unwillingness; each patient’s multidisciplinary records were reviewed and any 
advance directive was noted; the advice of the nursing staff caring for AWI 
about any advance directive were taken into consideration. Critically ill 
individuals who had previously expressed a wish not to participate in research 
were not recruited. 
For AWI, a senior member of the respective clinical care team obtained 
permission from the patient’s guardian/welfare attorney to be approached by 
a member of the research team. The guardian/welfare attorney should 
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themselves have had capacity at the material time and should have been 
prepared to be consulted by a member of the research team about the possible 
involvement of the AWI in the project. An information sheet similar to the 
patient information leaflet for patients with capacity was given to the patient’s 
guardian/welfare attorney and consent was sought (APPENDIX). Information 
and contact details about suitable independent sources of advice were 
provided. The guardian/welfare attorneys were able to advise the research 
team that the AWI would not want to continue participating at any stage of the 
study. In borderline cases, the recruiting member of the research team liaised 
with senior members of the respective direct clinical care team to decide 
whether a patient had capacity. 
For participants with fluctuating capacity, every effort was made to 
establish their general wishes during a period that they had capacity. For 
participants that had provided consent and experienced a sudden or gradual 
decline of their cognitive status, a guardian/welfare attorney was sought and 
was provided with information about the research study and the nature of the 
consent given by the participant. Lastly, for the sub-group of participants who 
were originally recruited without capacity that gradually recovered and 
regained capacity to consent, informed consent was sought (APPENDIX), as 
described above. 
Due to the potentially rapid onset of organ dysfunction in AP and 
especially as the aim of IMOFAP was to elucidate the mechanisms implicated 
in the genesis of AP-MODS, patients were given a maximum of 30 minutes to 
decide whether they would wish to participate. Nevertheless, deviations from 
this principle were allowed at the discretion of the WTCRF research nurse 
and/or the author based on individual patient circumstances. 
 
2.3.7 WITHDRAWAL OF PARTICIPANTS 
 
Participants were withdrawn from the study in the following 
circumstances: 
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i. In cases of withdrawal of informed consent, where capacity 
existed. 
ii. In cases of withdrawal of consent by the patient’s representative 
for AWI. 
In the event of participants deciding to withdraw from the study, an option had 
been given in advance to permit ongoing use of data and samples which had 
already been collected, and/or future recording and usage of routinely 
collected clinical data and results. The decision was clearly documented on 
the original consent form. 
When participants opted not to undergo venepuncture at any given 
time-point(s) for personal reasons, blood samples corresponding to the pre-
defined time-point(s) were not obtained, without participants being withdrawn 
from the study. 
 
2.3.8 STUDY PROCEDURES 
 
For each patient, the duration of participation in the study was 7 days 
or until hospital discharge, whichever occurred sooner. A summary of all study 
procedures is presented on TABLE 2.1. 
 
2.3.8.1 Calendar & software for time-point follow-up 
A diarized alert/reminder software application was developed to 
generate laptop screen notifications and automated email alerts for each study 
intervention (i.e. blood sampling, etc.) to the research nurses and the author, 
as soon as each participant’s identifier and recruitment details were recorded 
in the respective fields (FIGURE 2.1). This was particularly important to ensure 
all time-points were met when simultaneous and overlapping actions were due, 
as shown in FIGURE 2.2. In addition, a hand-written log was kept by the WTCRF 
research nurses to enter free text, notes and other information pertinent to the 
study for which no appropriate data field was available in the electronic study 
database, the details of which are described in section 2.3.9. Cross-
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referencing of the latter with the study database was performed at regular 
intervals. 
 
2.3.8.2 Clinical history 
For each participant, the clinical history obtained by the respective 
direct clinical care team was verified and any additional information necessary 
for the purposes of the IMOFAP study was collected ad-hoc by a member of 




Day 1 Day 2 Day 3-7 
Tminus T0 T3 T6 T12 T24 T48 T72 T168 
Recruitment &  
informed consent  x        
Clinical history x x        
Vital signs x x x x x x x x x 
Venous blood sampling x x x x x x x x x 
Arterial blood sampling x x x x x x x x x 
Saliva sampling  x        
Urine sampling  x x x x x x x x 
Transthoracic USS       x  x 
TABLE 2.1 – Summary and timing of study procedures for each participant. Routinely archived clinical 
samples (if available) were used to acquire venous blood samples at Tminus. Arterial blood samples 
were only obtained from participants with an A-line in situ. Urine samples were collected at the pre-
defined time-points only from catheterised patients, and by convenience from non-catheterised 
patients. Performance of early transthoracic ultrasound scans (LUSS) varied from day 2 to day 4 and 
for late scans from day 6 to day 8. 
 
2.3.8.3 Venous blood sampling 
Peripheral venous blood was sampled at recruitment (T0) and 3 (T3), 6 
(T6), 12 (T12), 24 (T24), 48 (T48), 72 (T72), and 168 (T168) hours (7 days) 
thereafter. An average maximum cumulative volume of approximately 80 mL 
of venous blood was retrieved from each patient over the course of their 
participation to IMOFAP. In addition, the respective original serum sample 
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obtained by the clinical care team upon each participant’s presentation to 
hospital (Tminus), was also collected from the Biochemistry Laboratory of the 
RIE and was analysed. 
 
FIGURE 2.1 – Screenshot of the bespoke software application developed to ensure 
procedure follow-up for overlapping participant time-points. The application would create 
automated alerts and would email the research nurse on-call as soon as each participant’s 
unique study identifier and details of recruitment were recorded in the respective field and 
the form was submitted. 
 
FIGURE 2.2 – Schematic representation of the progressively increasing complexity of study 
procedures with the recruitment of each consecutive participant. 
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Blood was sampled into gel clot-activator tubes for serum and into 
Ethylenediaminetetraacetic acid (EDTA) tubes for plasma, which were 
subsequently centrifuged at 3200 rpm for 8-10 minutes. All centrifuges had 
been serviced and calibrated prior to the start of the study. Serum and plasma 
were aliquoted and immediately frozen at -80°C, in freezers available in the 
WTCRF Unit of the RIE, until transfer on dry ice to long-term storage in a 
monitored, dedicated -80°C freezer in the Queen’s Medical Research Institute 
of the UoE. 
A sample history and tracking log was kept for all events. There were 
no breaches of the sample handling/storage protocol. Additionally, routine 
haematological and biochemical analyses were performed in accordance with 
standard RIE protocols used in clinical care. 
 
2.3.8.4 Arterial blood sampling 
For participants with an indwelling arterial cannula (A-line) in situ, 
arterial blood samples were collected at the same time-points as for venous 
blood, and these were processed as per routine local protocol. No arterial 
blood samples were taken from participants who did not already have an A-
line in situ. When arterial blood samples were not available, the partial arterial 
pressure of oxygen (PaO2) was extrapolated from the oxygen saturation values 
available from pulse oximetry measurements (SpO2) at the corresponding 
time-points, by applying the method described by Severinghaus 
(Severinghaus, 1979), also used in different settings by other research groups 
(Dean et al., 2012). For this purpose, a conversion table was created by 
applying the Severinghaus formula and was used when necessary (FIGURE 
2.3). 
 
2.3.8.5 Saliva sampling 
One salivary sample was obtained from each participant at T0, by using 
Sarstedt® Salivette®, as detailed on the respective section of the APPENDIX. 
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2.3.8.6 Urine sampling 
A series of urine samples were obtained from each participant on the 
pre-defined time-points if an indwelling urinary catheter was in situ, or by 
convenience if the participant was not catheterised. 
 
 
FIGURE 2.3 – Conversion table for the calculation of PaO2/FiO2 ratio of IMOFAP participants 
when an arterial blood sample was not available. The Severinghaus formula was used to 
calculate PaO2 from SpO2 at the corresponding time-point. PaO2 was measured in kPa. 
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2.3.8.7 Lung ultrasonography 
A nested cohort of participants in the IMOFAP study were recruited to 
additionally participate in the lung ultrasonography study, reported in Chapter 
3 of this thesis. 
 
2.3.9 DATA COLLECTION & DATA MANAGEMENT 
 
Apart from individual patient charts and clinical case notes, data were 
also collected from the following sources: 
i. WardWatcher software (Critical Care Audit Ltd, Menston, United 
Kingdom) 
ii. TrakCare® Patient Management System (InterSystems®, 
Massachusetts, USA) 
iii. SCI Store data repository (Scottish Care Information – NHS National 
Services Scotland, Paisley, United Kingdom) 
iv. Picture Archiving and Communication System (PACS) (AGFA-
Gevaert group, Mortsel, Belgium) 
v. Emergency Care Summary (ECS) database (National Information 
Systems Group, Paisley, United Kingdom) 
vi. iLaboratory information system (iLab – APEX Healthware, San 
Antonio, USA ) 
Data for each participant were collected by the bedside on a dedicated, 
password-protected study laptop, after software encryption by the UoE 
Information Services (IS). A bespoke data collection software application was 
developed in Java™ with set limits to minimize the risk of mistyping of data 
entries and mandatory fields to ensure comprehensive recording (FIGURE 2.4). 
Input from the data collection software application was recorded automatically 
to a specifically developed Microsoft® Access® database (FIGURE 2.5). 
Upon recruitment, each participant was delinked from the 
corresponding Unique Hospital Patient Identifier (UHPI), Community Health 
Index (CHI) and other identifiers such as name, date of birth and postcode, 
64 
and was assigned with a unique study number. The resulting link-anonymised 
data were stored separately from the identifiers and were regularly backed-up 
to minimize risk of loss, theft or unauthorized use, in accordance with the data 
protection principles of the UoE and the WTCRF. Back-up of the link-
anonymised data was performed regularly to a secure network drive (file 
server). After back-up, all data was securely removed from the dedicated 
laptop with the use of the McAfee® Shredder™ application. Physical study 
records regardless of format, were stored securely in dedicated storage 
facilities of the WTCRF. Access to the data during all stages of the study was 
available only to the author and the Principal Investigator. 
 
 
FIGURE 2.4 – Data collection software application screenshot. Set limits for all variables and 
mandatory fields were created to minimize mistyping of data entries and ensure 

































































































































































2.3.10 COMPOSITE CLINICAL SCORES 
 
For each participant, the APACHE II score (Knaus et al., 1985) was 
calculated on the day of admission, by using the most extreme values of the 
variables of interest (day 1 APACHE II) and on per time-point basis. Similarly, 
the MODS score, modified as detailed in the revised Atlanta Classification of 
AP, was calculated for each participant at each time-point and on a daily basis 
(Banks et al., 2013; Marshall et al., 1995). 
 
2.3.11 TRYPTOPHAN METABOLITE MEASUREMENT 
 
Kynurenine pathway metabolites were measured in plasma by two 
separate liquid chromatography–tandem mass spectrometry (LC-MS/MS) 
methods. For the detection of TRP, KYN, KYNA and 3-HAA, plasma (5 μL) 
was initially diluted in phosphate-buffered saline (45 μL). The diluted plasma 
was added to 5mM ammonium formate containing 0.1% trifluoroacetic acid 
(130 μL). Protein was precipitated by the addition of ice-cold 100% 
trichloroacetic acid (20 μL), samples were vortexed briefly, incubated for 30 
minutes at 4°C and centrifuged to obtain the supernatant. Separate standard 
curves were used to quantify levels of the individual metabolites.  
For TRP, the standard curve consisted of serial dilutions of d5-TRP (as 
surrogate analyte of TRP) in 10% pooled human plasma. For KYN, 1% BSA 
in phosphate-buffered saline was used. For KYNA and 3-HAA, 0.2% BSA in 
phosphate-buffered saline was used. Samples (10 μL) were injected onto a 
Waters Select HSS XP column (3mm x 100 mm, 2.5 μm, Waters, Elstree, 
Herts) using a Waters Acquity UHPLC system, coupled to an AB Sciex™ 
QTRAP 5500 mass analyser. The flow rate was 0.35 mL/min at 25°C. 
Separation was carried out using a water:methanol gradient (both containing 
0.1% formic acid). Chromatographic conditions were 50% methanol rising to 
60% over 60 seconds, then to 65% over 180 seconds; held for 110 seconds, 
returned to 50% over 10 seconds and re-equilibrated for a further 200 seconds, 
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giving a total run time of 10.2 minutes. The mass spectrometer was operated 
in positive electrospray ionization mode. The multiple reaction monitoring 
(MRM) transitions for the protonated analytes were: TRP (m/z 205-188), KYN 
(m/z 209-146), KYNA (m/z 190-144) and 3-HAA (m/z 154-136). The transitions 
for d5-TRP standard were (m/z 210-122). Collision energies were 11, 29, 31, 
33 and 37 eV respectively. 
For the analysis of 3-HK, plasma (100 μL) was added to a 40:60 mixture 
of acetonitrile in water containing 0.1% formic acid (130 μL) and 50 ng/mL of 
internal standard. Protein was precipitated by the addition of trichloroacetic 
acid (33 μL), samples were vortexed briefly, incubated for 30 minutes at 4°C 
and centrifuged to obtain the supernatant. A standard curve containing serial 
dilutions of 3-HK in 10% BSA diluted with phosphate-buffered saline enriched 
with 50 ng/mL internal standard was used. 10 μL volumes of each sample were 
injected onto a Waters Select HSS XP column (30mm x 100 mm, 2.5 µm, 
Waters Corp, Elstree, Herts) using a Waters Acquity UHPLC system, coupled 
to an AB Sciex™ QTRAP 5500 mass analyser. The flow rate was 0.8 mL/min 
at 30°C. Separation was carried out using a water:methanol gradient (both 
containing 0.1% formic acid). Conditions were 5% methanol rising to 95% over 
150 seconds, returning to 5% over 30 seconds, giving a total run time of 4 
minutes. The mass spectrometer was operated in positive ion electrospray 
mode. The transitions for the protonated analytes were 3-HK (m/z 225-208) 
and internal standard (m/z 228-211). Collision energies were 20 and 12eV 
respectively. 
Data were acquired and processed using Analyst® quantitation software 
version 1.3 (AB Sciex™, Framingham, USA). Results from retrieved from 
acute presentation samples (pre-recruitment samples) were excluded from the 
time-course analysis because serum-gel activator tube containers were 
routinely used by the clinical care teams, a fact that could have led to 
discrepancy upon comparison with results from the dedicated tripotasium-
ethylenediaminetetraacetate containers that were used for the IMOFAP study. 
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Four samples obtained from two IMOFAP participants of the severe AP 
group returned values of KYN concentration that were greater than 20 
standard deviations away from the remaining concentration values of the 
severe AP cohort, including temporally adjacent samples from the same 
patients. These samples were deemed to have resulted from contamination 
during sample analysis, were designated as extreme outliers and were 
removed from further analysis. 
 
2.3.12 CYTOKINE ANALYSIS 
 
Plasma cytokines were analysed using a custom-designed Human 
Magnetic Luminex Screening Assay according to the manufacturer’s 
instructions (R&D Systems, Minneapolis, USA). Levels of insulin, interleukin-1 
beta (IL-1B), insulin C-peptide and IFN-γ were measured using kit LXSAHM-
4, cancer antigen 15-3 (CA 15-3) using kit LXSAHM-1 and TNF-α, B7 homolog 
1 (B7-H1), chemokine (C-X-C motif) ligand 12 (CXCL 12), cluster of 
differentiation 163 (CD163), TNF superfamily member 10 (TNFS10), receptor 
for advanced glycation endproducts (RAGE), trefoil factor 3 (TFF3), cluster of 
differentiation 40 ligand (CD40 ligand), interleukin 6 (IL-6), interleukin 8 (IL-8), 
interleukin 10 (IL-10), interleukin 17A (IL-17A), cardiac troponin I and chemerin 
using kit LXSAHM-15, respectively. The concentrations of each cytokine were 
determined using Bio-Rad Bio-Plex 200 system (BioRad, California, USA). 
 
2.3.13 HEALTHY VOLUNTEERS 
 
Healthy volunteers over the age of 18 years were recruited with ethical 
approval (REC reference number: 08/S1103/38, United Kingdom). Volunteers 
were excluded from participation when any of the following conditions were 
present: renal dysfunction (eGFR < 30 mL/min); hepatic dysfunction (Child-
Pugh score B or C); pregnancy or breast feeding; blood dyscrasia or anaemia 
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(haemoglobin < 12 g/dL); active malignancy; chronic inflammatory condition; 
any intercurrent illness and/or any recent surgical procedure. 
 
2.3.14 STATISTICAL ANALYSIS 
 
A data analysis plan was formulated prospectively and was adhered to. 
Quantitative data are presented as median and interquartile range (IQR) or 
mean and standard deviation (SD), as appropriate. Qualitative data are 
presented by utilising absolute and/or relative frequencies. Data conformity to 
the normal distribution was analysed by one-sample Kolmogorov-Smirnov 
testing, and comparisons between patient groups were performed by using 
one-way ANOVA or the Kruskal-Wallis H test, as appropriate. Spearman’s rho 
was used to examine bivariate correlations of quantitative variables. 
Logarithmic transformations of non-normally distributed variables were used 
to establish the best linear regression fit during correlation. For the analysis of 
serial metabolite measurements, the method of summary measures was used 
(Matthews et al., 1990). The area under the curve (AUC) for each metabolite 
was calculated for each participant by using the trapezium rule, as described 
by Matthews et al (Matthews et al., 1990). These were standardized by 
duration of participation in the study, defined by the period between 
recruitment and the ultimate time-point of blood sampling for each participant. 
For the computation of each AUC, any uttermost missing values were omitted, 
whereas for any middle missing values AUCs were calculated by using the 
average of two immediately adjacent available values. The Kaplan-Meier 
method was used to compare time-to peak and time-to-minimum metabolite 
values between groups, and the log-rank test was applied to detect 
differences; only time-points between T0 up to and including T72 were 
considered in the latter analyses. 
All statistical tests were based on a two-sided α-value of 0.05. Data 
were analysed using IBM SPSS® Statistics version 22.0 (IBM Corporation, 
70 
Armonk, New York, USA) and graphs were drawn using GraphPad Prism® 
version 6.0 (GraphPad Software, Inc., La Jolla, California, USA). 
Achieved statistical power was calculated post-hoc using the G-Power 
algorithm: F tests – ANOVA: Fixed effects, omnibus, one-way (Faul et al., 
2007). The effect size was computed from measured 3-HK concentrations in 
tAP as f = 5.78, with α error probability of 0.05. The noncentrality parameter, 
λ = 1902.25; Critical F = 3.17; numerator df = 2; denominator df = 54; computed 




2.4.1 RECRUITMENT PERFORMANCE 
 
A total of 79 patients were recruited. Of those, 57 patients (72.2%) were 
diagnosed with AP according to the revised Atlanta guidelines (“true AP” – 
tAP), while the remaining 22 participants had a serum amylase level between 
100 and 299 IU/L, and were categorised in the ‘hyperamylasaemia’ participant 
group. Of the 57 tAP patients, 10 (17.5%) had a serum amylase level below 
300 IU/L upon presentation, and either a subsequent rise of the amylase 
concentration > 300 IU/L or an imaging confirmation of AP. The demographic 
characteristics of the study participants are summarized in TABLE 2.2, and a 
CONSORT diagram of the IMOFAP study is shown in FIGURE 2.6. No 
systematic bias was evident for the 29 potentially eligible patients that were 
not recruited due to no activation of the automated alert. Thirty patients 
declined to participate, of whom 12 had AP and 3 required admission to critical 
care. One male participant formally withdrew from the study within 12 hours 
from recruitment. 
There was no effect of day of the week (P = 0.317) or time of day (P = 
0.397) on recruitment and therefore no selection bias by time of day or by day 




FIGURE 2.6 – CONSORT diagram of the IMOFAP study. Reasons for patient exclusion are 
summarised, with post-hoc diagnoses for each exclusion category included in brackets (NA 
= not available). Patients of the moderate AP severity group were divided to three further 
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FIGURE 2.7 – Line graph demonstrating the cumulative number of participants enrolled 
during the recruitment phase of IMOFAP. The full line represents the number of overall 
participants and the dashed line the number of tAP participants. 
 
 
 Overall tAP Non-tAP 
N % N % N % 
Day of the week  
Monday 9 11 6 11 3 14 
Tuesday 12 15 8 14 4 18 
Wednesday 8 10 6 11 2 9 
Thursday 8 23 14 25 4 18 
Friday 9 11 7 12 2 9 
Saturday 9 11 7 12 2 9 
Sunday 14 18 9 16 5 23 
WD vs. WE  
Weekday 56 71 41 72 15 68 
Weekend 23 29 16 28 7 32 
Time of day  
08:00-15:59 23 29 13 23 10 46 
16:00-23:59 32 41 27 47 5 23 
00:00-07:59 24 30 17 30 7 32 
Overall 79 100 57 100 22 100 
TABLE 2.3 – Timing of hospital presentation of study 
participants by day of the week and time of day. WD: 




FIGURE 2.8 – Box plot showing time interval from acute hospital presentation to study 




FIGURE 2.9 – Bar chart summarizing numbers of obtained (blue bars) and missed samples 




of the recruitment phase and the absolute and relative frequencies of 
participant enrolment by weekday and time of day are shown on FIGURE 2.7 
and TABLE 2.3, respectively. 
Sampling performance was efficient, and a total of 508 samples were 
obtained an analysed. The median time interval between the acute 
presentation sample (pre-recruitment, Tminus) to recruitment was 5 hours and 
34 minutes (IQR: 182-611 minutes) for tAP participants (FIGURE 2.8). This 
interval included examination and consultation by the direct clinical care 
team(s), routinely collected presentation sample processing and analysis, 
verification of the result by the hospital laboratory staff, communication with 
the study team for confirmation of the clinical history and informed consent. 
Due to the high temporal resolution of IMOFAP design, some sample time-
points were missed, but no systematic bias was identified for the unobtained 
samples (FIGURE 2.9). 
 
2.4.2 INFLAMMATORY INDICES, COMPOSITE SCORES & 
CYTOKINES 
 
A clear rise in the level of CRP was evident for tAP participants 
(standardized AUC for CRP concentration, median (IQR): hyperamylasaemia  
group: 18.9 (5.8-45.4) mg/L; tAP participants 126.0 (49.9-201.1) mg/L; P < 
0.001), the magnitude of which was proportionate to AP severity (FIGURE 
2.10a) and in keeping with a substantial systemic inflammatory insult 
(standardized AUC for CRP concentration, median (IQR): mild: 58.9 (26.3-
131.2) mg/L; moderate: 148.1 (74.5-243.9) mg/L; severe: 225.6 (174.9-260.2) 
mg/L; P = 0.001) (FIGURE 2.10a & TABLE 2.4). The acute presentation (pre-
recruitment) mean CRP concentrations were higher in severe AP, but this 
difference was not statistically significant (pre-recruitment CRP concentration, 
median (IQR): mild: 11 (5-34) mg/L; moderate: 19 (9-39) mg/L; severe: 59 (30-
65) mg/L; P = 0.166). Resolution of inflammation, indicated by a fall in CRP, 
occurred between 48 and 72 hours for the majority of participants. Conversely, 
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serum amylase was more than three times higher than the upper limit of normal 
range upon recruitment, and normalised within 24 hours for the majority of 
participants. There was no association between serum amylase level upon 
presentation and disease severity (FIGURE 2.10b). Furthermore, mean and 
minimum concentrations of albumin, as well as the corresponding mean 
standardized AUC for albumin were significantly lower in the severe AP group 
(TABLE 2.4). 
Severe AP patients had a significantly higher modified MODS score 
upon presentation to hospital, when compared to the other two groups (mean 
MODS score, (SD; range): mild: 0.8 (0.7; 0-3); moderate: 0.8 (0.9, 0-4); severe: 
2.8 (2.5; 0-8); P = 0.003), followed by a further rise during the initial 12-hour 
period after recruitment and apparent resolution (a reduction of MODS score 
to < 2) beyond the 48-hour mark (FIGURE 2.10). No association was discovered 
between the time interval from the onset of symptoms to study recruitment and 
modified MODS score upon presentation of severe AP patients (Spearman’s 
rho = −0.037, P = 0.926). Both day 1 APACHE II and Tminus APACHE II scores 
were higher in the severe AP group (day 1 APACHE II score, mean (SD): mild: 
8.2 (4.4); moderate: 11.4 (3.8); severe 19.3 (11.0); P = 0.001, and Tminus 
APACHE II score, mean (SD): mild: 6.0 (3.6); moderate: 7.6 (3.8); severe: 12.0 
(5.6); P = 0.002). APACHE II scores declined after 48 hours, with the decrease 
being more prominent from T72 onwards (FIGURE 2.10d). Importantly the 
decline of both modified MODS and APACHE II scores (calculated for each 
time-point) coincided with and is due to the deaths of two patients in the severe 
AP group, who died within 55 and 101 hours after recruitment. The respective 
scores for the surviving severe AP patients remained relatively unchanged for 
the duration of their participation in the study.  
The inflammatory burden of the study cohort was further quantified by 
supplementary serial measurements of pro- and anti-inflammatory cytokines 
over the same time-points. The severe AP patient group was found to have 
significantly higher levels of peak and mean concentrations, as well as 




FIGURE 2.10 – Panel of comparisons between mild (n = 25), moderate (n = 23) and severe 
AP (n = 9) participant groups for (a) C-reactive protein; (b) Amylase; (c) Modified MODS 
score (as described in the revised Atlanta guidelines); (d) APACHE II score. Bar charts on 
the left hand side of the panel represent Tminus sample means (acute presentation – pre-
recruitment samples), while right-hand side plots depict the time-course for each variable 
mean per participant group. NS: not statistically significant difference; *: 0.05 > P ≥ 0.01; **: 
P < 0.01; error bars represent standard errors of the mean. 
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FIGURE 2.11 – Plasma concentrations of TRP and the kynurenine pathway metabolites in 
tAP participants over time, grouped by AP severity according to the revised Atlanta criteria 
(group sizes at recruitment: mild n = 25; moderate n = 23; severe n = 9 individuals). (a) 
TRP; (b) KYN; (c) 3-HK. For all panels, data points represent means and error bars 
represent standard errors of the mean. P-values for between-group comparisons of 
standardised AUC are appended. NS: not statistically significant. Dashed red lines 
represent healthy volunteer (n = 8) mean concentration of each metabolite. *: 0.05 > P ≥ 





FIGURE 2.11 – Plasma concentrations of TRP and the kynurenine pathway metabolites in 
tAP participants over time, grouped by AP severity according to the revised Atlanta criteria 
(group sizes at recruitment: mild n = 25; moderate n = 23; severe n = 9 individuals). (d) 
KYNA; (e) 3-HAA; (f) 3-HK/TRP ratio multiplied by 1000. For all panels, data points 
represent means and error bars represent standard errors of the mean. P-values for 
between-group comparisons of standardised AUC are appended. NS: not statistically 
significant. Dashed red lines represent healthy volunteer (n = 8) mean concentration of each 
metabolite. *: 0.05 > P ≥ 0.01; **: P < 0.01 
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2.4.3 TRYPTOPHAN METABOLITES 
 
Summary measures for the concentration of TRP and all studied TRP 
metabolites are presented in Error! Reference source not found.. TRP 
depletion was marked and proportionate to disease severity and especially 
profound in severe AP (standardised AUC for TRP concentration, mean (SD): 
mild: 24423.9 (8803.9) ng/mL; moderate: 19721.4 (8140.5) ng/mL; severe: 
13782.4 (3789.8) ng/mL; P = 0.004). Importantly, upon presentation to 
hospital, no statistically significant difference in TRP concentration was evident 
among the three groups (acute presentation TRP concentration, mean (SD): 
mild 29796.6 (10939.7) ng/mL; moderate: 26133.0 (9973.8) ng/mL; severe: 
24273.7 (9926.4) ng/mL; P = 0.281). Moreover, the observed effect on TRP 
levels was not a result of dilution due to resuscitation, as no statistically 
significant difference was observed in the standardised AUC of haematocrit  
between the three groups (standardized AUC for haematocrit, mean (SD): mild 
0.361 (0.04); moderate: 0.350 (0.045); severe 0.330 (0.034); P = 0.161), a 
surrogate marker of haemodilution (Aggarwal et al., 2014). 
No significant differences in peak level, mean level or standardized 
AUC of KYN, KYNA, and 3-HAA were detected amongst the three groups 
(Error! Reference source not found.). In specific, the observed difference of 3-
HAA concentration on FIGURE 2.11e, although visually substantial, did not 
reflect a statistically significant difference, and was driven by the extreme 
values of 3-HAA in two individual participants of the severe AP group. 
The severe AP group had a significantly higher peak 3-HK 
concentration across all study time-points (peak 3-HK concentration, median 
(IQR): mild: 13.5 (8.6-17.8) ng/mL; moderate: 20.0 (12.1-46.6) ng/mL; severe: 
25.2 (14.3-35.6) ng/mL; P = 0.013). The standardized AUC for 3-HK was also 
different amongst the three groups, although only a marginal difference was 
observed between the moderate and the severe group, as shown on Error! 
Reference source not found. (standardized AUC for 3-HK concentration, 
median (IQR): mild: 10.8 (7.4-13.9) ng/mL; moderate: 18.2 (11.4-38.1) ng/mL; 
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severe: 21.6 (11.7-28.0) ng/mL; P = 0.015). The median time interval required 
for the peak 3-HK concentration to be reached was 24 hours (95% C.I.: 0.0-
49.0 hours) in the severe AP group, compared to 12.0 hours (95% C.I.: 6.7-
17.3 hours) in the mild AP group, while the mean time interval of the moderate 
group was 46.0 hours (95% C.I.: 32.9-59.0 hours; P = 0.019). 
To provide an indication of flux through KMO we calculated the ratio 3-
HK/TRP, multiplied by 1000 for practical purposes. A significant increase in 
the pathway flux through KMO was observed, which was proportionate to 
disease severity (standardized AUC for 3-HK/TRP ratio x 1000, median (IQR): 
mild: 0.45 (0.26-0.89); moderate: 0.73 (0.51-2.64); severe: 1.67 (0.93-1.84); P 
= 0.003). Time-plots for the concentration of each analysed metabolite and the 
3-HK/TRP ratio are depicted on FIGURE 2.11. 
When considering all samples obtained from T0 up to and including 
T48, logarithmic 3-HK levels demonstrated a weak to moderate correlation 
with contemporaneous CRP (R2 = 0.132; rho = 0.455, P < 0.001) (FIGURE 
2.12a) and APACHE II score (R2 = 0.250; rho = 0.583; P < 0.001) (FIGURE 
2.12b). Furthermore, a moderate degree of correlation was discovered 
between logarithmic 3-HK and contemporaneous levels of TFF3 (rho = 0.604, 
P < 0.001), albumin (rho = −0.568, P < 0.001), creatinine (rho = 0.531, P < 
0.001), TNF-α (rho = 0.462, P < 0.001), and RAGE (rho = 0.455, P < 0.001), 
and a weaker correlation with IL-10 (rho = 0.357, P < 0.001), IL-6 (rho = 0.352, 
P < 0.001), IL-17A (rho = 0.349, P < 0.001), CD163 (rho = 0.298, P < 0.001), 
IL-8 (rho = 0.293, P < 0.001), TNFS10 (rho = −0.259, P < 0.001), chemerin 
(rho = 0.247, P < 0.001), IL-1 (rho = 0.220, P < 0.001), insulin C-peptide (rho 
= 0.230, P < 0.001), cardiac troponin I (rho = 0.217, P < 0.001), CXCL12 (rho 
= 0.195, P = 0.001), and CD40 ligand (rho = 0.181, P = 0.003). Conversely, no 
correlation was found with insulin (rho = 0.057, P = 0.352), CA 15-3 (rho = 
−0.079, P = 0.199), B7-H1 (rho = –0.062, P = 0.312), and IFN-γ (rho = −0.019, 
P = 0.758). Differences between participant groups for all studied cytokines 
are summarized in TABLE 2.4, and post-hoc pairwise comparisons of 
significantly different standardized AUC are depicted on TABLE 2.7. 
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TABLE 2.4 – Summary measures of serial CRP, albumin and cytokine measures, per patient group. 
Comparisons were performed by utilising one-way ANOVA or Kruskal-Wallis H testing, as appropriate, 
following normality testing (Kolmogorov-Smirnov). Time-to-Peak and Time-to-Min analyses were performed 
by applying the Kaplan-Meier method on concentration levels from T0 up to and including T72. *: mean value. 
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FIGURE 2.12 – Dot-plots of correlations between (a) Plasma concentrations of CRP and 3-
HK, for the tAP cohort grouped by AP severity (mild AP n = 25; moderate AP n = 23; severe 
AP n = 9). Data points represent means; error bars show SD on both axes. The dashed red 
line represents mean 3-HK plasma concentration in healthy volunteers (n = 9). (b) APACHE 
II score and contemporaneous log10 3-HK plasma concentrations. Due to the non-normal 
distribution of plasma concentrations of 3-HK, a logarithmic transformation was used for the 
correlation to provide a better fit. For both correlations, results from samples obtained from 
T0 up to and including T48 were analysed. Results of respective Spearman correlations 




Metabolite Pairwise Standardized AUC Comparison (Adjusted P-values) Mild vs. Moderate Mild vs. Severe Moderate vs. Severe 
TRP* 0.128 0.003 0.156 
3-HK 0.040 0.064 1.000 
3-HK/TRPx1000 0.057 0.004 0.493 
Albumin 0.028 <0.001 0.171 
CRP 0.031 0.001 0.367 
IL-1 Beta 0.144 0.005 0.311 
IL-6 0.090 0.003 0.304 
IL-8 1.000 0.043 0.032 
CA 15-3 0.058 1.000 0.158 
Insulin 1.000 0.044 0.086 
TFF3 1.000 0.014 0.028 
CD163 1.000 0.025 0.083 
TNF-α 1.000 0.026 0.024 
CXCL12 1.000 0.031 0.035 
TABLE 2.7 – Summary of P-values from post-hoc pairwise comparisons of statistically 
different standardized AUC of metabolites between patient groups, adjusted according 





The kynurenine pathway of TRP metabolism and especially KMO, the 
enzyme that determines the metabolic fate of KYN, is increasingly recognized 
as a key contributor to the pathogenesis of AP-MODS. The IMOFAP study 
defined with precision the temporal profile of kynurenine pathway metabolite 
concentrations in peripheral blood in relation to the onset and severity of AP in 
humans (Skouras et al., 2016b). Data arising from IMOFAP show a noteworthy 
association between plasma concentrations of 3-HK and AP severity, as 
defined by standard classification systems. Furthermore, a weak to moderate 
correlation was discovered between 3-HK concentrations and the systemic 
inflammatory burden, measured by contemporaneous CRP levels and 
APACHE II score. Additionally, the classical paradigm pro-inflammatory 
cytokine profile in AP was observed, namely TNF-α and IL-6, as well as RAGE 
and TFF3, that correlated well with 3-HK in this cohort (Skouras et al., 2016b). 
These novel findings add depth to the previously reported association 
between serum concentrations of KYN and the requirement for invasive renal 
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and respiratory support during AP-MODS (Mole et al., 2008). Moreover, these 
findings build on the recent discovery that genetic deletion of KMO and 
administration of a highly-specific KMO inhibitor protect against pulmonary and 
renal injury in experimental rodent models of AP (Mole et al., 2016b). Together, 
these data strongly support the translational potential of KMO inhibition as a 
therapeutic strategy to protect against MODS in human AP (Skouras et al., 
2016b). 
Strengths of the IMOFAP study include the efficiency of recruitment, 
sampling process, sampling frequency and high coverage, thus minimal 
sampling bias. Based on the knowledge that AP and the consequent systemic 
inflammatory response evolve rapidly, we hypothesise that KMO inhibition is 
likely to be most effective when delivered as early as possible in the course of 
the disease and therefore sought and achieved to define the evolving trajectory 
of the inflammatory response with high definition during the early phase. 
The burden of systemic inflammation in the cohort – as measured by 
the magnitude of CRP rise – was substantial. The fact that the APACHE II 
score correlated well with disease severity as classified by the revised Atlanta 
criteria, and that the modified MODS score followed the same trajectory as 
CRP, provide additional reassurance that interpreting plasma concentrations 
of 3-HK and other KYN metabolites in this context is valid and appropriate 
(Skouras et al., 2016b). 
In the present study, the magnitude of TRP depletion was proportional 
to AP severity and became more prominent over time, suggesting increased 
TRP metabolism. Although TRP levels can fluctuate diurnally (Fernstrom et 
al., 1979; Young et al., 1969), diurnal variation does not account for the 
difference in TRP metabolism between AP severity strata, because the time of 
day at which recruitment occurred was random. Furthermore, although it is 
possible that fasting due to hospital admission and/or critical illness may in 
theory account for part of the observed TRP depletion, Poesen et al  
demonstrated that plasma levels of TRP, KYN, and KYNA were not 
significantly different in healthy humans with low or high protein intake (Poesen 
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et al., 2015), hence a correlation with AP severity would not be expected if 
fasting was the cause. The extent of TRP depletion is too great to be due to 
haemodilution after intravenous fluid resuscitation, and indeed no statistically 
significant change was observed in haematocrit, and no dilution effect was 
recorded in other plasma analytes. It therefore seems reasonable to conclude 
that the observed decrease in TRP levels is likely to be the result of increased 
catabolism (Skouras et al., 2016b). 
The increase in steady state 3-HK concentrations in plasma is 
consistent with increased flux through the kynurenine pathway. This change is 
proportionate to disease severity and augments with time. Importantly, 
elevated 3-HK was associated with increased inflammatory burden, as 
indicated by the correlation of plasma 3-HK levels with contemporaneous CRP 
concentrations. While it is curious that no significant changes were observed 
in other TRP metabolites, studies in rodents indicate that KMO represents the 
predominant route for this pathway. For this reason, the 3-HK/TRP ratio 
(multiplied by 1000 for practical purposes) was used in an attempt to express 
the pathway flux through KMO. Changes of this ratio were found to be time-
dependent and proportionate to AP severity, with a lead-time of 12 hours in 
comparison to the timing of peak serum CRP, recorded at T24 for the severe 
AP group. Lastly, the elevation of 3-HK/TRP was greater in those few patients 
with specific respiratory, renal and cardiac dysfunction as defined by those 
specific components of the modified MODS score. 
 
2.6 CONCLUSIONS OF CHAPTER 
 
The IMOFAP study demonstrates that metabolic flux through KMO is 
elevated proportionately to disease severity in human AP. Plasma 
concentrations of 3-HK correlate with the burden of inflammation, incidence of 
organ dysfunction and AP severity. These findings reinforce the rationale for 
investigating early phase KMO inhibition as a therapeutic strategy to protect 














3.1 SUMMARY OF CHAPTER 
 
The purpose of this prospective pilot study was to investigate the value 
of lung ultrasonography (LUSS) in the diagnosis of respiratory dysfunction and 
severity stratification in patients with AP. Over a 90-day period, 41 patients 
(median age: 59.1 years; 21 males) presenting with a diagnosis of potential 
AP were recruited through the IMOFAP study (Chapter 2). Each participant 
underwent LUSS and the number of comet tails was linked with 
contemporaneous clinical data. Group comparisons, AUC and respective 
measures of diagnostic accuracy were examined in relation to, 1) respiratory 
dysfunction, 2) disease severity, as defined by the revised Atlanta criteria for 
AP, 3) CRP contemporaneous with LUSS and, 4) maximum value of CRP 
during the first week of hospital admission. 
A greater number of comet tails was evident in patients with respiratory 
dysfunction (P = 0.021), those with severe disease (P < 0.001) and when 
contemporaneous and maximum CRP exceeded 100 mg/L (P = 0.048 and P 
= 0.003 respectively). AUC of receiver operating characteristic (ROC) plots 
were greater when examining upper lung quadrants, using respiratory 
dysfunction (AUC = 0.783, 95% C.I. = 0.544-0.962) and AP severity (AUC = 
0.996, 95% C.I. = 0.982-1.000) as the variables of interest. Examining all lung 
quadrants except for the lower lateral resulted in greater AUC for 
contemporaneous (AUC = 0.708, 95% C.I. = 0.510-0.883) and maximum CRP 
(AUC = 0.800, 95% C.I. = 0.640-0.929). 
In conclusion, ultrasonography of non-dependent lung parenchyma was 
shown to have the potential to reliably detect evolving respiratory dysfunction 
in AP. This simple, easily repeatable, bedside technique shows promise as an 







The aim of the present study was to investigate the value of LUSS in 
the diagnosis of evolving respiratory dysfunction and severity stratification in 




The LUSS study was performed as part of the IMOFAP observational 
clinical research study, which received ethical approval by the Scotland A 
Research Ethics Committee and regulatory approval by the NHS Lothian 
Research & Development department, as detailed in section 2.3.1. Written 
informed consent was obtained from all participants or in cases of AWI, from 




Participants from the IMOFAP cohort were recruited to additionally 
participate in the LUSS study by convenience, with no conscious or deliberate 
selection bias. Data collection was planned in advance and was performed 
prospectively. 
 
3.3.2 TRANSTHORACIC LUNG ULTRASOUND SCANS 
 
All scans were performed by two consultant radiologists and a specialist 
registrar in radiology, in collaboration with the author. Bilateral intercostal 
LUSS was performed with participants in the supine position, after applying 
acoustic gel on the skin to provide an airless interface. In order to optimize the 
quality of imaging, the intercostal spaces were widened by raising each 
patient’s ipsilateral arm up to or above the head level during the scan, and the 
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transducer was held perpendicular to the skin surface. For the purposes of the 
study, either a Micromaxx® portable ultrasound system fitted with a C60/5-2 
MHz transducer (SonoSite, Inc., Washington, USA), an Acuson S2000™ 
system with a 4C1 transducer (Siemens Medical Solutions USA, Inc., 
California, USA) or an Acuson Antares™ Premium Edition ultrasound system 
with a CH4-1 transducer (Siemens Medical Solutions USA, Inc., California, 
USA) was used. 
Each hemithorax was divided into anterior and lateral, upper and lower 
areas (FIGURE 3.1.a & b). For each hemithorax, the anterior area was 
delineated between the clavicle and the diaphragm and from the parasternal 
to the anterior axillary line. The lateral area was delineated between the axilla 
and the diaphragm and from the anterior to the posterior axillary line. The 
upper quadrants were demarcated from the 1st to the 3rd intercostal space and 
the lower quadrants from the 4th to the 6th intercostal space. Each of the 8 
chest areas were visualised during normal respiration. The pattern analysed 
was the comet-tail artefact arising from the lung-wall interface (the 
hyperechogenic interface between the chest wall and the lung surface), which 
was defined as a hyperechogenic narrow-base reverberation artefact, 
spreading like a laser-ray up to the edge of the screen (Lichtenstein et al., 
1997) (FIGURE 3.2). For each of the 8 quadrants, the number of identified 
comet-tail artefacts was recorded and was linked with contemporaneous, 
prospectively collected clinical data. 
Based on findings from previous studies (Bouhemad et al., 2007; 
Lichtenstein et al., 1997; Wernecke et al., 1987), comet-tail artefacts may be 
present in dependent regions of normally aerated lungs, and can be observed 
in healthy patients. Therefore, in order to optimize the imaging protocol for 
sensitive detection of comet-tail artefacts, three scan zones for each 
participant were compared, namely: i) All lung quadrants, ii) All lung quadrants 
except for the lower lateral, and iii) Upper lung quadrants only, and the results 




FIGURE 3.1.a – Lateral view of the right lung. Schematic representation of the areas scanned 
in relation to ribs (numbered) and intercostal spaces. FIGURE 3.1.b – Anterior view of the lungs. 
Schematic representation of the areas scanned (right hemithorax) in relation to ribs and 
intercostal spaces. (PA: posterior axillary line; AA: anterior axillary line; PS: parasternal line; 
RUL: right upper lateral area; RLL: right lower lateral area; RUA: right upper anterior area; 
RLA: right lower anterior area). 
 
 





FIGURE 3.2.b – Anterior view of the lungs from a patient with AIS: Sonographic 
pattern of comet-tail artefacts fanning out vertically from the lung-wall interface 
and spreading up to the edge of the screen (B-lines). 
 
With the exception of one patient who underwent an early scan on day 
5 and a late scan on day 11 after recruitment, scans performed within 4 days 
from patient recruitment were defined as early scans and those performed later 




3.3.3.1 Diagnosis of acute pancreatitis & severity stratification 
 
The diagnosis of AP, the definition of organ failure and severity 
stratification were performed in accordance with the revised Atlanta guidelines 
for AP (Banks et al., 2013). 
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3.3.3.2 C-reactive protein 
 
Plasma levels of CRP have been shown to correlate well with the 
presence of pancreatic necrosis and severity of AP. However due to the 
relatively late peak of CRP (36-72 hours after admission), CRP levels upon 
admission may not be useful in assessing severity (Banks et al., 2006). 
Therefore, both CRP contemporaneous with the LUSS (highest value within 
the same 24-hour period) and maximum CRP value during the first week of 
admission were used as additional surrogate markers of AP severity, by using 
100 mg/L as the cut-off for the binary classification of the cohort (Mayer et al., 
1984; Puolakkainen et al., 1987). 
 
3.3.3.3 Alveolar-interstitial syndrome 
 
Pulmonary diseases with involvement of the alveolar space and the 
interstitium are grouped under the term alveolar-interstitial syndrome (AIS) and 
include ARDS, pneumonia, acute cardiogenic pulmonary oedema, 
exacerbation of chronic interstitial lung disease and miscellaneous other 
pulmonary conditions (Lichtenstein et al., 1997; Stefanidis et al., 2012). The 
radiological diagnosis of AIS in the LUSS study was based on the presence of 
alveolar opacities (ill-defined shadowing, confluent opacities with air 
bronchograms) and/or interstitial opacities (septal lines, linear, reticular, or 
nodular opacities) on each participant’s chest X-rays, as previously proposed 
by Lichtenstein et al (Lichtenstein et al., 1997). 
 
3.3.3.4 Respiratory dysfunction 
 
The lowest value of PaO2/FiO2 for the 24-hour period when each LUSS 
was performed was used as a metric of potential respiratory dysfunction. A 
threshold value of 300 was used to divide the cohort into two groups, since 
those with PaO2/FiO2 < 300 have a modified MODS score equal or greater than 
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2 on the modified MODS score, used by the revised Atlanta guidelines. When 
an arterial blood sample was not available, PaO2 was extrapolated from SpO2 
by applying the method described by Severinghaus (Severinghaus, 1979). For 
non-ventilated patients receiving supplemental oxygen, the fraction of inspired 
oxygen (FiO2) was estimated as described Banks et al (Banks et al., 2013), 
modified as shown in TABLE 3.1. 
 
Supplemental oxygen (L/min) FiO2 (ratio) 







Table 3.1 – FiO2 for non-ventilated patients (modification of the 
values provided in the revised Atlanta guidelines for acute 
pancreatitis) 
 
3.3.3.5 Statistical analysis 
 
Data for continuous variables are presented as mean ± SD or as median 
and IQR. Categorical variables are presented as absolute and relative 
frequencies. Comparisons between independent groups were performed 
using the Mann-Whitney U-test. Spearman’s rho was used to examine 
correlations between pairs of non-parametric variables. All statistical tests 
were based on a two-sided α-value of 0.05. 
For early and late scans, independent samples analysis was performed 
with the cohort stratified by: i) respiratory dysfunction (PaO2/FiO2 < 300 vs. 
PaO2/FiO2 ≥ 300), ii) disease severity (severe vs. non-severe), based on the 
revised Atlanta criteria for AP (modified MODS score < 2 vs. modified MODS 
score ≥ 2), iii) CRP value contemporaneous with LUSS (contemporaneous 
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CRP < 100 mg/L vs. CRP ≥ 100 mg/L), and, iv) maximum CRP value within 
the first week of admission (maximum CRP < 100 mg/L vs. CRP ≥ 100 mg/L). 
ROC curves were plotted for each comparison. AUC and measures of 
diagnostic accuracy with respective confidence intervals were calculated, with 
the use of ‘pROC’ package (Robin et al., 2011) of RStudio version 0.98.1091 
(RStudio, Inc., Massachusetts, USA), after identifying ROC curve thresholds 
by the use of Youden’s index. AUC for paired ROC curves were compared with 
the DeLong method (DeLong et al., 1988). Additional statistical analyses were 
performed with IBM SPSS® Statistics Version 22.0 (IBM Corporation, Armonk, 
New York, USA). Figures were designed using GraphPad Prism® Version 6.0 
(GraphPad Software, Inc., La Jolla, California, USA). Formal blinding of the 
LUSS assessors was not feasible due to the nature of the investigations. The 
principles of the STARD (STAndards for the Reporting of Diagnostic accuracy 






Forty-one patients were enrolled in the LUSS study. Based on the 
revised Atlanta guidelines, 32 of 41 participants had a diagnosis of ‘true’ AP 
(2.3.3), whereas the remaining 9 patients had hyperamylasaemia that did not 
satisfy the revised Atlanta definition of AP. All patients were included in the 
analysis. Of the tAP group, 12 participants had mild AP, 15 had moderately 
severe and 5 had severe disease. The demographic characteristics are 
summarized in TABLE 3.2. 
Fifty-one LUSS were performed, of which 33 (64.7%) were performed 
early in the disease course, and 18 (35.3%) were performed at a late stage. 





elevated serum amylase (IQR = 1.5-4 days), and late scans after a median of 
6 days (IQR = 5-9.3 days). Regarding the onset of symptoms, early scans were 
performed after a median of 5 days (IQR = 3-7 days), and late scans after a 
median of 8.5 days (IQR = 6-12.3 days). Twenty-three participants (53.7%) 
underwent an early scan only, 8 (22%) underwent a late scan and 10 (24.4%) 
underwent both. One late scan performed on day 4 after recruitment on a 
 Overall  Hyperamylasaemia Mild AP Moderate AP Severe AP 
n 41 9 12 15 5 
Age (years)  
Median 59.1 59.1 69.7 57 49.4 
IQR 49.2-67.5 50.7-64.6 50-81.6 49.2-67.5 45.8-63.9 
Gender  
ratio, (%)  
Males  21/41 (51.2) 5 6 8 2 
BMI  
Median 28 26 27 29 32 
IQR 23-32 23-28 23-30 24-35 30-33 
AP Aetiology 
ratio, (%)  
Gallstones 19 (59.4) N/A 7 11 1 
Alcohol 6 (18.8) N/A 2 1 3 
Idiopathic 5 (15.6) N/A 2 2 1 
Other 2 (6.3) N/A 1 1 0 
N/A 9 (22.0) 9 N/A N/A N/A 
Amylase (IU/L)   
Median 507 145 1045 642 669 
IQR 230-1143 138-197 434-1435 324-2314 654-1143 
CRP (mg/L)  
Median 66 13 29 154 133 
IQR 24-146 6-26 12-71 46-241 119-146 
APACHE II score  
Median  10 12 9 10 17 
IQR 8.5-16.5 9-17 6-12 9-15 10-31 
SIRS  
Ratio (%) 23 (56.1%) 6 6 6 5 
Modified MODS  
Score  
Median (IQR) 1 (1-2) 2 (1-3) 1 (1-2) 1 (1-2) 3 (2-8) 
PaO2/FiO2 ratio   
Median 328 360 360 319 223 
IQR 282-361 268-390 333-390 291-337 95-223 
TABLE 3.2 – Demographic characteristics of study participants. (BMI: Body Mass Index; LOS: 
Length of hospital stay; N/A: Not applicable; SIRS: systemic inflammatory response syndrome). 
The maximum value of CRP and serum amylase during the first 24 hours of admission were 
used to calculate group medians and IQR. SIRS and APACHE II calculations were based on 
the most extreme values of the first 24 hours of admission. 
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participant who underwent an early scan on day 1 was excluded from further 
analysis. 
 
3.4.2 EARLY SCANS 
 
In patients with respiratory dysfunction (n = 7), a greater number of 
comet tails were evident on LUSS when compared to patients without 
respiratory dysfunction (n = 26), both when all lung quadrants except for the 
lower lateral were examined, and when upper quadrants alone were 
considered (P = 0.030 and P = 0.021 respectively). When all lung quadrants 
were taken into consideration this difference did not reach statistical 
significance (P = 0.067). When severity status was used as the defining 
parameter for the cohort, patients with severe AP (n = 5) had a greater number 
of comet tails than others (n = 28), by all three methods. 
The number of comet tails was significantly different by all three 
methods when maximum CRP value of the first week of admission was 
examined. Conversely, for contemporaneous CRP a marginally significant 
difference was shown when scanning all lung quadrants and all quadrants 
except for the lower lateral (P = 0.048 for both methods), but only a non-
significant difference when scanning upper quadrants alone (P = 0.074). The 
number of comet tails identified by each method is summarized in TABLE 3.3 
and group comparisons are depicted in FIGURE 3.3. 
Of the three LUSS approaches, the AUC of the ROC curve was greater 
for the method examining upper lung quadrants alone when the cohort was 
categorised by respiratory dysfunction (AUC = 0.783, 95% C.I. = 0.544-0.962, 
P = 0.023) and disease severity (AUC = 0.996, 95% C.I. = 0.986-1.000, P < 
0.001). Pairwise AUC comparisons between methods examining all quadrants, 
all quadrants except the lower lateral and upper quadrants alone, did not reveal 
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3 3 8 3 3 4 3 5 8 6 9 9 3 5 7 
Threshold 
0.667 (10/15; 0.400-0.867) 
0.733 (11/15; 0.467-0.933) 
0.733 (11/15; 0.467-0.933) 
0.550 (11/20; 0.350-0.750) 
0.650 (13/20; 0.450-0.850) 
0.750 (15/20; 0.550-0.900) 
0.615 (8/13; 0.308-0.846) 
0.692 (9/13; 0.462-0.923) 
0.692 (9/13; 0.462-0.923) 
1.000 (5/5; 1.000-1.000) 
0.800 (4/5; 0.400-1.000) 
1.000 (5/5; 1.000-1.000) 
0.857 (6/7; 0.571-1.000) 
0.857 (6/7; 0.571-1.000) 





0.923  (12/13; 0.769-1.000) 
0.846 (11/13; 0.615-1.000) 
0.923 (12/13; 0.769-1.000) 
0.846 (11/13; 0.615-1.000) 
0.846 (11/13; 0.615-1.000) 
0.846 (11/13; 0.615-1.000) 
0.750 (15/20; 0.550-0.900) 
0.750 (15/20; 0.550-0.900) 
0.750 (15/20; 0.550-0.950) 
0.964 (27/28; 0.893-1.000) 
0.964 (27/28; 0.893-1.000) 
0.821 (23/28; 0.679-0.964) 
0.731 (19/26; 0.539-0.885) 
0.692 (18/26; 0.500-0.846) 



























































FIGURE 3.3 – Scatterplot of the total number of comet tails per patient group as determined 
by: a. Respiratory dysfunction status (PaO2/FiO2 < 300 vs. PaO2/FiO2 ≥ 300). Red lines 
represent median and IQR for each patient group. (A: PaO2/FiO2 ≥ 300; B: PaO2/FiO2 < 
300) – b. AP severity status (Severe vs. Non-severe). Red lines represent median and 
interquartile range for each patient group. ns: P ≥ 0.05; *: P < 0.05 ****: P < 0.001. 
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FIGURE 3.3 – Scatterplot of the total number of comet tails per patient group as determined 
by: c. Contemporaneous CRP – d. Maximum value of CRP. Red lines represent median 





FIGURE 3.4 – ROC curves of the number of comet tails by: a. Respiratory dysfunction status 
– b. AP severity status. 
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FIGURE 3.4 – ROC curves of the number of comet tails by: c. Contemporaneous CRP – d. 





The greatest AUC for contemporaneous and maximum CRP resulted 
from examining all lung quadrants except for the lower lateral (AUC = 0.708, 
95% C.I. = 0.510-0.883, P = 0.047, and AUC = 0.800, 95% C.I. = 0.640-0.929, 
P = 0.004 respectively), as depicted on FIGURE 3.4.b. For contemporaneous 
CRP, pairwise comparisons did not reveal superiority of either of the three 
methods whereas for maximum CRP, examining all quadrants except for the 
lower lateral was superior to upper quadrants alone (P = 0.011). 
For each LUSS method, the derived threshold for the number of comet 
tails, the corresponding sensitivity (SE), specificity (SP), positive (PPV) and 
negative predictive values (NPV), along with respective 95% C.I., likelihood 
ratios, as well as the correlation coefficients of the number of comet tails with 
PaO2/FiO2, modified MODS score, contemporaneous and maximum CRP are 
presented in ERROR! REFERENCE SOURCE NOT FOUND.. 
 
3.4.3 LATE SCANS 
 
None of the 19 patients who underwent LUSS late in the course of the 
disease had concurrent respiratory dysfunction, therefore it was not feasible to 
examine the diagnostic accuracy of late scans in this context. No significant 
correlation between the number of late LUSS comet tails and either 
corresponding disease severity (contemporaneous modified MODS score), 
respiratory dysfunction (PaO2/FiO2), disease severity on admission (as defined 
by the revised Atlanta criteria), or contemporaneous/maximum CRP was 




Twenty-eight of the 33 participants who underwent an early LUSS, also 
had at least one prior CXR as part of their routine clinical management, and 
15 of these showed AIS. Although LUSS were performed a median of 2 days 
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(IQR: 1-3 days) after the CXR, a satisfactory diagnostic association was 
demonstrated between CXR diagnosed AIS and LUSS findings (ERROR! 




The findings of the LUSS study confirm a useful diagnostic association 
of early lung ultrasound scans with AP severity and respiratory dysfunction, for 
all three scanning methods applied, particularly when all lung quadrants 
excluding the lower lateral and when upper quadrants alone were examined. 
More comet tail artefacts are present in patients with respiratory dysfunction, 
severe AP and elevated CRP, and thresholds for the number of comet-tails 
have been discovered. The routine use of LUSS in the early stage of AP 
appears to be attractive as an initial proposition for further research, as a non-
invasive, easily repeatable bedside adjunct that provides an accurate 
evaluation of disease severity and respiratory dysfunction (Skouras et al., 
2016a). 
Furthermore, in ITU, LUSS can support clinical decision making when 
patient pronation is under consideration, and offers the potential to monitor its 
effects in real time (Tsubo et al., 2004). It can be effective in the detection of 
derecruited pulmonary areas, allowing for optimization of ventilatory strategy, 
for example by means of postural therapy, and can assist in the diagnosis of 
several other pulmonary conditions which are common in critical illness, such 
as pulmonary atelectasis, pneumonia, pleural effusion, and/or pneumothorax, 
and to differentiate between cardiogenic pulmonary oedema and 
decompensated COPD (Via et al., 2012; Volpicelli et al., 2006). Importantly, 
as shown in the present pilot study, high patient BMI does not appear to affect 
LUSS accuracy (overall patient sample median BMI = 28; severe AP subgroup 
median BMI = 32). 
The LUSS study has several potential limitations. The cohort size is 
relatively small, however as a pilot evaluation of this diagnostic approach it is 
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considered adequate. The number of late scans performed is insufficient to 
comment on its utility in the late phase of the AP and the small number of 
patients who underwent both early and late scans (n = 10) has not allowed for 
a valid comparison between these two groups. However, the fact that organ 
dysfunction and mortality are early events in AP does not obviate the utility of 
a late imaging approach. A potentially slower resolution of the pathological 
pulmonary changes in comparison to the anticipated clinical recovery of 
patients with non-severe AP may raise challenges on the potential application 
of late LUSS in monitoring disease progress. 
Although the interobserver variability of LUSS findings has not been 
examined in the presented pilot study, evidence from previous studies reveal 
a satisfactory interobserver agreement for the detection of AIS, and offer an 
important appraisal for the quality of the findings arising from a method 
generally characterised by operator dependency. Volpicelli et al report 
interobserver variability of less than 5% (183 concordant and 9 discordant 
diagnoses) in a random set of 24 examinations performed by two independent 
investigators, whereas Lichtenstein et al report a kappa statistic of 0.74 from 
the assessment of 288 lung regions (Lichtenstein et al., 2004; Volpicelli et al., 
2006). Accordingly, these reports support the robustness of the findings 
presented herein. 
The most pertinent question regarding this novel method concerns its 
clinical relevance to the management of patients with AP. From the arising 
findings, it remains uncertain whether lung ultrasonography will offer an 
advantage in the prediction of severity or respiratory dysfunction when 
compared to the standard clinical assessment or use of existing composite 
scores. Although the present pilot study provides encouraging evidence about 
the value of LUSS as a diagnostic adjunct, additional evidence is required to 
support its role in the identification of AIS when it is clinically undiscernible, 
and further studies are required to clarify whether lung ultrasonography can 
pragmatically assist in stratifying AP patients that present with subtle or 
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established respiratory dysfunction to those who will develop persistent organ 
failure. 
With regard to methodology, the convention used to extrapolate 
PaO2/FiO2 from SatO2 may have introduced unknown error in the analysis, as 
the Severinghaus equation has not been validated for calculation of the 
modified MODS score in AP patient cohorts. Nevertheless, SpO2 has 
previously been used for similar approximations, with reasonable accuracy 
(Pandharipande et al., 2009b; Serpa Neto et al., 2013). Additionally, the timing 
of chest X-rays for study participants was not altered from ordinary clinical 
care. LUSS were in general performed after X-rays, therefore the accuracy of 
the association between the findings of the two imaging methods may be 
confounded by this discrepancy. 
The fact that early scans were performed a median of 3 days after the 
first finding of an elevated serum amylase, may have concealed an even 
greater prognostic association with early respiratory dysfunction. The exact 
prognostic features of early LUSS deserve further investigation and future 
studies are likely to benefit from standardizing the timing of scans within the 
first 48 hours. Nevertheless, the fact that scans performed very early may carry 
a high false negative ratio must be taken into consideration, as at that stage 
developing pulmonary involvement may not yet be identifiable with this 
method. 
 
3.6 CONCLUSIONS OF CHAPTER 
 
Ultrasonography of non-dependent lung parenchyma can reliably 
detect evolving respiratory dysfunction in AP, and shows promise as an 
adjunct to severity stratification. This simple, easily repeatable bedside test 












4.1 SUMMARY OF CHAPTER 
 
The effect of early organ dysfunction during AP on the long-term 
survival is unknown. A retrospective study was performed to ascertain whether 
the life expectancy of hospital survivors following AP-MODS is affected. 
Data were collected on consecutive patients admitted to the Royal 
Infirmary of Edinburgh with AP during a 5-year period commencing January 
2000. A MODS score ≥ 2 during the first week of admission was used to define 
early organ dysfunction. After accounting for in-hospital deaths, long-term 
survival probabilities were estimated using the Kaplan-Meier method. The 
prognostic significance of patient characteristics was assessed by univariate 
and multivariate analyses using Cox's proportional hazards methods. 
694 patients were studied. Median follow-up was 8.8 years. Patients 
with early organ dysfunction died prematurely (mean survival = 8.6 years; 95% 
C.I. = 7.9-9.3 years), compared to those who did not develop organ dysfunction 
(mean survival = 11.5 years; 95% C.I. = 11.1-11.9 years, Wilcoxon P < 0.001, 
log-rank P < 0.001). Importantly, this effect was independent of age and 
persisted after the exclusion of in-hospital deaths. Multivariate analysis 
confirmed MODS as an independent negative predictor of long-term survival 
(Cox’s Hazard Ratio = 1.528, 95% C.I. = 1.72-2.176, P = 0.019) along with age 
(HR = 1.062, P < 0.001), alcohol (HR = 2.027, P = 0.001) and idiopathic 
aetiology (HR = 1.548, P = 0.048). 
Early organ dysfunction in AP is an independent negative predictor of 
long-term survival even when in-hospital deaths are accounted for. Negative 
predictors also include age, idiopathic and alcohol aetiology. This study 
demonstrates that the damaging effects of critical illness persist even after the 
initial organ dysfunction has resolved and adds a new dimension to the 






The aim of the AP long-term survival study was to determine whether 
early organ dysfunction during an episode of AP is associated with altered life 




4.3.1 STUDY APPROVAL 
 
Caldicott Guardian approval was obtained to allow the use of 
confidential patient data. The study was assessed by the UoE/NHS Lothian 
ACCORD Research and Development office and the South East Scotland 
Research Ethics Service and was declared exempted from formal Research 
Ethics Committee review as a quality improvement project. 
 
4.3.2 DATA COLLECTION AND INCLUSION CRITERIA 
 
In 2013, a retrospective analysis of long-term survival data was 
performed for a prospectively maintained database of patients with AP, 
admitted to the Royal Infirmary of Edinburgh (RIE) during the 5-year period 
between January 2000 and December 2004. This historical cohort was 
originally identified from the Lothian Surgical Audit database (Aitken et al., 
1997), and the clinical details and immediate outcomes have been previously 
reported (Mofidi et al., 2007b). For this cohort, existing data on age, gender, 
organ dysfunction, aetiology of AP, necrosectomy and disease severity were 
supplemented with newly collected survival data. Patients for whom data on 
these characteristics were unavailable were excluded from subsequent 
analysis. For those patients with recurrent attacks of AP, the earliest episode 
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during the study period was taken as the index episode for the purposes of 
survival analysis. 
Patient inclusion in the original cohort was based on clinical features 
compatible with AP, supported by the finding of elevated serum amylase (three 
times higher than the upper limit of the normal reference range). CT evidence 
of AP was required for the diagnosis in instances where a strong clinical 
suspicion of AP existed without a diagnostic level of serum amylase. Patients 




Severity stratification was performed according to the original version of 
the Atlanta consensus definition of 1992 (Bradley, 1993), which was the 
classification system in use at the RIE at the time when the patients of the 
study cohort had presented with AP. Patients were not retrospectively 
reclassified according to the revised Atlanta criteria of 2012 (Banks et al., 
2013) to avoid introducing error. Patients with an APACHE II score of ≥ 8 were 
categorised in the severe AP group. 
Gallstones were considered to be the precipitating cause of AP when 
gallbladder or bile duct calculi had been detected by any imaging modality. In 
the absence of gallstones and when excessive consumption of alcohol had 
been reported by the patient or the patient’s family, AP was classified as 
alcohol induced. When no definite cause was identified, the disease was 
characterised as idiopathic. Rarer established causes were categorised 
collectively under the group ‘other’. 
Organ dysfunction scores were calculated for all patients at 24 hours, 
48 hours and at 7 days, based on the most extreme laboratory values or clinical 
measurements during each 24-hour period, for five of six organ systems that 
constitute the MODS score reported by Marshall et al: respiratory, 
cardiovascular, renal, haematological, central nervous system (Marshall et al., 
1995). Hepatic dysfunction – measured by the level of serum bilirubin – was 
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excluded to avoid the confounding effects of potential biliary obstruction. A 
MODS score of ≥ 2 (based on dysfunction of a single, or more than one organ 
system) at one or more time points was required for the definition of organ 
dysfunction. The duration and persistence of organ dysfunction could not be 
retrospectively ascertained from the existing database. 
 
4.3.4 FOLLOW-UP & MORTALITY 
 
In-hospital mortality, overall mortality and long-term survival were the 
main outcome measures of the long-term survival study. NHS Lothian 
electronic patient records were individually reviewed and survival data were 
collected. For surviving patients, the date of the most recent GP or hospital 
visit (outpatient clinic attendance or hospital discharge) was defined as the 
point of last known contact, whereas for non-survivors the date of death was 
recorded. 
 
4.3.5 STATISTICAL ANALYSIS 
 
Data for continuous variables are presented by using the mean and SD 
or median and IQR. Categorical variables are presented as absolute and 
relative frequencies. Comparisons between groups were performed by using 
Student's t-test, Mann-Whitney U-test, Kolmogorov-Smirnov test and χ2 tests, 
as appropriate. 
The Kaplan-Meier method was used to estimate survival probabilities. 
The generalized Wilcoxon test was used to detect early death rate differences 
between patient groups and the log-rank test was used to detect differences 
manifesting throughout the duration of the follow-up period. Survival times 
were calculated from the date of admission to the date of death from any 
cause, or date of last contact for survivors. Patients lost to follow-up were 
censored at the date of confirmed last contact. 
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The prognostic impact of patient characteristics on survival was 
assessed by univariate and multivariate Cox's proportional hazards 
regression. For univariate analyses, the proportional hazard assumption was 
examined graphically with the use of pairwise Cox log(-log) plots, revealing 
approximately parallel curves between groups for each of the categorical 
covariates: MODS, gender, severity and aetiology. Linear regression was 
implemented to test for goodness of fit of Schoenfeld partial residuals 
(Schoenfeld, 1982) against natural logarithmic survival times for each of the 
aforementioned covariates and no violation of the proportional hazards 
assumption was revealed. The linearity assumption for age was confirmed 
graphically by examining the respective Cox log(-log) plots, after 
transformation to a categorical variable with 6 strata. Similar procedures were 
used for the multivariate analyses. 
Selection of variables for the multivariate Cox regression model was 
performed according to the ‘Purposeful Selection’ algorithm (Bursac et al., 
2008; Heinze, 2008), originally described by Hosmer and Lemeshow (Hosmer 
et al., 2008.). Variables with a univariate P-value < 0.25 were originally 
selected as candidates for the multivariate analysis. Covariates were 
subsequently removed from the model if they were found to be non-significant 
at the α = 0.1 level and not to be confounders. Confounding was defined as a 
change of > 15% in any of the remaining covariate estimates. Variables that 
were not selected for the original model was added back one at a time, and 
any that were significant at the α = 0.15 level were retained (Bursac et al., 
2008). This procedure resulted in a multivariate model containing age, MODS, 
gender, severity and aetiology. The necrosectomy variable did not satisfy the 
proportional hazards assumption and was examined with the use of Stratified 
Cox regression. 
Results of the Cox models are presented as hazard ratios (HR) with 
95% C.I., together with the P-values from Wald's tests. All statistical tests were 
based on a two-sided alpha level of 0.05. Statistical analysis was performed 
using IBM SPSS® Statistics version 19.0 (IBM Corporation, Armonk, New 
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York, USA) and figures were designed on GraphPad Prism® version 6 
(GraphPad Software, Inc., La Jolla, California, USA). This double-arm cohort 
study followed the principles of the STROBE (strengthening the reporting of 






Unique patient identifiers with corresponding survival data and variables 
of interest were available for 694 of 759 (91.4%) AP patients in the database 
and were included in the study. With regard to classification of disease severity 
based on APACHE II score, 256 (36.9%) patients were predicted to have a 
severe attack, although ultimately 268 (38.6%) suffered from some degree of 
organ dysfunction during the first week of admission. A total of 235 (33.9%) 
patients had a MODS score of ≥ 2 at one or more time-points during the first 
week of their hospital stay and were classified as having organ dysfunction 
(denoted as ‘MODS group’). Sixty-nine (9.9%) patients underwent one or more 
necrosectomy procedures during the study interval. These were preformed 
predominantly as open procedures since minimally invasive retroperitoneal 
pancreatic (MIRP) necrosectomy was not routinely performed in the RIE during 
the study period. The demographic characteristics are summarized in ERROR! 
REFERENCE SOURCE NOT FOUND.. 
 
4.4.2 STUDY FOLLOW-UP 
 
The median follow-up for the whole patient cohort was 8.8 years. After 
excluding in-hospital deaths, median follow-up was 9.0 years. This period was 
marginally comparable between the MODS group and non-MODS group, after 
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= 4.7-10.5 years vs. non-MODS median follow-up: 9.1 years, IQR = 6.6-10.6 
years; Mann-Whitney U-test: P = 0.046, Kolmogorov-Smirnov test: P = 0.105). 
 
4.4.3 OVERALL SURVIVAL 
 
In total, there were 36 (5.2%) in-hospital deaths, 35 of which occurred 
within 2.2 months following admission to hospital. During the follow-up period,  
179 patients died, resulting in an overall mortality rate of 31.0% (215 of 694 
patients). Median survival in the overall cohort could not be defined, because 
more than 50% of patients were still alive at the end of the follow-up period. 
The overall mean survival was 10.6 years (95% C.I. = 10.2-10.9 years), which 
after exclusion of the in-hospital deaths increased to 11.1 years (95% C.I. = 
10.8-11.5 years) (FIGURE 4.1). 
 
 
FIGURE 4.1 – Kaplan-Meier survival curve for the overall sample of patients (N = 694), 
representing percentage of surviving patients per time in years. A distinct, steep decrease 
is evident during the first 2.2 months of the study, corresponding to in-hospital deaths. The 
dashed red line represents the time-point of the last observed in-hospital death. Vertical 
tick-marks represent right-censored cases. The survival curve has been truncated when the 




4.4.4 ORGAN FAILURE AND SURVIVAL 
 
Analysis of the overall patient sample demonstrated a clear difference 
in survival between the MODS and non-MODS groups (FIGURE 4.2). Mean 
survival in the MODS group (8.6 years, 95% C.I. = 7.9-9.3years ) was 
significantly lower than that of the non-MODS group (11.5 years, 95% C.I. = 
11.1-11.9 years) (Wilcoxon test: P < 0.001, log-rank test: P < 0.001). The 
highest frequency of death occurred during the in-hospital period; the majority 
of these patients had a MODS score of ≥ 2. Four of the 36 patients who died 
during their hospital stay had a MODS score of < 2. 
Next, to investigate long-term mortality, in-patient deaths were removed 
from the analysis. Importantly, with this exclusion, mean survival of the MODS 
group hospital survivors (10.0 years, 95% C.I. = 9.4-10.6 years) remained 
significantly shorter than that in non-MODS group hospital survivors (11.6 
years, 95% C.I. = 11.2-11.9 years) (Wilcoxon test: P = 0.002, log-rank test: P 
= 0.001). Furthermore, the survival curves continued to diverge for several 
years after the index episode of AP (FIGURE 4.3). Again, median survival was 
not defined; however the 75th percentiles of survival were 6.5 years and 9.9 
years for the MODS and non-MODS groups, respectively. The survival rates 
for each group at 1, 3, 5 and 10 years are shown in TABLE 4.2. 
To account for the mean age difference between the MODS (59.9 ± 
17.1 years) and the non-MODS (54.3 ± 17.9 years) groups (P < 0.001), and 
for the impact other AP characteristics may have on long-term survival, a 
multivariate analysis was performed. The MODS score was shown to be an 
independent predictor of patient survival, with the MODS group carrying a 
higher level of risk for post-discharge death than the non-MODS group, in both 
univariate and multivariate analyses. Age and cause of AP were also 
established as individual predictors, whereas severity and gender were 
identified as confounding factors (TABLE 4.3). 
Notably, apart from alcohol, idiopathic aetiology was associated with an 
increased risk of reduced long-term survival in the multivariate analysis. As 
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shown in ERROR! REFERENCE SOURCE NOT FOUND., a relatively high proportion 
of patients (13.1%) in the overall cohort suffered from idiopathic AP, which was 
even higher for patients who died following their discharge from hospital 
(15.1%). The idiopathic subgroup is likely to include patients with undiagnosed 
causes, in particular microlithiasis, who are likely to suffer from recurrent 
attacks of AP. This fact may potentially explain why idiopathic aetiology 
predisposes to reduced life expectancy, although unfortunately these data 
were not available for confirmation in the present study. When necrosectomy 
was added on the multivariate Cox regression model by stratification, a 
negligible effect was observed. Specifically, the resulting HR for the MODS 
group was 1.573 (95% C.I. = 1.102-2.246, P = 0.013). 
A supplementary univariate Cox regression analysis was performed on 
the MODS group alone (after exclusion of in-hospital deaths) in order to 
examine whether the magnitude of MODS score (worst MODS score value of 
days 1, 2 and 7 of admission) or APACHE II score on the day of admission 
had any effect on long-term survival. No significant effects were revealed for 
either the MODS score (HR = 0.876, 95% C.I. = 0.748-1.026; P = 0.102) or the 




The long-term survival study demonstrated that organ dysfunction has 
a lasting negative impact on life expectancy after an attack of AP. Importantly, 
this effect is seen after excluding in-hospital deaths and is independent of age, 
aetiology and gender. In addition, age and an alcohol or idiopathic aetiology 
were also confirmed as factors with deleterious impact (Skouras et al., 2014). 
The extent to which the consequences of critical illness contribute to 
post-discharge mortality is poorly understood (Angus et al., 2003; Kaplan and 
Angus, 2002; Keenan et al., 2002; Williams et al., 2005), especially in AP. No 
previous study has specifically investigated the impact of early organ 




FIGURE 4.2 – Kaplan-Meier survival plot by group of patients (black line: non-MODS group, 
n = 459 – red line: MODS group, n = 235), representing cumulative percentage of surviving 
patients per time in years. A distinct, steep decrease is evident on the MODS curve during 
the first months of the study, corresponding to in-hospital deaths. A clear difference in 
survival is observed between the two groups. Vertical tick-marks represent right-censored 
cases. Survival curves have been truncated when the number of patients at risk reached 




















1 year 178.5 0.92 0.02 426.5 0.97 0.01 
3 years 162.5 0.85 0.03 401.5 0.91 0.01 
5 years 151 0.79 0.03 367.5 0.86 0.02 
10 years 54.5 0.55 0.04 123.5 0.72 0.02 
 
TABLE 4.2 – Number of patients at risk and survival rates for each group at 1, 3, 5 and 10 






FIGURE 4.3 – Kaplan-Meier survival curves for each group of patients, after exclusion of in-
hospital deaths (black line: non-MODS group, n = 455 – red line: MODS group, n = 203), 
representing percentage of surviving patients per time in years. A clear, moderately increasing 
difference in survival is observed between the two groups. Vertical tick-marks represent right-
censored cases. Survival curves have been truncated when the number of patients at risk 




Univariate Analyses Multivariate Analysis 
Crude HR 95% C.I. P-value Adjusted HR 95% C.I. P-value 
MODS   
Yes 1.661 1.232-2.240 0.001 1.528 1.072-2.176 0.019 
Gender   
Male 1.181 0.879-1.585 0.269 1.302 0.946-1.793 0.106 
Age 1.050 1.040-1.061 <0.001 1.062 1.049-1.075 <0.001 
Severity   
Severe 1.862 1.387-2.499 <0.001 0.850 0.587-1.231 0.390 
Cause   
Gallstones 1   1   
Alcohol 0.927 0.662-1.296 0.656 2.027 1.359-3.024 0.001 
Idiopathic 1.350 0.878-2.076 0.171 1.548 1.004-2.387 0.048 
Other 0.788 0.365-1.701 0.544 1.488 0.679-3.263 0.321 
 





of AP. Findings of the available long-term studies in AP, have been equivocal 
in associating multiple organ failure or various surrogate markers of organ 
dysfunction with long-term survival. Lund et al, found that an increased 
Ranson’s score and prolonged length of stay in ITU were associated with an 
increased long-term incidence of mortality in univariate, but not multivariate 
analyses (Lund et al., 2006). Conversely, Halonen et al reported that a smaller 
proportion of late-death patients had suffered multiple organ failure than had 
long-term survivors (Halonen et al., 2003). There was no statistical analysis 
supporting this finding as the study had different objectives pertaining to quality 
of life outcomes, but this surprising result is difficult to rationalise. However, 
median follow-up in this study was limited to 61 months, the rate of capture 
rate of events (deaths) was low, and the number of participants relatively small 
(Halonen et al., 2003). Furthermore, acute organ dysfunction has been shown 
to be associated with reduced life expectancy amongst survivors of critical 
illness compared with matched controls in a number of other conditions (Ulvik 
et al., 2007; Wright et al., 2003). 
In addition to early organ dysfunction, increasing age was found to be 
an independent predictor of reduced survival. It is important not to dismiss this 
finding as obvious, albeit expected, because this observation refers to more 
than just the fact that older people die sooner, from all causes. Although age 
has been established as an independent predictor in the present and previous 
studies, (Dragsted, 1991; Niskanen et al., 1996; Thoner, 1987) it has been 
suggested that poorer outcomes in elderly patients may reflect residual 
functional disability and dysfunction of organ systems caused by critical illness 
(Ridley et al., 1990). This may be supported by the findings of Lankisch et al 
who reported that the most common causes of death were cardiovascular and 
cerebrovascular diseases (Lankisch et al., 2009). This finding was echoed by 
Nøjgaard et al. with reference to cardiovascular disease (Nøjgaard et al., 
2011).  
The exact pathophysiological mechanisms and long-term confounding 
effects that predispose to reduced long-term survival in survivors of critical 
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illness are yet unknown and deserve further investigation in AP and in general 
(Skouras et al., 2014). One of the proposed processes implicated in the 
reduction of life expectancy after an episode of critical illness is accelerated 
telomere shortening (Blasco, 2005). A potential decrease in telomerase activity 
levels is accompanied by shorter telomeres, premature loss of fitness and 
decreased lifespan. In addition, many other proteins that are important in 
regulating telomere length and function may also have an important role as 
they can regulate the action of telomerase at telomeres (Blasco, 2005). 
Telomere shortening may lead to premature senescence and has been 
implicated in numerous metabolic and inflammatory diseases, where external 
factors that promote telomere attrition – such as inflammatory and oxidative 
stress – play a key role (Kong et al., 2013). In the future, the aforementioned 
hypothesis warrants validation in the context of AP and critical illness. 
With regard to AP-specific long-term sequelae, progression to chronic 
pancreatitis can predispose to reduced life expectancy of hospital survivors. In 
the study of Nøjgaard et al, patients who developed chronic pancreatitis 
carried 2.7 times higher long-term mortality compared to those who did not, 
and up to 6.5 times higher long-term mortality compared to the general 
population (Nojgaard et al., 2011). Furthermore, the incidence of chronic 
pancreatitis is higher following episodes of severe AP and it is more common 
when alcohol is the cause (Ammann and Muellhaupt, 1994). The resultant 
development of endocrine (type 3c diabetes mellitus) or exocrine insufficiency 
(maldigestion and malabsorption), as well as the associated predisposition to 
cardiovascular, infectious and malignant complications constitute additional 
long-term risk factors (Gudipaty and Rickels, 2015; Spanier et al., 2008). 
It is known that the aetiology of AP can influence morbidity of hospital 
survivors, but the influence of aetiology on long-term mortality has been less 
well researched. Nøjgaard et al reported a significantly higher rate of long-term 
mortality in patients with AP related to high alcohol consumption (Nøjgaard et 
al., 2011), in keeping with the results of the present study. Compared to biliary 
AP, alcohol seems to have additional deleterious effects by precipitating 
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exocrine insufficiency and morphologic changes to the pancreas (Lankisch et 
al., 2009), thus it may be unsurprising that patients with alcohol-related AP 
have a shorter life expectancy than that reported for gallstone AP. 
The longitudinal design of the present study, its long follow-up period 
with a median of approximately 9 years, and the fact that it was conducted in 
a single centre by including consecutive AP patients regardless of disease 
severity are amongst its strengths. Potential weaknesses include the 
retrospective design, although a prospective long-term survival study of this 
duration would be a major undertaking. Secondly, there is little information 
regarding the mode of death or any subsequent co-morbidities of survivors, 
which would certainly merit further investigation. Furthermore, it was not 
feasible to retrieve and include in the analysis data on the comorbid status of 
the presented cohort. It is therefore possible, and indeed one might argue 
reasonable, that patients with comorbidities may have been at higher risk of 
organ dysfunction during AP, which as a consequence resulted in shorter 
survival. Future studies would benefit from including details on important 
confounders such as detailed patient co-morbid status, presence of pancreatic 
necrosis, incidence of pancreatic insufficiency and other long-term sequelae, 
as well as specific duration and severity of organ system dysfunction. Lastly, 
the duration of follow-up for survivors was determined by the date of last known 
contact (GP or hospital visit) via their electronic records, as detailed in the 
methods section. More accurate information would have been obtained by 
contacting patients directly or via their GPs, with an aim to achieve longer and 
possibly more objective follow-up. 
Notwithstanding these weaknesses, the long-term survival study in AP 
identifies an important negative long-term impact of organ dysfunction in AP, 
which extends beyond the injury seen in the critical care unit during the index 
episode. This work reinforces the importance of early identification, and 




4.6 CONCLUSIONS OF CHAPTER 
 
Early organ dysfunction in AP is associated with a shortened lifespan. 
It is hypothesised that patients who sustain organ dysfunction during their 
index episode, and who survive, accrue systemic changes which impact 
negatively on life expectancy in comparison to hospital survivors without organ 
dysfunction. In AP, the effects of critical illness do not cease after the initial 
insult has subsided. This study reinforces the cardinal need to identify and pre-
empt organ dysfunction, and introduces a need to consider interventions that 



























5.1 PHARMACOLOGICAL THERAPY IN ACUTE 
PANCREATITIS 
 
Until now, a great part of research in pancreatitis has focused on 
improving accuracy and timeliness of identification of severe disease. Despite 
extensive efforts for the last several years, a reliable method to predict AP 
severity with high accuracy is not yet available. This fact may indicate a need 
to shift focus from improving prediction of severity, towards discovering novel 
methods to halt progression to organ dysfunction. 
The onset of AP-MODS is an early event during the course of AP which 
may evolve within hours from the onset of symptoms (Mole et al., 2016a). As 
a consequence of this, and based on my work in the present thesis, I propose 
that future trials and clinical studies in AP should aim to examine the effects of 
treatment administered as soon as possible after symptom onset, aiming to 
maximize the potential of any novel agent to interrupt the inflammatory 
cascade (Park, 2015). Although the goal would be to investigate any reduction 
of incidence and severity of AP-MODS which occurs only in a subset of 
patients with AP, it is possible that the way forward may be to recruit and treat 
‘all-comers’ immediately after presentation to hospital, irrespective of AP 
severity and aetiology, in an effort to address the lack of a robust and highly 
accurate predictive system. In order to support this concept, the candidate 
drug should be safe, cheap and easily administered. 
In recent years, advances in the understanding of basic science and 
pathophysiology of AP have led to the development of novel pharmacological 
agents. Although encouraging findings are available for some drug targets, the 
vast majority of the proposed novel drugs have failed to demonstrate 
consistent benefits in large validation studies (Park, 2015). Due to this lack of 
firm evidence, no therapeutic agent is yet recognised for the treatment of AP 
in clinical practice (Bi and Vege, 2015). Discrepancy exists between findings 
from animal studies and human clinical trials, a fact which can in part be 
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attributed to methodological flaws in human clinical study design. This makes 
the highly accurate and robust, unbiased approach that I have taken in this 
thesis all the more translationally relevant. 
The role of the kynurenine pathway of TRP metabolism as a key 
contributory mechanism of remote organ injury in AP has recently been shown 
in the preclinical rodent study by Mole et al (Mole et al., 2016b). Furthermore, 
KMO was found to be susceptible to therapeutic blockade, and KMO inhibition 
was shown to protect against extrapancreatic organ injury, irrespective of the 
gravity of the initiating pancreatic tissue injury, findings that strongly support a 
potential therapeutic role for KMO inhibitors in human AP (Mole et al., 2016b). 
The next logical step would be to evaluate the efficacy of KMO inhibition in 
human AP, and the novel data arising from IMOFAP constitute an invaluable 
resource for the design and execution of such studies. Currently, our group is 
working on the development of KMO inhibitors and candidate drugs are 
already being progressed into clinical research. 
Despite past shortcomings, there remains promise in the discovery of 
an effective pharmacological therapy for AP. Better designed RCTs – based 
on lessons learned from the past – along with recent knowledge advances will 
open the way for such a discovery which may fundamentally change the 
current approach of supportive management to one of directed therapy. 
 
5.2 LESSONS IN THE DESIGN OF CLINICAL STUDIES 
IN ACUTE PANCREATITIS 
 
It is well established that the factors and underlying mechanisms that 
contribute or predispose to organ dysfunction during an episode of AP are 
complex; hence, accurate early prediction of AP severity is challenging. Apart 
from its significance in clinical practice, this fact has had considerable 
implications for clinical research in AP thus far. Several previous clinical 
studies investigating management strategies in AP have been deemed 
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suboptimal due to poorly standardized patient classification, or due to the fact 
that only few participants went on to develop severe disease or the 
complication of interest, contrary to prognoses, while in others, patients were 
recruited late in the course of AP (Ebbehoj et al., 1985; Eckerwall et al., 2006; 
Isenmann et al., 2004; Johnson et al., 2001). Consequently, many previous 
drug studies in AP were not adequately powered, a fact which may have led 
to inappropriate conclusions and the dismissal of potentially beneficial 
treatment strategies (De Waele, 2007). 
Disease trajectories clearly indicate that AP evolves extremely rapidly, 
and this can be additionally supported by studies on early and pre-hospital 
mortality by our group and others (Andersson et al., 2004; Andersson and 
Andren-Sandberg, 2003; Johnson and Abu-Hilal, 2004; McKay et al., 1999; 
Mole et al., 2016a). Based on the nature and rapidity of AP evolution, a 
rationale for prompt patient enrolment in clinical research can be supported. 
Findings from the IMOFAP study presented herein, reinforce the argument for 
expedited recruitment, which should be aimed at the time of patient 
presentation to the ED. Notably, most interventions designed to inhibit the 
mechanisms implicated in the genesis of organ dysfunction may work better if 
administered at an early stage, with an aim to prevent progression to organ 
dysfunction rather than to reverse established failure (Park, 2015). Thus, 
intervention at this early pathophysiological stage of the disease process will 
be critical. 
Furthermore, a rapid approach allows for timely enrolment of patients 
presenting to hospital with already established organ dysfunction, who 
constitute a substantial proportion of the AP population, that cannot afford to 
be missed from any clinical study or trial. In addition, expedited recruitment 
offers the potential to minimize participant selection bias and recruitment 
discrepancies. Nevertheless, subjectivity in severity stratification of 
participants remains an issue, which can be minimized by adopting universally 
accepted guidelines. To this aim, the revised Atlanta classification (Banks et 
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al., 2013), although imperfect, is a valuable tool that provides a simple, 
objective and replicable approach. 
As shown by the findings of IMOFAP, expedited recruitment in AP 
studies is realistic and feasible, but is associated with additional challenges, 
that would not be present in routine clinical research. Our endeavour was 
expected to be resource intensive on many levels. Firstly, a full roster – 
consisting of more than 30 dedicated research nurses and support staff – was 
required to succeed in minimizing the time interval between patient 
presentation to hospital and recruitment. To this effect, a recruitment rota was 
formulated with an aim to screen patients, recruit participants, and obtain 
samples around the clock for 90 days. Furthermore, recruiting patients from 
the ED and critical care, as well as out-of-hours recruitment, is associated with 
considerably more challenges than usual elective participant enrolment in an 
outpatient or ward setting, and as such necessitates appropriate training of the 
research staff. For example, special ‘lone working’ training sessions were 
required for all research nurses participating in the IMOFAP study, and two 
preparatory lectures were held, apart from providing all the necessary 
paperwork and associated preparatory material. Arrangements for appropriate 
supervision and coordination of research staff were also made, particularly 
during out-of-hours recruitment, and the author acted as the point of contact to 
provide support when necessary. 
Moreover, expedited recruitment requires appropriate infrastructure; 
sampling and sample handling equipment, centrifuges and processing 
equipment, freezers and storage facilities, should be available in close 
proximity and easily accessible at any time from the ED  and critical care. 
Importantly, data collection in this acute setting poses another significant 
challenge, as data input may need to be performed ad-hoc at the bedside, 
either in the ED, critical care or the ward, without the luxury of time, particularly 
when time-point sampling is expected. For this reason, a bespoke data 
collection software application was built for IMOFAP, and it is recommended 
that this approach is considered in future studies. 
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Next, a close collaboration between research and clinical teams is 
particularly important. Although clinical care always comes first, it is imperative 
that clinical departments are research-aware to facilitate the actions of 
research staff without compromising the provision of clinical care. Apart from 
obtaining appropriate permissions from all senior clinical staff of the 
departments involved, as well as the medical director, much can be done by 
the investigator and research staff during an acute AP study to cultivate a good 
spirit of collaboration. Open discussion boards can be held prior to the 
commencement of the study thus providing an opportunity to clinical team 
members to ask questions, raise concerns and/or make practical suggestions.  
Information sheets can be distributed to ED and critical care staff, posters can 
be appended to key clinical areas, and frequent updates of the recruitment 
phase progress can be provided by means of email newsletters. It is also 
considered important to provide regular feedback during the course of the 
recruitment. These measures are particularly useful in busy centres which 
have the potential to offer a greater volume of participants, but have a heavy 
workload, with involvement of multiple teams and healthcare professionals. 
Importantly, to achieve an expedited recruitment with a short time 
interval from presentation, the means for identification of potential participants 
should be disconnected from the duties of associated clinical teams, otherwise 
considerable delays may be caused in recruitment. Therefore, we devised a 
strategy of participant identification, which would be rapid, objective and 
automated. In IMOFAP, the biochemistry laboratory staff was trusted with this 
duty, alerting researchers for any new finding of elevate serum amylase, with 
an acceptable ratio of missed potential participants, rapid identification, and 
relative protection from selection bias. The choice of serum amylase as the 
identifying parameter appears to be the most attractive approach due to its 
widespread availability, low cost, and high diagnostic value. 
Lastly, the fact that a significant proportion of patients with severe AP 
often lie in the spectrum of incapacity due to their critical illness, should alert 
research teams to prepare for recruiting patients with incapacity. This would 
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require appropriate ethical approval, information and consent form authoring, 
as well as staff training in this field. Ultimately, there is an argument about 
approaching acute clinical research in AP similar to research in other hyper-
acute clinical conditions, such as stroke, trauma, or cardiac arrest, where rapid 
enrolment and sample acquisition is crucial and may necessitate a waiver of 
informed consent (Luce, 2003). As this remains a matter of debate, the 
currently established ethical principles should be adhered to, but further 
discussion is deemed necessary. 
 
5.3 ACUTE PANCREATITIS IN CLINICAL RESEARCH 
OF INFLAMMATORY DISEASES 
 
Systemic inflammation is almost invariably present in critical illness, 
regardless of the underlying cause (Wunsch et al., 2011). It is induced by 
infectious and non-infectious insults and is characterized by dysregulation of 
the innate immune system and overproduction of pro-inflammatory cytokines 
(Duffin et al., 2016). The complications that develop in the majority of critically 
ill patients are uniform, and existing evidence suggests that the activation of 
the pro-inflammatory cascade follows common routes (Wilson et al., 1998), 
while the inflammatory reaction is driven by common mediators and shared 
signalling pathways (Dulhunty et al., 2008; Fullerton et al., 2014; Xu et al., 
2009; Zhang et al., 2010). Despite copious research on this field, our 
understanding of the precise underlying mechanisms remains incomplete 
(Duffin et al., 2016). 
AP constitutes a sterile initiator of systemic inflammation that may result 
in multiple organ dysfunction, and although it is not yet fully understood how 
the initial insult to the pancreas escalates to systemic response, AP can be 
used as a clinical research model on inflammatory conditions. Patients with AP 
offer certain advantages over other patient groups on the study of SIRS and 
related conditions (Wilson et al., 1998). Firstly, SIRS is common in AP and is 
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frequently severe enough to precipitate organ failure (Winslet et al., 1992). In 
addition, a lot more is already known about the inflammatory cascade in AP, 
in comparison to existing knowledge for other inflammatory conditions. 
Conversely, many challenges may be associated with other conditions that 
result in systemic inflammation, such as sepsis, as patients of this group are 
often suffering from widely disparate pathology and severity can be even more 
difficult to be defined at presentation (Wilson et al., 1998). 
In the foreseeable future, the application of clinical data from AP 
patients in the study of inflammation is expected to increase and play an 
important role. As an example, interleukin 22 data from participants of the 
IMOFAP study were used in the study by Duffin et al (Duffin et al., 2016), 
exploring the mechanistic involvement of prostaglandin E2 in the suppression 
of systemic inflammation. 
 
5.4 LUNG ULTRASONOGRAPHY IN ACUTE 
PANCREATITIS 
 
Current composite severity scores appear to have reached their 
maximum efficacy, therefore novel approaches need to be introduced to 
expedite and further improve accuracy of disease severity stratification. The 
respiratory system is the organ system that most commonly fails in severe AP, 
secondary to accumulation of fluid between the alveolar membrane and the 
pulmonary capillaries, leading to reduced gas exchange and low partial arterial 
pressure of oxygen (Johnson, 2015). Hence, lung ultrasonography constitutes 
an attractive field of research in AP, since its application in monitoring critically 
ill patients is increasing. As shown in the pilot study presented in Chapter 3, 
LUSS can reliably detect evolving respiratory dysfunction in AP, and deserves 
further validation in a larger cohort. 
LUSS has specific limitations. It provides less information than CT; 
visualisation of lung parenchyma may be difficult in obesity, and adequate 
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interpretation of sonographic findings requires formal training and related 
experience. However, it does not involve radiation exposure, intravenous 
contrast administration is not required, it does not require patient transportation 
from ITU (which in the case of patients with respiratory failure can be 
challenging), it is less costly, easily repeatable, and can be performed rapidly 
(Lichtenstein et al., 2004). Furthermore, the operator learning curve is 
estimated to be less than six weeks (Bouhemad et al., 2007). The hope is that 
this technique will progress further to a rapid, easily applicable test for patients 
at risk of developing AP-MODS, and may evolve into an important component 
of severity prediction in the future. Validation of this method in larger AP 
studies is deemed necessary (Skouras et al., 2016a). 
 
5.5 SHIFTING THE RATIONALE OF ACUTE 
PANCREATITIS MANAGEMENT 
 
Long-term survival following critical illness is reduced when compared 
to age- and gender-matched general populations (Williams et al., 2008). The 
finding that life expectancy of survivors may be substantially reduced after an 
episode of AP associated with early organ dysfunction constitutes a novel and 
significant reason for supporting change in the rationale of AP management. 
Based on these data, the existing follow-up policy for severe AP survivors may 
require to be re-examined, and long-term follow-up may be deemed 
appropriate for high risk patient subgroups. Additionally, survival until 
discharge should no longer be considered a complete success, as functional 
recovery and quality of life are increasingly becoming important patient-
centred goals (Williams and Leslie, 2011). Therefore, care should focus not 
only on the management of established organ failure and the prevention of its 
deterioration, but should also aim to maximise quality of survival and post-
discharge function of critically ill AP patients.  
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The InS:PIRE scheme (Intensive care Syndrome: Promoting 
Independence and Return to Employment), led by the NHS Greater Glasgow 
and Clyde Health Board in partnership with the University of Glasgow 
constitutes a paradigm of change in the post-discharge management of 
critically ill patients (Quasim and McPeake, 2016). This five-week peer-
supported programme focuses on patient education and aims to facilitate and 
empower patients and relatives to improve their health and well-being following 
discharge from ITU. It entails interventions from a multidisciplinary team, 
including weekly physiotherapy sessions and individualised sessions with 
healthcare professionals, such as pharmacists, psychologists, and dieticians, 
amongst others. The preliminary effects of InS:PIRE are encouraging, and the 
scheme is being expanded to five further centres across four Health Boards in 
Scotland(Quasim and McPeake, 2016). Similar schemes have been adopted 
elsewhere (Lasiter et al., 2016; Modrykamien, 2012; Wood, 2015). 
Nevertheless, despite the increasing acknowledgement that follow-up 
of survivors of critical illness is important, the ideal follow-up scheme has yet 
to be established (Williams and Leslie, 2011), and this field warrants 
investigation in future AP studies (Lasiter et al., 2016). Importantly, these 
findings offer further justification for the need to shift the focus of AP research 
towards prevention of organ dysfunction, in those patients where the 




In human AP, plasma concentrations of kynurenine metabolites are 
altered proportionately to disease severity. Transthoracic ultrasonography 
shows promise in the detection of respiratory dysfunction in AP-MODS. Lastly, 
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Abstract
Background: The effect of early organ dysfunction on long-term survival in acute pancreatitis (AP)
patients is unknown.
Objective: The aim of this study was to ascertain whether early organ dysfunction impacts on long-term
survival after an episode of AP.
Methods: A retrospective analysis was performed using survival data sourced from a prospectively
maintained database of patients with AP admitted to the Royal Infirmary of Edinburgh during a 5-year
period commencing January 2000. A multiple organ dysfunction syndrome (MODS) score of ≥ 2 during
the first week of admission was used to define early organ dysfunction. After accounting for in-hospital
deaths, long-term survival probabilities were estimated using the Kaplan–Meier test. The prognostic
significance of patient characteristics was assessed by univariate and multivariate analyses using Cox's
proportional hazards methods.
Results: A total of 694 patients were studied (median follow-up: 8.8 years). Patients with early organ
dysfunction (MODS group) were found to have died prematurely [mean survival: 10.0 years, 95%
confidence interval (CI) 9.4–10.6 years] in comparison with the non-MODS group (mean survival: 11.6
years, 95% CI 11.2–11.9 years) (log-rank test, P = 0.001) after the exclusion of in-hospital deaths.
Multivariate analysis confirmed MODS as an independent predictor of long-term survival [hazard ratio
(HR): 1.528, 95% CI 1.72–2.176; P = 0.019] along with age (HR: 1.062; P < 0.001), alcohol-related
aetiology (HR: 2.027; P = 0.001) and idiopathic aetiology (HR: 1.548; P = 0.048).
Conclusions: Early organ dysfunction in AP is an independent predictor of long-term survival even when
in-hospital deaths are accounted for. Negative predictors also include age, and idiopathic and alcohol-
related aetiologies.
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Introduction
Acute pancreatitis (AP) is a common disease characterized by
acute inflammation of the pancreas, usually triggered by the
passage of gallstones or excessive alcohol consumption.1,2 Usually
an episode of AP will resolve with supportive measures, but the
disease may also be fatal and results in reported mortality of 6–9%
in the UK.3–6
Many systems have been devised to stratify the subgroup of
patients who present with, or are predicted to develop, the severe
form of AP, but these systems focus on the severity of the index
episode. According to the widely accepted and updated definition
of severe acute pancreatitis (SAP),7 which incorporates evidence
of persistent organ failure, approximately one in four patients
with AP will experience a severe episode.5,8,9 Unsurprisingly, mor-
tality rates in SAP are considerably higher than in mild disease and
range from 14% to 30%.5,10,11 It is well established that the major-
ity of deaths occur early in the disease course; up to 60% of all AP
deaths occur during the first 7 days of hospital admission and are
mostly attributable to deteriorating organ function.3,4,6,12–14 It is
DOI:10.1111/hpb.12259 HPB






understandable, therefore, that clinical research in AP to date has
largely focused on improving early outcomes; relatively little is
known about late deaths amongst hospital survivors.
Few contemporary studies have investigated long-term survival
and the relevant prognostic factors in AP.15,16 Long-term studies
have for the most part examined morbidity outcomes, such as
progression to chronic pancreatitis, or have focused upon a severe
pancreatitis subgroup. Those that do report survival suggest that
SAP hospital survivors may carry a reduced life expectancy.17 After
the exclusion of inpatient mortality, death rates amongst AP
patients are reported to be in the order of one death in every four
to eight cases, over 5–8 years.17,18 Late deaths seem to be most
commonly attributed to cardiovascular disease or malignancy,15,16
but the factors that reduce long-term survival are likely to be
complex.
The aim of this study was to determine whether early acute
organ dysfunction is associated with altered long-term survival in
hospital survivors of AP.
Materials and methods
Study approval
Caldicott Guardian approval was obtained to allow the use of
confidential patient data. The study was assessed by the University
of Edinburgh/National Health Service (NHS) Lothian ACCORD
Research and Development Office and the South East Scotland
Research Ethics Service and was declared exempt from require-
ments for formal research ethics committee review as a clinical
audit.
Data collection and inclusion criteria
In 2013, a retrospective analysis was performed using long-term
survival data sourced from a prospectively maintained database of
patients with AP admitted to the Royal Infirmary of Edinburgh
during the 5-year period between January 2000 and December
2004. This historical cohort was originally identified from the
Lothian Surgical Audit database,19 and its clinical details and
immediate outcomes have been previously reported.20 For this
cohort, existing data on age, gender, organ dysfunction, aetiology
of pancreatitis, necrosectomy and disease severity were sup-
plemented with survival data. Patients for whom data on these
characteristics were unavailable were excluded from subsequent
analysis. For those patients with recurrent attacks of AP, the ear-
liest episode during the study period was taken as the index
episode for the purposes of survival analysis.
Patient inclusion in the original patient cohort was based on the
presence of clinical features compatible with AP, supported by
the finding of elevated serum amylase (three times higher than the
upper limit of the laboratory reference range). In instances in
which a strong clinical suspicion of AP in the context of a non-
diagnostic amylase result existed, radiological evidence of AP by
means of computed tomography or the finding of pancreatitis at
laparotomy was required for inclusion. Patients admitted with
chronic pancreatitis were excluded.
Definitions: severity, aetiology and organ dysfunction
Severity stratification was performed in accordance with the origi-
nal version of the Atlanta consensus definition,21 which was the
classification system in use at the time when patients in the study
cohort presented with AP. Patients were not retrospectively reclas-
sified according to the revised 2012 Atlanta criteria7 in order to
avoid introducing error. Patients with an admission APACHE II
(Acute Physiology and Chronic Health Evaluation) score of ≥ 8
were classified as predicted severe.
Gallstones were considered to be the precipitating cause of pan-
creatitis when gallbladder or bile duct calculi were detected by any
imaging procedure. In the absence of gallstones and when exces-
sive consumption of alcohol was reported by the patient or the
patient’s family, the pancreatitis was classified as alcohol-induced.
When no definite cause was identified, the disease was character-
ized as idiopathic. Rarer established causes were collated under the
category ‘other’.
Organ dysfunction scores were calculated for all patients at
24 h, 48 h and 7 days, based on the most extreme laboratory
values or clinical measurements during each 24-h period, for five
(respiratory, cardiovascular, renal, haematological, central
nervous system) of six organ systems that constitute the multiple
organ dysfunction score (MODS).22 Hepatic dysfunction (serum
bilirubin) was excluded in order to avoid the confounding effects
of biliary obstruction. A MODS score of ≥ 2 (based on dysfunc-
tion of a single or more than one organ system) at one or more
time-points was considered to define organ dysfunction. The
duration and persistence of organ dysfunction could not be retro-
spectively ascertained from the existing database; attempts to
retrieve archived primary records to gather these data were not
successful.
Follow-up and mortality
In-hospital mortality, overall mortality and long-term survival
were the main outcome measures of the present study. NHS
Lothian electronic patient records were individually reviewed; for
surviving patients, the date of the most recent general practitioner
and/or hospital visit, outpatient clinic attendance or hospital dis-
charge were defined as the point of last known contact. Dates of
death were retrieved and recorded for non-survivors.
Statistical analysis
Data for continuous variables are presented as the mean ± stand-
ard deviation (SD) or as the median and interquartile range
(IQR). Categorical variables are presented as absolute and relative
frequencies. Comparisons between groups were performed using
Student’s t-test, the Mann–Whitney U-test, the Kolmogorov–
Smirnov test and the chi-squared test, as appropriate.
The Kaplan–Meier method was used to estimate survival prob-
abilities. The generalized Wilcoxon test was used to detect early
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death rate differences between groups and the log-rank test was
applied to detect differences manifesting throughout the entire
follow-up period. Survival times were calculated from the date of
admission to the date of death from any cause or date of last
contact in survivors. Patients lost from follow-up were censored at
the date of confirmed last contact. The prognostic impact of
patient characteristics on survival was assessed by univariate and
multivariate Cox’s proportional hazards regression. For univariate
analyses, the proportional hazards assumption was examined
graphically with the use of pairwise Cox log(-log) plots, revealing
approximately parallel curves between groups for each of the cat-
egorical covariates MODS, gender, severity and aetiology. Linear
regression was implemented to test for goodness-of-fit of
Schoenfeld partial residuals23 against natural logarithmic survival
times for each of the aforementioned covariates; no violation of
the proportional hazards assumption was revealed. The linearity
assumption for age was confirmed graphically by examining the
respective Cox log(-log) plots, after transformation to a categori-
cal variable with six strata. Similar procedures were used for mul-
tivariate analyses.
Selection of variables for the multivariate Cox regression model
was performed in accordance with the ‘purposeful selection’ algo-
rithm,24,25 originally described by Hosmer and Lemeshow.26 Vari-
ables with a univariate P-value of > 0.25 were originally selected as
candidates for multivariate analysis. Covariates were subsequently
removed from the model if they were found to be non-significant
at the α = 0.1 level and not to be confounders. Confounding was
defined as a change of > 15% in any of the remaining covariate
estimates. Variables that were not selected for the original model
were returned one at a time, and any that were significant at the
α = 0.15 level were retained.24 This procedure resulted in a multi-
variate model containing age, MODS, gender, severity and aetiol-
ogy. The necrosectomy variable did not satisfy the proportional
hazards assumption and was examined with the use of stratified
Cox regression.
Results of the Cox models are presented as hazard ratios (HRs)
with 95% confidence intervals (95% CIs) together with the
P-values from Wald’s tests. All statistical tests were based on a
two-sided α-value of 0.05. Statistical analysis was performed using
IBM spss Statistics Version 19.0 (IBM Corp., Armonk, NY, USA).
Figures were designed using GraphPad Prism Version 6.0
(GraphPad Software, Inc., La Jolla, CA, USA). This double-arm
cohort study followed the principles of the STROBE (strengthen-




Unique patient identifiers with corresponding survival data and
variables of interest were available for 694 of 759 (91.4%) AP
patients in the database and were included in the present study.
With regard to classification of disease severity according to
APACHE II scores, 256 (36.9%) patients were predicted to have a
severe attack, although ultimately 268 (38.6%) suffered from
some degree of organ dysfunction during the first week of admis-
sion. A total of 235 (33.9%) patients had a MODS score of ≥ 2 at
one or more time-points during the first week of their hospital
stay and were classified as having organ dysfunction (denoted as
the ‘MODS group’). Sixty-nine (9.9%) patients underwent one or
more necrosectomy procedures during the study interval. These
were performed predominantly as open procedures because mini-
mally invasive retroperitoneal pancreatic (MIRP) necrosectomy
was not routinely performed in the department during the study
period. Patients’ demographic characteristics are summarized in
Table 1.
Study follow-up
The median follow-up in the whole patient series was 8.8 years.
After excluding in-hospital deaths, median follow-up was 9.0
years. This period was marginally comparable between the MODS
group (8.7 years, IQR: 4.7–10.5 years) and non-MODS group (9.1
years, IQR: 6.6–10.6 years) after the exclusion of in-hospital
deaths (Mann–Whitney U-test, P = 0.046; Kolmogorov–Smirnov
test, P = 0.105).
Overall survival
There were 36 (5.2%) in-hospital deaths in total, 35 of which
occurred during the first 2.2 months. During the follow-up
period, 179 patients died, giving an overall mortality rate of 31.0%
(215 of 694 patients). Median survival in the overall patient
sample remained undefined because more than 50% of patients
were still alive at the end of follow-up. The overall mean survival
was 10.6 years (95% CI 10.2–10.9 years); after the exclusion of
in-hospital deaths this increased to 11.1 years (95% CI 10.8–11.5
years).
Organ failure and survival
Analysis of the overall patient sample demonstrated a clear
difference in survival between the MODS and non-MODS
groups (Fig. 1). Mean survival in the MODS group (8.6 years,
95% CI 7.9–9.3 years) was significantly lower than that in the
non-MODS group (11.5 years, 95% CI 11.1–11.9 years)
(Wilcoxon test, P < 0.001; log-rank test, P < 0.001). The highest
frequency of death occurred during the in-hospital period; the
majority of these patients had a MODS score of ≥ 2. Four
(11.1%) of the 36 patients who died as inpatients had a MODS
score of < 2.
To investigate long-term mortality, inpatient deaths were
removed from the analysis. Interestingly and importantly, with
this exclusion, mean survival in MODS group hospital survivors
(10.0 years, 95% CI 9.4–10.6 years) remained significantly lower
than that in non-MODS group hospital survivors (11.6 years, 95%
CI 11.2–11.9 years) (Wilcoxon test, P = 0.002; log-rank test,
P = 0.001). Furthermore, the survival curves continued to diverge
several years after the index episode of AP (Fig. 2). Again, median
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survival was not defined; however the 75th percentiles of survival
were 6.5 years and 9.9 years in the MODS and non-MODS groups,
respectively. Survival rates in each group at 1, 3, 5 and 10 years are
shown in Table 2.
To account for the difference in mean ± SD age between the
MODS (59.9 ± 17.1 years) and non-MODS (54.3 ± 17.9 years)
groups (P < 0.001), and because other AP characteristics may
impact on long-term survival, a multivariate analysis was per-
Table 1 Demographic characteristics of patients with acute pancreatitis





Sample size, n (%) 694 (100%) 455 (69.1%) 203 (30.9%) 36 (5.2%) 479 (72.8%) 179 (27.2%)
Age, years, median (IQR) 57.1 (43.2–71.2) 54.3 (40.3–69.3) 59.9 (47.7–74.0) 70.9 (79.9–57.4) 52.1 (39.0–65.0) 66.7 (79.5–54.2)
Gender, n (%)
Male 355 (51.2%) 228 (50.1%) 106 (52.2%) 21 (58.3%) 236 (49.3%) 98 (54.7%)
Female 339 (48.8%) 227 (49.9%) 97 (47.8%) 15 (41.7%) 243 (50.7%) 81 (45.3%)
Aetiology of pancreatitis, n (%)
Gallstones 337 (48.6%) 223 (49.0%) 104 (51.2%) 10 (27.8%) 237 (49.5%) 90 (50.3%)
Alcohol 223 (32.1%) 159 (34.9%) 54 (26.6%) 10 (27.8%) 158 (33.0%) 55 (30.7%)
Idiopathic 92 (13.3%) 54 (11.9%) 27 (13.3%) 11 (30.6%) 54(11.3%) 27 (15.1%)
Other 42 (6.1%) 19 (4.2%) 18 (8.9%) 5 (13.9%) 30 (6.3%) 7 (3.9%)
Severity, n (%)
Mild 438 (63.1%) 380 (83.5%) 56 (27.6%) 2 (5.6%) 338 (70.6%) 98 (54.7%)
Severe 256 (36.9%) 75 (16.5%) 147 (72.4%) 34 (94.4%) 141 (29.4%) 81 (45.3%)
Necrosectomy, n (%) 69 (9.9%) 17 (3.7%) 42 (20.7%) 10 (27.8%) 43 (9.0%) 16 (8.9%)
In-hospital deaths, n (%) 36 (5.2%) N/A N/A N/A N/A N/A
Post-discharge deaths, n (%) 179 (25.8%) 107 (59.8%) 72 (40.2%) N/A N/A 179 (100%)
MODS, n (%) 235 (33.9%) N/A N/A 32 (88.9%) 131 (27.3%) 72 (40.2%)
aAfter exclusion of in-hospital deaths.
MODS, multiple organ dysfunction syndrome; IQR, interquartile range; N/A, not available.
Figure 1 Kaplan–Meier survival plot by group of patients (non-MODS group, n = 459; MODS group, n = 235), representing cumulative
percentages of surviving patients by time in years. A distinct, steep decrease is evident on the MODS curve during the first months of the
study, corresponding to in-hospital deaths. A clear difference in survival is observed between the two groups. Vertical tick-marks represent
right-censored patients. MODS, multiple organ dysfunction syndrome
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formed. The MODS score was shown to be an independent pre-
dictor of patient survival, with the MODS group carrying a higher
level of risk for post-discharge death than the non-MODS group
in both univariate and multivariate analyses. Age and cause of
pancreatitis were also established as individual predictors, whereas
severity and gender were identified as confounding factors
(Table 3). When necrosectomy was added by stratification on the
multivariate Cox regression model, a negligible effect was
observed. Specifically, the resulting HR for the MODS group was
1.573 (95% CI 1.102–2.246; P = 0.013).
A supplementary univariate Cox regression analysis was per-
formed in the MODS group alone (after the exclusion of
in-hospital deaths) in order to examine whether the magnitude
of the MODS score (worst MODS score value of days 1, 2 and 7 of
admission) or APACHE II score on the day of admission had any
effect on long-term survival.No significant effects were revealed for
either the MODS score (HR: 0.876, 95% CI 0.748–1.026; P = 0.102)
or APACHE II score (HR: 1.019, 95% CI 0.954–1.088; P = 0.573).
Discussion
This study demonstrates that organ dysfunction has a lasting
negative impact on long-term survival after an attack of AP.
Importantly, this effect is seen after the exclusion of in-hospital
deaths and is independent of age, aetiology and gender. In addi-
tion, age and an alcohol-related or idiopathic aetiology were also
found to negatively influence long-term survival.
The extent to which the consequences of critical illness contrib-
ute to post-discharge mortality is poorly understood,28–31 espe-
cially in AP. No previous study has specifically investigated the
impact of early organ dysfunction as a predictive marker for long-
term mortality. Findings of the available long-term AP studies
have been equivocal in associating multiple organ failure or
various surrogate markers of organ dysfunction with long-term
survival. Lund et al.32 found that an increased Ranson’s score and
length of stay in the intensive care department were associated
with an increased long-term incidence of mortality in univariate
Figure 2 Kaplan–Meier survival plot by group of patients, after the exclusion of in-hospital deaths (non-MODS group, n = 455; MODS group,
n = 203), representing the percentages of surviving patients by time in years. A clear, moderately increasing difference in survival is observed
between the two groups. Vertical tick-marks represent right-censored patients. MODS, multiple organ dysfunction syndrome
Table 2 Number of patients at risk and survival rates for each group at 1, 3, 5 and 10 years of follow-up, after exclusion of in-hospital deaths













1 year 181 0.92 0.02 429 0.97 0.01
3 years 163 0.85 0.03 404 0.91 0.01
5 years 151 0.79 0.03 370 0.86 0.02
10 years 63 0.55 0.04 152 0.72 0.02
MODS, multiple organ dysfunction syndrome.
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but not multivariate analyses. Conversely, Halonen et al.17
reported that a smaller proportion of late-death patients had suf-
fered multiple organ failure than had long-term survivors. There
was no statistical analysis of this frequency as the study had other
objectives pertaining to quality of life outcomes, but this is a
surprising result and is difficult to rationalize. However, median
follow-up in this study was limited to 61 months, the rate of
capture of events (deaths) was subsequently low and the number
of participants relatively small.17 Furthermore, acute organ dys-
function has been shown to be associated with reduced life expec-
tancy amongst survivors of critical illness compared with matched
controls in a number of other conditions.33,34
In addition to early organ dysfunction, increasing age was
observed to be an independent predictor of reduced survival. It is
important not to dismiss this finding as obvious, albeit expected,
because the observation refers to more than just the fact that older
people die sooner from all causes. Although age has been estab-
lished as an independent predictor in the present and previous
studies,35–37 it has been suggested that poorer outcomes in elderly
patients may reflect residual functional disability and dysfunction
of organ systems caused by critical illness.38 This may be sup-
ported by the findings of Lankisch et al., who reported that the
most common causes of death were cardiovascular and cerebro-
vascular diseases.16 This finding was echoed by Nøjgaard et al.
with reference to cardiovascular disease.39 The pathophysiological
mechanisms and exact long-term confounding effects of critical
illness on individual patient subgroups, particularly elderly
patients, deserve further investigation.
It is known that the aetiology of AP can influence morbidity
amongst hospital survivors, but the influence of aetiology on
long-term mortality has been less well researched. Compared with
biliary pancreatitis, alcohol seems to have greater deleterious
effects in AP with regard to exocrine insufficiency and morpho-
logical changes to the pancreas16 and thus it may be unsurprising
that patients with alcohol-related pancreatitis have a life expec-
tancy lower than that reported for gallstone pancreatitis. Nøjgaard
et al.39 reported significantly higher long-term mortality in
patients with AP related to high alcohol consumption, in keeping
with the results of the present study.
The longitudinal design of the present study, its long follow-up
with a median of approximately 9 years, and the fact that it was
conducted in a single centre and included consecutive AP patients
regardless of disease severity or treatment are amongst its
strengths. Potential weaknesses include the study’s retrospective
design, although a prospective long-term survival study of this
duration would be a major undertaking. Secondly, there is little
information regarding the mode of death or any subsequent
comorbidity of survivors. The latter detail would certainly merit
further investigation. Furthermore, it was not feasible to retrieve
and include in the analysis data on the comorbid status of the
present cohort. It is therefore possible, and indeed one might
argue reasonable, that patients with comorbidities may have been
at higher risk for organ dysfunction during AP, which as a conse-
quence resulted in shorter survival. Future studies would benefit
from including details on important confounders such as detailed
patient comorbid status, the presence of pancreatic necrosis,
occurrence of pancreatic insufficiency and other long-term
sequelae, as well as specific organ system dysfunction duration
and severity. Notwithstanding these weaknesses, the present study
identifies an interesting and important long-term negative impact
Table 3 Association of patient characteristics with overall survival, after exclusion of in-hospital deaths
Factors Overall survival
Univariate analyses Multivariate analysis
Crude HR 95% CI P-value Adjusted HR 95% CI P-value
MODS
Yes 1.661 1.232–2.240 0.001 1.528 1.072–2.176 0.019
No 1 1
Gender
Male 1.181 0.879–1.585 0.269 1.302 0.946–1.793 0.106
Female 1 1
Age 1.050 1.040–1.061 < 0.001 1.062 1.049–1.075 < 0.001
Severity




Alcohol 0.927 0.662–1.296 0.656 2.027 1.359–3.024 0.001
Idiopathic 1.350 0.878–2.076 0.171 1.548 1.004–2.387 0.048
Other 0.788 0.365–1.701 0.544 1.488 0.679–3.263 0.321
HR, hazard ratio; 95% CI, 95% confidence interval; MODS, multiple organ dysfunction syndrome.
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of organ dysfunction in AP, which extends beyond the injury seen
in the critical care unit during the index episode. This work
reinforces the importance of the early identification, stratification
and correct management of extrapancreatic organ dysfunction in
AP.
Early organ dysfunction in AP is associated with a shortened
lifespan. It is hypothesized that patients who sustain organ dys-
function during their index episode, and who survive, accrue sys-
temic changes which impact negatively on life expectancy in
comparison with hospital survivors without multiple organ dys-
function. In AP, the effects of critical illness do not cease after the
initial insult has subsided. This study reinforces the cardinal need
to identify and pre-empt organ dysfunction, and introduces the
need to consider interventions that impact on long-term out-
comes in high-risk individuals.
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Lung ultrasonography as a direct measure of evolving
respiratory dysfunction and disease severity in patients
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Abstract
Background: The value of lung ultrasonography in the diagnosis of respiratory dysfunction and severity
stratification in patients with acute pancreatitis (AP) was investigated.
Methods: Over a 3-month period, 41 patients (median age: 59.1 years; 21 males) presenting with a
diagnosis of potential AP were prospectively recruited. Each participant underwent lung ultrasonography
and the number of comet tails was linked with contemporaneous clinical data. Group comparisons, areas
under the curve (AUC) and respective measures of diagnostic accuracy were investigated.
Results: A greater number of comet tails were evident in patients with respiratory dysfunction
(P = 0.021), those with severe disease (P < 0.001) and when contemporaneous and maximum CRP
exceeded 100 mg/L (P = 0.048 and P = 0.003 respectively). Receiver-operator characteristic plot area
under the curve (AUC) was greater when examining upper lung quadrants, using respiratory dysfunction
and AP severity as variables of interest (AUC = 0.783, 95% C.I.: 0.544–0.962, and AUC = 0.996, 95%
C.I.: 0.982–1.000, respectively). Examining all lung quadrants except for the lower lateral resulted in
greater AUCs for contemporaneous and maximum CRP (AUC = 0.708, 95% C.I.: 0.510–0.883, and
AUC = 0.800, 95% C.I.: 0.640–0.929).
Discussion: Ultrasonography of non-dependent lung parenchyma can reliably detect evolving respi-
ratory dysfunction in AP. This simple bedside technique shows promise as an adjunct to severity
stratification.
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Introduction
Acute pancreatitis (AP) complicated by organ dysfunction has a
high mortality, which ranges from 14% to 30%.1–4 Up to 53% of
all deaths occur during the first week of admission, as a result of
progressive organ failure.5,6 Respiratory dysfunction is the most
prevalent and one of the most deleterious systemic manifesta-
tions of severe acute pancreatitis (SAP). Lung injury may be
subclinical, manifest as mild hypoxaemia or, in extreme cases,
severe acute respiratory distress syndrome (ARDS).7–9
Therefore, it is important to identify patients with developing
respiratory dysfunction in order to implement appropriate
monitoring and supportive measures early in the course of the
disease.10
Pulmonary conditions with diffuse involvement of the inter-
stitium and impairment of the alveolo-capillary exchange ca-
pacity can be classified under the term Alveolar-Interstitial
Syndrome (AIS) and are common in the critically ill.11 This
syndrome includes acute pulmonary oedema, ARDS, interstitial
pneumonia, exacerbation of chronic interstitial lung disease, and
other miscellaneous conditions.9,12–14 The use of transthoracic
lung ultrasonography (LUSS) has been proposed as a useful non-*: Denotes joint senior authors.










invasive method for diagnosing AIS in critically ill patients, based
on the detection and quantification of comet-tail artefacts,
generated by the ultrasound beam reverberation.11,12,14 Although
the accuracy of LUSS has been evaluated in generic critical care
populations,15 the specific diagnostic features of lung sonography
in patients with AP have not been examined to date.
The aim of the present study was to investigate the value of
LUSS in the diagnosis of evolving respiratory dysfunction and
severity stratification in patients with AP.
Methods
Study approval
The present study was performed with Research Ethics Com-
mittee approval (REC reference number: 13/SS/0136) and
institutional regulatory approval (ACCORD Project No: 2013/
0098). Written consent was obtained from all participants or in
cases of Adults with Incapacity, the named individual responsible
for their welfare.
Recruitment
Over a three-month period from September 2013 to December
2013, adult patients presenting with potential AP were identified.
The initial screening criterion was a presentation serum amylase
>100 U/L, following which a definite diagnosis of AP, the defi-
nition of organ failure and severity stratification were performed
in accordance with the revised Atlanta guidelines for AP,
published by the Acute Pancreatitis Classification Working
Group in 2013.16 Patient recruitment to this study was by con-
venience, with no conscious or deliberate selection bias. Data
collection was planned in advance and was performed
prospectively.
Transthoracic lung ultrasound scans
All scans were performed by two consultant radiologists (JS,
JTM) and a specialist registrar in radiology (ZAD). Bilateral
intercostal LUSS were performed with participants in the supine
position, after applying acoustic gel on the skin to provide an
airless interface. In order to optimize imaging, the intercostal
spaces were widened by raising each patient’s ipsilateral arm up
to or above the head level during the procedure, and the trans-
ducer was held perpendicular to the skin surface. For the pur-
poses of the study, either a Micromaxx® portable ultrasound
system fitted with a C60/5-2 MHz transducer (SonoSite, Inc.,
WA, USA), an Acuson S2000™ system with a 4C1 transducer
(Siemens Medical Solutions USA, Inc., CA, USA) or an Acuson
Antares™ Premium Edition ultrasound system with a CH4-1
transducer (Siemens Medical Solutions USA, Inc., CA, USA)
was used.
Each hemithorax was divided into anterior and lateral, upper
and lower areas (Fig. 1). For each hemithorax, the anterior area
was delineated between the clavicle and the diaphragm and from
the parasternal to the anterior axillary line. The lateral area was
delineated between the axilla and the diaphragm and from the
anterior to the posterior axillary line. The upper quadrants were
demarcated from the 1st to the 3rd intercostal space and the
lower quadrants from the 4th to the 6th intercostal space. Each of
the 8 chest areas where visualised during normal respiration. The
pattern analysed was the comet-tail artefact arising from the
lung–wall interface (the hyperechogenic interface between the
Figure 1 a: Lateral view of the right lung. Schematic representation of the areas scanned in relation to ribs (numbered) and intercostal spaces.
b: Anterior view of the lungs. Schematic representation of the areas scanned (right hemithorax) in relation to ribs and intercostal spaces. (PA:
posterior axillary line; AA: anterior axillary line; PS: parasternal line; RUL: right upper lateral area; RLL: right lower lateral area; RUA: right upper
anterior area; RLA: right lower anterior area)









chest wall and the lung surface), which was defined as a hyper-
echogenic narrow-based reverberation artefact, spreading like a
laser-ray up to the edge of the screen14 (Fig. 2). For each of the 8
quadrants, the number of comet-tail artefacts present was
recorded and was linked with contemporaneous, prospectively
collected clinical data.
Based on findings from previous studies,14,15,17 comet-tail
artefacts may be present in dependent regions of normally
aerated lungs, and can be observed in healthy patients. Therefore,
in order to optimize the protocol for sensitive detection of the
comet-tail artefacts, three scan zones for each participant were
compared, namely: (i). All lung quadrants, (ii). All lung quad-
rants except for the lower lateral, and (iii). Upper lung quadrants
only, and the results were analysed.
Definitions
C-reactive protein
Plasma levels of C-reactive protein (CRP) have been shown to
correlate well with the presence of pancreatic necrosis and
severity of AP. However due to the late peak (36–72 h after
admission) admission levels of CRP may not be useful in
assessing severity.18 Therefore, both CRP contemporaneous with
the LUSS (highest value within the same 24-h period) and
maximum CRP value during the first week of admission were
used as surrogate markers of AP severity, by using 100 mg/L as
the cut-off for the binary classification of the cohort.19,20
Alveolar-interstitial syndrome
Pulmonary diseases with involvement of the alveolar space and
the interstitium are grouped under the term alveolar-interstitial
syndrome (AIS) and include ARDS, pneumonia, acute cardio-
genic pulmonary oedema, exacerbation of chronic interstitial
lung disease and miscellaneous other pulmonary conditions.11,14
The radiological diagnosis of AIS was based on the presence of
alveolar opacities (ill-defined shadowing, confluent opacities
with air bronchograms) and/or interstitial opacities (septal lines,
linear, reticular, or nodular opacities) on chest X-ray (CXR), as
previously proposed by Lichtenstein et al.14
Respiratory dysfunction
The worst value of PaO2/FiO2 for the 24-h period when each
LUSS was performed was used as a metric of respiratory
dysfunction. In accordance with the modified Multiple Organ
Dysfunction Syndrome (MODS) score recommended in the
revised Atlanta guidelines for AP,16 a threshold value of 300 was
used to divide the cohort into two groups, since those with PaO2/
FiO2 < 300 have a modified MODS score equal or greater than 2.
When an arterial blood gas (ABG) measurement was not avail-
able, the partial arterial pressure of oxygen (PaO2) was extrap-
olated from the pulse oximetric oxygen saturation (SatO2) by
applying the method described by Severinghaus,21 previously
used in different settings.22 For patients receiving supplemental
oxygen, the fraction of inspired oxygen (FiO2) was estimated as
described Banks et al.,16 modified as shown in Table 1.
Statistical analysis
Data for continuous variables are presented as mean ± standard
deviation (SD) or as median and interquartile range (IQR).
Figure 2 a: Sonographic image of normal lung. b: Anterior view of the lungs from a patient with AIS: Sonographic pattern of comet-tail artefacts
vertical fanning out from the lung–wall interface and spreading up to the edge of the screen (B-lines)
Table 1 Fraction of inspired oxygen for non-ventilated patients
(modification of the values provided in the revised Atlanta guidelines
for acute pancreatitis)


















Categorical variables are presented as absolute and relative fre-
quencies. Comparisons between independent groups were
performed using the Mann–Whitney U-test. Spearman’s rho was
used to examine correlations between pairs of non-parametric
variables. All statistical tests were based on a two-sided a-value
of 0.05.
For early and late scans, independent samples analysis was
performed with the cohort stratified by, (i) respiratory
dysfunction (PaO2/FiO2 < 300 versus PaO2/FiO2 ! 300), (ii)
disease severity (severe versus non-severe), based on the revised
Atlanta criteria for AP (modified MODS score <2 vs. score !2),
(iii) CRP value contemporaneous with LUSS (contemporaneous
CRP < 100 mg/L vs. CRP! 100 mg/L), and, (iv) maximum CRP
value within the first week of admission (maximum
CRP < 100 mg/L vs. CRP ! 100 mg/L).
Receiver Operator Characteristic (ROC) curves were plotted
for each comparison. Areas under the curve (AUC) and measures
of diagnostic accuracy with respective 95% confidence intervals
(95% C.I.) were calculated, with the use of ‘pROC’ package23 of
RStudio version 0.98.1091 (RStudio, Inc.), after identifying ROC
curve thresholds by the use of Youden’s index. AUC for paired
ROC curves were compared with the DeLong method.24 Addi-
tional statistical analyses were performed with IBM SPSS Sta-
tistics Version 22.0 (IBM Corp., Armonk, NY, USA).
Figures were designed using GraphPad Prism Version 6.0
(GraphPad Software, Inc., La Jolla, CA, USA). Formal blinding of
the LUSS readers was not feasible due to the nature of the in-
vestigations. The principles of the STARD (STAndards for the




Forty-one patients were enrolled in the study. Based on the
revised Atlanta guidelines, 32 of 41 (78%) participants had a
clear diagnosis of AP, whereas the remaining 9 patients had
hyperamylasaemia that did not satisfy the revised Atlanta defi-
nition of AP. All patients were included in the analysis. Of the
patients with definite AP, 12 participants (37.5%) had mild AP,
15 (46.9%) had moderately severe and 5 (15.6%) had severe
disease. The demographic characteristics are summarized in
Table 2.
Fifty-one LUSS were performed, of which 33 (64.7%) were
performed early in the disease course, and 18 (35.3%) were
performed at a late stage. With the exception of one patient who
underwent an early scan on day 5 and a late scan on day 11 after
recruitment, scans performed within 4 days from patient
recruitment were defined as early scans and those performed
later than 4 days were defined as late. Early scans were performed
after a median of 3 days from the initial finding of elevated
amylase (IQR: 1.5–4 days), and late scans after a median of 6
days (IQR: 5–9.3 days). With regard to onset of symptoms, early
scans were performed after a median of 5 days (IQR: 3–7 days),
and late scans after a median of 8.5 days (IQR: 6–12.3 days).
Twenty-three participants (53.7%) underwent an early scan only,
8 (22%) underwent a late scan and 10 (24.4%) underwent both.
One late scan performed on day 4 after recruitment (on a
participant who underwent an early scan on day 1) was excluded
from further analysis.
Early scans
In patients with respiratory dysfunction (n = 7), a greater
number of comet tails were evident on LUSS when compared to
patients without respiratory dysfunction (n = 26), both when all
lung quadrants except for the lower lateral were examined, and
when upper quadrants alone were considered (P = 0.030 and
P = 0.021 respectively). When all lung quadrants were taken into
consideration the difference did not reach statistical significance
(P = 0.067). Conversely, when contemporaneous CRP was
examined, borderline significant difference was shown with the
methods using all lung quadrants and all quadrants except for the
lower lateral (P = 0.048 for both methods), but only a tendency
for the method using only upper quadrants (P = 0.074). When
severity status was used as the defining parameter for the cohort,
patients with severe AP (n = 5) had a greater number of comet
tails than others (n = 28), by all three methods. Lastly, the
number of comet tails was significantly different by all three
methods when maximum CRP value of the first week of
admission was examined. The number of comet tails identified
by each method is summarized in Table 3 and group compari-
sons are depicted in Fig. 3.
With respect to respiratory dysfunction and disease severity,
the AUC was greater for the method examining upper lung
quadrants alone (AUC = 0.783, 95% C.I.: 0.544–0.962, P = 0.023
and AUC = 0.996, 95% C.I.: 0.986–1.000, P < 0.001, respec-
tively). Pairwise AUC comparisons between methods examining
all quadrants, all quadrants except the lower lateral and upper
quadrants alone, did not reveal superiority for either variable of
interest (Fig. 4).
The greatest AUC for contemporaneous and maximum CRP
resulted form examining all lung quadrants except for the lower
lateral (AUC = 0.708, 95% C.I.: 0.510–0.883, P = 0.047, and
AUC = 0.800, 95% C.I.: 0.640–0.929, P = 0.004 respectively), as
depicted on Fig. 4. For contemporaneous CRP, pairwise com-
parison did not reveal superiority of either of the three methods
whereas for maximum CRP, examining all quadrants except for
the lower lateral was superior to upper quadrants alone
(P = 0.011).
For each method, the derived threshold for the number of
comet tails, the corresponding sensitivity (SE) and specificity
(SP), positive (PPV) and negative predictive values (NPV), along
with respective 95% C.I., as well as the correlation coefficients of
the number of comet tails with PaO2/FiO2, modified MODS
score, contemporaneous and maximum CRP are presented in
Table 4.









Table 2 Demographic characteristics of study participants
Overall Patient sample Hyperamylasaemiaa Mild AP Moderate AP Severe AP
n 41 9 12 15 5
Age (years)
Median 59.1 59.1 69.7 57 49.4
IQR 49.2–67.5 50.7–64.6 50–81.6 49.2–67.5 45.8–63.9
Gender – ratio, (%)
Males 21/41 (51.2) 5/9 6/12 8/15 2/5
Females 20/41 (48.8) 4/9 6/12 7/15 3/5
BMI
Median 28 26 27 29 32
IQR 23–32 23–28 23–30 24–35 30–33
AP Aetiology – ratio, (%)
Gallstones 19/32 (59.4) N/A 7/12 11/15 1/5
Alcohol 6/32 (18.8) N/A 2/12 1/15 3/5
Idiopathic 5/32 (15.6) N/A 2/12 2/15 1/5
Other 2/32 (6.25) N/A 1/12 1/15 0/5
N/A 9/41 (22.0) 9/9 N/A N/A N/A
Severity – ratio, (%)
Mild 12/41 (29.3) N/A 16/16 N/A N/A
Moderately Severe 15/41 (35.6) N/A N/A 11/11 N/A
Severe 5/41 (12.2) N/A N/A N/A 5/5
N/A 9/41 (22.0) 9/9 N/A N/A N/A
Amylase (IU/L)b
Median 507 145 1045 642 669
IQR 230–1143 138–197 434–1435 324–2314 654–1143
CRP (mg/L)c
Median 66 13 29 154 133
IQR 24–146 6–26 12–71 46–241 119–146
APACHE II scored
Median 10 12 9 10 17
IQR 8.5–16.5 9–17 6–12 9–15 10–31
SIRSe
Ratio (%) 23/41 (56.1%) 6/9 6/12 6/15 5/5
Modified MODS score
Median 1 2 1 1 3
IQR 1–2 1–3 1–2 1–2 2–8
PaO2/FiO2 ratiof
Median 328 360 360 319 223
IQR 282–361 268–390 333–390 291–337 95–223
BMI, body mass Index; LOS, length of hospital stay; CRP, C-reactive protein; MODS, multiple organ dysfunction syndrome; APACHE, Acute
Physiology and Chronic Health Evaluation score; PaO2, partial arterial pressure of oxygen; FiO2, fraction of inspired oxygen; IQR, interquartile
range; N/A, not applicable.
a Participants who did not meet the criteria for acute pancreatitis, according to the 2012 revised Atlanta guidelines.
b Worst value of serum amylase on the first 24 h of admission.
c Worst value of CRP on the first 24 h of admission upon recruitment.
d Based on most extreme values of the first 24 h of admission.
e Based on most extreme values of the first 24 h of admission.
f As defined in methods section.











None of the 19 patients who underwent LUSS late in the course
of the disease had concurrent respiratory dysfunction, therefore
it was not feasible to examine the diagnostic accuracy of late
scans in this context. No significant correlation between the
number of late LUSS comet tails and either corresponding dis-
ease severity (contemporaneous modified MODS score), respi-
ratory dysfunction (PaO2/FiO2), disease severity on admission
(as defined by the revised Atlanta criteria), or contemporaneous
and maximum CRP was discovered, regardless of the method
used (data not presented).
X-rays
Twenty-eight of the 33 participants (84.8%) who underwent an
early LUSS, also had at least one prior CXR as part of their
routine clinical management, and 15 (53.6%) of these showed
AIS. Although LUSS were performed a median of 2 days (IQR:
1–3 days) after the CXR, a satisfactory diagnostic association was
demonstrated between CXR diagnosed AIS and LUSS findings
(Table 4).
Discussion
Respiratory dysfunction is the most frequent and clinically
relevant manifestation of extra-pancreatic organ injury in
AP.6,7,26 In patients with SAP, it constitutes a major determinant
of mortality and often precedes renal, cardiovascular and hepatic
dysfunction.7,27,28 Several hypotheses have been explored and
several associated inflammatory mediators and signalling path-
ways have been identified regarding the underlying pathophysi-
ology,8,29,30 however the exact mechanisms remain incompletely
understood. The spectrum of sequelae of AP-associated respi-
ratory dysfunction ranges from subclinical hypoxaemia to severe
ARDS,31,32 and radiologically evident complications such as
Table 3 Descriptive summary of the number of comet tails identified by each method (early scans)
Respiratory dysfunction




n Median IQR n Median IQR
All lung quadrants 7 9 7–10 26 2 1–8 0.067 −0.456 (0.008)
All lung quadrants except
for the lower lateral
7 7 5–9 26 2 0–6 0.030 −0.470 (0.006)






(P-value)n Median IQR n Median IQR
All lung quadrants 5 11 10–20 28 2 1–8 0.001 0.388 (0.026)
All lung quadrants except
for the lower lateral
5 10 9–13 28 2 0–6 0.001 0.426 (0.014)




Correlationb with CRP on the
day of LUSS
(P-value)n Median IQR n Median IQR
All lung quadrants 13 9 6–10 20 2 1–8 0.048 0.406 (0.019)
All lung quadrants except
for the lower lateral
13 6 2–9 20 2 0–5 0.048 0.354 (0.043)






n Median IQR n Median IQR
All lung quadrants 20 8 4–10 13 2 0–2 0.005 0.395 (0.023)
All lung quadrants except
for the lower lateral
20 6 2–9 13 0 0–2 0.003 0.391 (0.024)
Upper lung quadrants 20 3 1–6 13 0 0–2 0.040 0.323 (0.066)
a Independent samples Mann–Whitney U test.
b Spearman correlation coefficient.









atelectasis, pleural effusion, and pulmonary infiltrates and/or
oedema may frequently be present, amongst others.33,34 Never-
theless, hypoxaemia may precede radiological findings and has
been described as an early indicator of pathological pulmonary
changes.10 Consequently, a timely and accurate detection of
evolving respiratory dysfunction may aid in identifying high risk
patients and may expedite the implementation of appropriate
management.
Although the lung parenchyma has historically been consid-
ered not amenable to assessment by ultrasound, lung sonography
has undergone rapid development and its diagnostic potential
has improved in recent years.13 Several studies exploring the
value of LUSS in the diagnosis of AIS in acutely ill patients have
emerged,11,12,14,15,35 with reports of high sensitivity and speci-
ficity.11,14,36 The sonographic diagnosis of AIS relies on the
detection of multiple and diffuse comet tail B lines,12 described
as vertical artefacts fanning out from the lung–wall interface and
spreading up to the edge of the screen, resulting from thickened
interlobular septa and extravascular lung water.14 In addition,
LUSS has been proposed as advantageous to other imaging
techniques; bedside X-rays pose diagnostic challenges14,15
whereas CT can be time-consuming and hazardous for criti-
cally ill patients requiring transfer,11,37 and is associated with
significant radiation exposure.
Stratifying severity in AP is challenging. Early stratification into
moderately severe (transient organ dysfunction) and severe AP
(persistent organ dysfunction) disease groups for clinical and
academic purposes is bound by limitations inherent in the defi-
nitions, such as the requirement for a period of at least 48 h before
a definite conclusion about severity has been reached. Similar to
several previous classification systems,31,38–40 the revised Atlanta
guidelines use the long established PaO2/FiO2 ratio as ameasure of
respiratory dysfunction, which although undoubtedly invaluable,
constitutes a relatively non-specific prognostic marker, a fact
Figure 3 Scatterplot of the total number of comet tails per patient group as determined by: a. The respiratory dysfunction status (PaO2/
FiO2 < 300 vs. PaO2/FiO2 ! 300). Red lines represent median and IQR for each patient group. A: PaO2/FiO2 ! 300; B: PaO2/FiO2 < 300; ns:
P ! 0.05; *: P < 0.05 – b. The severity status (Severe vs. Non-severe). Red lines represent median and interquartile range for each patient group.
****: P < 0.001 – c. Contemporaneous CRP – d. Maximum value of CRP. **: P < 0.01










already noted by Ranson et al. four decades ago.41 The introduc-
tion of transthoracic lung ultrasound as a method supplementary
to PaO2/FiO2 would aim to increase prognostic efficiency in AP.
The hope is that it may potentially provide a valid and accurate
measure of respiratory dysfunction and severity early in the dis-
ease course, by differentiating between established pathological
pulmonary changes and transient physiological impairment. If
validated, this non-invasive, easily repeatable bedside method
would allow for amore timely patient stratification in comparison
to and/or complementary to existing scores.
The findings of the present study demonstrate a useful diag-
nostic association of early LUSS with disease severity and respi-
ratory dysfunction, for all three methods applied, particularly
when all lung quadrants excluding the lower lateral and when
upper quadrants only were examined. More comet tail artefacts
are present in patients with respiratory dysfunction, severe dis-
ease and/or elevated CRP, and thresholds for the number of
comet-tails have been proposed. The routine use of LUSS in the
early stage of AP appears to be attractive as an initial proposition
for further research, as a non-invasive, easily repeatable bedside
adjunct that provides an accurate evaluation of disease severity
and respiratory dysfunction.
The present study has several potential limitations. The cohort
size is relatively small, however as a pilot evaluation of this
diagnostic approach it is considered adequate. The number of
late scans performed is insufficient to comment on its utility in
the late phase of the disease and the small number of patients
who underwent both early and late scans (n = 10) has not
allowed for a valid comparison between these two groups.
However, given that organ dysfunction and mortality are early
events in AP, this fact does not obviate the utility of this
approach, and a possibly slower resolution of the pathological
pulmonary changes in comparison to the anticipated clinical
recovery of patients with non-severe AP may raise questions on
the potential application of late scans in monitoring disease
progress.
Figure 4 Receiver operator characteristic curves of the number of comet tails by: a. Respiratory dysfunction status – b. Disease severity status
– c. Contemporaneous CRP – d. Maximum value of CRP









Moreover, the inter-observer variability of scan findings has
not been examined, and despite the fact that satisfactory results
are already available from previous studies,35 such data would
have provided useful information on a method generally
characterized by operator dependency. With regard to meth-
odology, the convention used to extrapolate PaO2/FiO2 from
SatO2 may have introduced unknown error in the analysis, as
the Severinghaus equation has not been validated for calculation
Table 4 Areas under the curve, thresholds for the number of comet tails and parameters of diagnostic accuracy for eachmethod, with regard
to respiratory dysfunction, disease severity status and CRP. In order to examine the diagnostic association between the scan findings and







































































































































































































































AUC, area under the curve; 95% C.I., 95% confidence interval, ×2000 bootstrap; PPV, positive predictive value; NPV, negative predictive value;
N/A, not applicable.










of the modified MODS score in AP patient cohorts. Never-
theless, SatO2 has previously been used for similar approxi-
mations, with reasonable accuracy.42,43 Additionally, the timing
of CXRs for study participants was not altered from ordinary
clinical care. LUSS were in general performed after CXRs,
therefore the accuracy of the association between the findings of
the two imaging methods may be confounded by this
discrepancy.
The fact that early scans were performed a median of 3 days
after the first finding of an elevated serum amylase, may have
concealed an even greater prognostic association with early res-
piratory dysfunction. The exact prognostic features of early LUSS
deserve further investigation and future studies are likely to
benefit from standardizing the timing of scans within the first
48 h. Nevertheless, the fact that scans performed very early may
carry a high false negative ratio has to be taken into consider-
ation, as at that stage developing pulmonary involvement may
not yet be identifiable with this method.
In conclusion, ultrasonography of non-dependent lung pa-
renchyma can reliably detect evolving respiratory dysfunction in
AP, and shows promise as an adjunct to severity stratification.
This simple, easily repeatable bedside test warrants further
validation in a larger cohort.
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Increased levels of 
3-hydroxykynurenine parallel 
disease severity in human acute 
pancreatitis
Christos Skouras1, Xiaozhong Zheng2, Margaret Binnie3, Natalie Z. M. Homer4, 
Toby B. J. Murray2, Darren Robertson5, Lesley Briody6, Finny Paterson6, Heather Spence6, 
Lisa Derr6, Alastair J. Hayes2, Andreas Tsoumanis7, Dawn Lyster8, Rowan W. Parks1, 
O. James Garden1, John P. Iredale2, Iain J. Uings9, John Liddle9, Wayne L. Wright10, 
George Dukes11, Scott P. Webster3 & Damian J. Mole1,2
Inhibition of kynurenine 3-monooxygenase (KMO) protects against multiple organ dysfunction 
(MODS) in experimental acute pancreatitis (AP). We aimed to precisely define the kynurenine pathway 
activation in relation to AP and AP-MODS in humans, by carrying out a prospective observational study 
of all persons presenting with a potential diagnosis of AP for 90 days. We sampled peripheral venous 
blood at 0, 3, 6, 12, 24, 48, 72 and 168 hours post-recruitment. We measured tryptophan metabolite 
concentrations and analysed these in the context of clinical data and disease severity indices, cytokine 
profiles and C-reactive protein (CRP) concentrations. 79 individuals were recruited (median age: 
59.6 years; 47 males, 59.5%). 57 met the revised Atlanta definition of AP: 25 had mild, 23 moderate, 
and 9 severe AP. Plasma 3-hydroxykynurenine concentrations correlated with contemporaneous 
APACHE II scores (R2 = 0.273; Spearman rho = 0.581; P < 0.001) and CRP (R2 = 0.132; Spearman 
rho = 0.455, P < 0.001). Temporal profiling showed early tryptophan depletion and contemporaneous 
3-hydroxykynurenine elevation. Furthermore, plasma concentrations of 3-hydroxykynurenine 
paralleled systemic inflammation and AP severity. These findings support the rationale for investigating 
early intervention with a KMO inhibitor, with the aim of reducing the incidence and severity of AP-
associated organ dysfunction.
Acute pancreatitis (AP) is a sterile, localized inflammation of the pancreas. In approximately 25% of affected 
patients, AP results in a systemic inflammatory response leading to multiple organ dysfunction syndrome 
(MODS)1,2. MODS commonly develops early after the onset of AP3. Persons who develop AP–MODS require 
invasive monitoring and organ support in a critical care environment, with an in-hospital mortality rate that may 
reach 36–50%4,5. Moreover, survivors of AP-MODS require a prolonged hospital stay and have a reduced overall 
life expectancy compared to those with mild AP6. Therefore, early recognition and stratification of AP severity is 
essential.
The exact pathological mechanisms that drive AP–MODS remain unclear, but the kynurenine pathway 
of tryptophan metabolism (Fig. 1) is emerging as a potentially important contributory mechanism7,8. In an 
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inflammatory context, metabolism of tryptophan through the kynurenine pathway is dramatically increased 
through induction of indoleamine 2,3-dioxygenase (IDO) expression by pro-inflammatory cytokines, in par-
ticular, interferon gamma (IFN-γ )9. IDO upregulation increases substrate flux through downstream enzymes, in 
particular kynurenine 3-monooxygenase (KMO), thereby generating biologically–active metabolites that partic-
ipate in multiple physiological and pathological processes10–15. In rodent models of AP, 3-hydroxykynurenine, the 
product of the gate-keeper enzyme kynurenine 3-monooxygenase (KMO), appears to be critical to the pathogen-
esis of AP-MODS7. 3-hydroxykynurenine causes tissue injury via oxidative stress and pathological cross-linking 
of proteins16. Therapeutic blockade of KMO by genetic deletion in mice or pharmacological inhibition in rats 
reduces 3-hydroxykynurenine formation and protects against lung and kidney injury in experimental models 
of AP7. Other metabolites in the kynurenine pathway have been postulated to mediate immunological toler-
ance dependent on signalling via the aryl hydrocarbon receptor, whilst kynurenine specifically may contribute to 
T-helper Th17 and T-regulatory lymphocyte differentiation17,18.
In critically ill individuals, rapid and profound tryptophan degradation can occur19. Indeed, tryptophan deple-
tion and/or elevated concentrations of kynurenine metabolites have been detected in the plasma of major trauma 
patients, and in patients following cardiac bypass surgery, while elevated serum kynurenine concentrations are 
associated with the need for renal replacement therapy and invasive ventilation in persons with AP-MODS8,11,20,21. 
However, the detailed profile of the kynurenine pathway and its role in the pathophysiology of AP has not been 
elucidated. In considering the therapeutic potential of KMO inhibition for AP, it is important to establish the pre-
cise timing and magnitude of activation of the kynurenine pathway in relation to the onset of AP and the devel-
opment of AP-MODS, the inflammatory burden and overall AP severity. The aim of the present study, therefore, 
was to define the precise temporal and quantitative relationship between kynurenine pathway metabolism and the 
onset and severity of AP-associated organ dysfunction.
Results
Recruitment Performance. A total of 79 patients were recruited, 57 patients (72.2%) of whom were diag-
nosed with AP in accordance with the revised Atlanta guidelines (“true AP” – tAP). Of the 57 tAP patients, 10 
had an amylase level below 300 upon presentation, and either a subsequent amylase rise or a confirmation of 
AP by imaging. The demographic characteristics of the study participants are summarized in Supplementary 
Table S1, and a CONSORT diagram is shown in Fig. 2. There was no effect of day of the week (P = 0.317) or time 
of day (P = 0.397) on recruitment. Moreover, time of day for recruitment (T0) followed a random distribution. 
The cumulative frequency of participant enrolment by calendar day of the recruitment phase and the relative 
frequency of enrolment by weekday are shown in Fig. 3a and Supplementary Table S2, respectively. No systematic 
bias was present for the twenty-nine potentially eligible patients that were not recruited. Thirty patients declined 
Figure 1. The kynurenine pathway of tryptophan metabolism. The key step of kynurenine conversion to 
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to participate, of whom 12 had AP and 3 required admission to critical care. One male participant formally with-
drew from the study within 12 hours from recruitment.
Sampling performance was efficient, and a total of 508 samples were obtained and analysed. Due to the high 
temporal resolution design of the study, some sample time-points were missed, but no systematic bias was iden-
tified for the non-obtained samples. The median time from acute presentation to hospital (pre-recruitment sam-
ple) to recruitment was 5 hours 34 minutes (IQR: 182–611 minutes) for tAP participants (Fig. 3b). This interval 
included examination and consultation by the direct clinical care team(s), routinely collected acute presentation 
sample (pre-recruitment) receipt, processing and analysis, verification of the result by the hospital laboratory staff 
and contact with the study team for verification of the clinical history, and informed consent.
Inflammatory Indices, Composite Scores & Cytokines. A clear rise in CRP level was evident for tAP 
participants (standardized AUC for CRP concentration, median (IQR): hyperamylasaemia participants: 18.9 
(5.75–45.4) mg/L; tAP participants: 126.0 (49.9–201.1); P < 0.001), the magnitude of which was proportionate to 
AP severity (Fig. 4a) and in keeping with a substantial systemic inflammatory insult (standardized AUC for CRP 
concentration, median (IQR): mild: 58.9 (26.3–131.2) mg/L; moderate: 148.1 (74.5–243.9) mg/L; severe: 225.6 
Figure 2. CONSORT diagram of the IMOFAP study. Reasons for patient exclusion are summarised, 
with post-hoc diagnoses for each exclusion category included in brackets (NA = not available). Patients of 
the moderate AP severity group were divided to three further sub-groups according to the revised Atlanta 
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(174.9–260.2) mg/L; P = 0.001). The acute presentation (pre-recruitment) mean CRP concentrations were higher 
in severe AP, but this difference was not statistically significant (CRP concentration, median (IQR): mild: 11 (5–34) 
mg/L; moderate: 19 (9–39) mg/L; severe: 59 (30–65) mg/L; P = 0.166) (Fig. 4a and Supplementary Table S3). 
Resolution of inflammation, indicated by a fall in CRP, occurred between 48 and 72 hours for the majority of 
patients. Conversely, serum amylase was more than three times higher than the upper limit of the normal range 
upon recruitment, and normalised within 24 hours for the majority of participants. There was no association 
between serum amylase level upon presentation and disease severity (Fig. 4b). Furthermore, mean and minimum 
concentrations of albumin, as well as the corresponding mean standardized AUC for albumin were significantly 
lower in the severe AP group (Supplementary Table S3).
Severe AP patients had a significantly greater modified MODS score at presentation, when compared to the 
other two participant groups (mean MODS score, (SD; range): mild: 0.8 (0.7; 0–3); moderate: 0.8 (0.9, 0–4); 
severe: 2.8 (2.5; 0–8); P = 0.003), followed by a further rise during the initial 12-hour period after recruitment and 
apparent resolution (a reduction in MODS score to ≤ 2) beyond the 48-hour mark (Fig. 4c). No association was 
discovered between the time interval from the onset of symptoms to recruitment and the modified MODS score 
upon presentation of severe AP patients (Spearman’s rho = − 0.037, P = 0.926). Both day 1 APACHE II and Tminus 
APACHE II scores were higher in the severe AP group (day 1 APACHE II score, mean (SD): mild: 8.2 (4.4); mod-
erate: 11.4 (3.8); severe 19.3 (11.0); P = 0.001, and Tminus APACHE II score, mean (SD): mild: 6.0 (3.6); moderate: 
7.6 (3.8); severe: 12.0 (5.6); P = 0.002). APACHE II scores also declined after 48 hours, with the decrease being 
more prominent from T72 onwards (Fig. 4d). Importantly, the decline of both modified MODS and APACHE II 
scores (calculated for each time-point) coincided with and is due to the deaths of two patients in the severe AP 
group, who died within 55 and 101 hours after recruitment. The respective scores for the surviving severe AP 
patients remained relatively unchanged for the duration of their participation in the study.
The inflammatory burden of the study cohort was further quantified by supplementary serial measurements of 
pro- and anti-inflammatory cytokines over the same time-points. The severe AP patient group was found to have 
significantly higher levels of peak and mean concentrations, as well as standardized AUC levels of IL-1B, IL-6, 
IL-10, TFF3, and CD163 (Supplementary Table S3).
Tryptophan Metabolites. Summary measures for the concentration of tryptophan and all studied tryp-
tophan metabolites are presented in Table 1. Tryptophan depletion was marked and proportionate to disease 
Figure 3. (a) Cumulative number of enrolled participants per calendar day of the recruitment phase of the 
study. Solid line: overall study participants; dashed line; tAP participants. (b) Box & whiskers plot of the 
time interval from patient presentation to hospital to study recruitment, in minutes. Blue box: overall study 
participants; red box tAP participants. Boxes: 1st and 3rd quartile; horizontal lines: median values; error bars: 
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severity and especially profound in severe AP (standardised AUC for tryptophan concentration, mean (SD): 
mild: 24423.9 (8803.9) ng/mL; moderate: 19721.4 (8140.5) ng/mL; severe: 13782.4 (3789.8) ng/mL; P = 0.004). 
Figure 4. Panel of comparisons between mild (n = 25), moderate (n = 23) and severe AP (n = 9) participant 
groups for (a) C-reactive protein; (b) Amylase; (c) Modified MODS score (as described in the revised Atlanta 
guidelines); (d) APACHE II score. Bar charts on the left hand side of the panel represent Tminus sample means 
(acute presentation – pre-recruitment), while right-hand side plots depict the time-course for each variable 
mean per participant group. NS: not statistically significant difference; *0.05 > P > 0.01; **P < 0.01; error bars 
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Importantly, upon presentation to hospital, no statistically significant difference in tryptophan concentration 
levels was evident among the three groups (tryptophan concentration, mean (SD): mild 29796.6 (10939.7) ng/
mL; moderate: 26133.0 (9973.8) ng/mL; severe: 24273.7 (9926.4) ng/mL; P = 0.281). Moreover, the observed 
effect on tryptophan levels was not a result of dilution due to resuscitation, as no statistically significant difference 
was observed in the standardised AUC of haematocrit22 between the three groups (standardized AUC for haema-
tocrit, mean (SD): mild 0.361 (0.04); moderate: 0.350 (0.045); severe 0.330 (0.034); P = 0.161).
No significant differences in peak level, mean level or standardized AUC of kynurenine, kynurenic acid, and 
3-hydroxyanthranilic acid were detected among the three patient groups (Table 1). In specific, the observed dif-
ference of 3-hydroxyanthranilic acid concentration plots on Fig. 5e, although visually substantial, did not reflect 
a statistically significant difference, and was driven by the extreme values on two individual participants in the 
severe AP group.
Summary Measure Mild Moderate Severe P-value HV
Tryptophan (ng/mL)
Minimum values, median 
(IQR) 16407.2 (13334.9–20463.6) 13993.6 (10714–20941.9) 8820.4 (7295.3–11355.6) 0.071 39763.4
Mean values, mean (SD) 23840.4 (8970.0) 20346.2 (8144.3) 14421.2 (4317.7) 0.014 25215.8 (21675.9–33362.4)
Time-to-Minimum, 
median hours (95% C.I.) 12 (3.5–20.5) 12 (0.0–27.7) 12 (3.2–20.8) 0.542 —
Standardized AUC, mean 
(SD) 24423.9 (8803.9) 19721.4 (8140.5) 13782.4 (3789.8) 0.004 —
Kynurenine (ng/mL)
Peak values, median 
(IQR) 694.9 (429.4–857.9) 677.8 (408.2–900.8) 742.0 (626.6–1182.8) 0.680 622.3
Mean values, median 
(IQR) 520.5 (338.8–708.0) 470.6 (302.1–874.4) 599.4 (547.1–912.4) 0.533 429.2 (353.0–463.1)
Time-to-Peak, median 
hours (95% C.I.) 12 (0.0–29.6) 24 (6.3–41.7) 12 (0.0–25.2) 0.288 —
Standardized AUC, 
median (IQR) 554.8 (360.3–734.0) 522.7 (370.8–782.5) 634.3 (570.4–840.7) 0.584 —
3-Hydroxykynurenine  
(ng/mL)
Peak values, median 
(IQR) 13.5 (8.6–17.8) 20.0 (12.1–46.6) 25.2 (14.3–35.6) 0.013 10.5
Mean values, median 
(IQR) 10.7 (8.1–13.5) 15.6 (8.6–38.3) 22.3 (11.8–27.0) 0.039 8.1 (7.6–9.0)
Time-to-Peak, median 
hours (95% C.I.) 12 (6.7–17.3) 46.0* (32.9–59.0) 24 (0.0–49.0) 0.019 —
Standardized AUC, 
median (IQR) 10.8 (7.4–13.9) 18.2 (11.4–38.1) 21.6 (11.7–28.0) 0.015 —
Kynurenic Acid (ng/mL)
Peak values, median 
(IQR) 211.5 (165.0–404.3) 184.8 (48.2–364.4) 198.4 (182.4–201.6) 0.303 372.1
Mean values, median 
(IQR) 194.9 (146.0–364.4) 141.8 (41.8–184.8) 186.4 (172.1–197.5) 0.104 301.6 (267.7–327.5)
Time-to-Peak value, 
median hours (95% C.I.) 6 (3.2–8.9) 6 (2.7–9.3) 3 (0.0–7.2) 0.102 —
Standardized AUC, 
median (IQR) 296.7 (155.4–406.6) 74.1 (34.8–203.9) 208.3 (173.8–374.3) 0.110 —
3-Hydroxyantranilic  
Acid (ng/mL)
Peak values, median 
(IQR) 48.8 (37.3–118.6) 48.8 (33.4–64.7) 65.0 (46.2–394.2) 0.236 54.3
Mean values, median 
(IQR) 38.4 (25.9–85.3) 34.8 (26.0–62.8) 53.6 (41.9–215.1) 0.186 37.5 (28.7–48.8)
Time-to-Peak value, 
median hours (95% C.I.) 6 (0.0–12.1) 6 (0.0–15.1) 6 (0.0–14.8) 0.686 —
Standardized AUC, 
median (IQR) 45.7 (28.0–98.4) 34.9 (26.8–56.0) 51.2 (44.1–107.5) 0.165 —
3-Hydroxykynurenine/
Tryptophan ratio x1000
Peak values, median 
(IQR) 0.673 (0.417–1.523) 0.878 (0.532–4.515) 1.876 (1.505–3.600) 0.052 0.46
Minimum values, median 
(IQR) 0.341 (0.201–0.804) 0.428 (0.283–1.513) 0.872 (0.637–1.420) 0.005 0.18
Mean value, median 
(IQR) 0.429 (0.321–1.255) 0.645 (0.409–2.902) 1.550 (0.831–1.769) 0.022 0.326 (0.248–0.384)
Time-to-Peak value, 
median hours (95% C.I.) 12.0 (0.0–26.6) 48 (21.6–74.4) 12 (0.0–24.5) 0.110 —
Standardized AUC, 
median (IQR) 0.447 (0.262–0.892) 0.734 (0.506–2.635) 1.667 (0.930–1.841) 0.003 —
Table 1.  Summary analysis measures1 of serial tryptophan and tryptophan metabolite concentrations for 
the three patient groups of AP severity (T0 to T168). Standardised AUC were calculated as detailed in the 
methods section. T168 values were excluded from Time-to-Peak/Minimum analyses. P-values correspond to 
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The severe AP patient group had a significantly higher peak 3-hydroxykynurenine concentration across 
all study time-points (peak 3-hydroxykynurenine concentration, median (IQR): mild: 13.5 (8.6–17.8) ng/mL; 
moderate: 20.0 (12.1–46.6) ng/mL; severe: 25.2 (14.3–35.6) ng/mL; P = 0.013). The standardized AUC for 
3-hydroxykynurenine was also significantly different among the three groups, although only a marginal dif-
ference was observed between the moderate and the severe group, as shown on Table 1 (standardized AUC 
for 3-hydroxykynurenine concentration, median (IQR): mild: 10.81 (7.4–13.9) ng/mL; moderate: 18.2 (11.4–
38.1) ng/mL; severe: 21.6 (11.7–28.0) ng/mL; P = 0.015). The median time interval required to reach peak 
3-hydroxykynurenine concentration was 24 hours (95% C.I.: 0.0–49.0 hours) in the severe AP group, compared 
to 12.0 hours (95% C.I.: 6.7–17.3 hours) in the mild AP group and to a mean time interval of 46.0 hours (95% C.I.: 
32.9–59.0 hours) in the moderate group (P = 0.019).
To provide an indication of flux through KMO we calculated the 3-hydroxykynurenine/tryptophan ratio, 
multiplied by 1000 for practical purposes. We observed a significant increase in KMO flux in proportion to dis-
ease severity (standardized AUC for 3-hydroxykynurenine/tryptophan ratio x 1000, median (IQR): mild: 0.45 
(0.26–0.89); moderate: 0.73 (0.51–2.64); severe: 1.67 (0.93–1.84); P = 0.003). Time-plots for the concentration of 
each analysed metabolite are depicted on Fig. 5.
When considering all samples obtained from T0 up to and including T48, logarithmic 3-hydroxykynurenine 
levels correlated well with contemporaneous CRP (R2 = 0.132; rho = 0.455, P < 0.001) (Fig. 6a) and APACHE II 
score (R2 = 0.250; rho = 0.583; P < 0.001) (Fig. 6b). Furthermore, moderate correlation of logarithmic 
3-hydroxykynurenine was discovered with contemporaneous levels of TFF3 (rho = 0.604, P < 0.001), albu-
min (rho = − 0.568, P < 0.001), creatinine (rho = 0.531, P < 0.001), TNF-a (rho = 0.462, P < 0.001), and RAGE 
(rho = 0.455, P < 0.001), and weaker correlation with IL-10 (rho = 0.357, P < 0.001), IL-6 (rho = 0.352, P < 0.001), 
IL-17a (rho = 0.349, P < 0.001), CD163 (rho = 0.298, P < 0.001), IL-8 (rho = 0.293, P < 0.001), TNFS10 
(rho = − 0.259, P < 0.001), chemerin (rho = 0.247, P < 0.001), IL-1 (rho = 0.220, P < 0.001), insulin C-peptide 
(rho = 0.230, P < 0.001), cardiac troponin I (rho = 0.217, P < 0.001), CXCL12 (rho = 0.195, P = 0.001), and 
CD40 ligand (rho = 0.181, P = 0.003). Conversely, no correlation was found with insulin (rho = 0.057, P = 0.352), 
CA 15-3 (rho = − 0.079, P = 0.199), B7-H1 (rho = − 0.062, P = 0.312), and IFN-γ (rho = − 0.019, P = 0.758). 
Differences between participant groups for all studied cytokines are summarized in Supplementary Table S3, 
and post-hoc pairwise comparisons of significantly different standardized AUC are depicted on Supplementary 
Table 4.
Discussion
The kynurenine pathway of tryptophan metabolism and especially KMO, the enzyme that determines the met-
abolic fate of kynurenine, is increasingly recognized as a key contributor to the pathogenesis of AP-MODS. 
The present study precisely defines the temporal profile of kynurenine pathway metabolite concentrations in 
peripheral blood in relation to the onset and severity of AP in humans. Our data show a noteworthy association 
between plasma concentrations of 3-hydroxykynurenine and AP severity as defined by standard classification 
systems. Furthermore, an important correlation was discovered between 3-hydroxykynurenine concentrations 
and the systemic inflammatory burden measured by CRP levels. Additionally, we observed the classical paradigm 
pro-inflammatory cytokine profile in AP, namely TNF-α and IL-6, as well as RAGE and TFF3, that correlated 
strongly with 3-hydroxykynurenine concentrations in this cohort. Our novel findings add depth to the previously 
reported association between serum kynurenine concentrations and the requirement for invasive renal and res-
piratory support during AP-MODS8. Moreover, these findings build on our recent discovery that genetic deletion 
of KMO in mice and administration of a highly-specific KMO inhibitor protects against lung and kidney injury 
in experimental rodent models of AP7. Together, these data strongly support the translational potential of KMO 
inhibition as a therapeutic strategy to protect against MODS in human AP.
Strengths of this study include the efficiency of recruitment, sampling process, sampling frequency and high 
coverage, thus minimal sampling bias. Based on the knowledge that AP and the consequent systemic inflamma-
tory response evolve rapidly, we hypothesise that KMO inhibition is likely to be most effective when delivered as 
early as possible in the course of the disease and therefore sought to define the evolving trajectory of the inflam-
matory response with high definition during the early phase.
The burden of systemic inflammation in the cohort as measured by the magnitude of CRP rise was clear. The 
fact that APACHE II score correlated well with disease severity as classified by the revised Atlanta criteria, and 
that the modified MODS score followed the same trajectory as CRP, provide additional reassurance that inter-
preting plasma concentrations of 3-hydroxykynurenine and other kynurenine metabolites in this context is valid 
and appropriate.
In the present study, the magnitude of tryptophan depletion was proportional to AP severity and was more 
prominent over time, suggesting increased tryptophan metabolism. Although tryptophan levels can fluctu-
ate diurnally23,24, diurnal variation does not account for the difference in tryptophan metabolism between AP 
severity strata, because the time of day at which recruitment occurred was distributed randomly. Furthermore, 
although it is possible that fasting due to hospital admission and/or critical illness may in theory account for 
part of the observed tryptophan depletion, Poesen et al.25 previously demonstrated that plasma levels of trypto-
phan, kynurenine, and kynurenic acid were not significantly different in healthy humans with low or high protein 
intake, and one would not expect to observe a correlation with AP severity if fasting was the cause. The extent of 
tryptophan depletion is too great to be due to haemodilution after intravenous fluid resuscitation, and there was 
no observed change in the haematocrit or dilution effect seen in other plasma analytes. It therefore seems reason-
able to conclude that the observed decrease in tryptophan levels is likely to be the result of increased metabolism.
The increase in steady state 3-hydroxykynurenine concentrations in plasma is consistent with increased 
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Figure 5. Plasma concentrations of tryptophan and the kynurenine pathway metabolites in tAP 
participants over time, grouped by AP severity according to the revised Atlanta criteria (group sizes at 
recruitment: mild n = 25; moderate n = 23; severe n = 9 individuals). (a) Tryptophan; (b) Kynurenine; 
(c) 3-hydroxykynurenine; (d) Kynurenic acid; (e) 3-hydroxyanthranilic acid; (f) 3-hydroxykynurenine to 
tryptophan ratio multiplied by 1000. For all panels, data points represent means and error bars represent 
standard errors of the mean. P-values for between-group comparisons of standardised AUC are appended. NS: 
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Importantly, elevated 3-hydroxykynurenine is associated with increased inflammatory burden, as indicated by 
the correlation of plasma 3-hydroxykynurenine levels with contemporaneous CRP concentrations. While it is 
curious that no significant changes were observed in other tryptophan metabolites, the indications from studies 
in rodents are that KMO represents the predominant route for this pathway. For this reason, the ratio between 
3-hydroxykynurenine to tryptophan (multiplied by 1000 for practical purposes) was used to try and express the 
pathway flux through KMO. This ratio was found to be time-dependent and proportionate to AP severity, with 
a lead-time of 12 hours when compared to the timing of the peak serum CRP that occurred at 24 hours for the 
severe AP group. Lastly, the elevation in 3-hydroxykynurenine/tryptophan ratio was greater in those few patients 
with specific respiratory, renal and cardiac dysfunction as defined by those specific components of the MODS 
score.
In conclusion, this study demonstrates that metabolic flux through KMO is elevated proportionately to disease 
severity in human AP. Plasma concentrations of 3-hydroxykynurenine correlate with the burden of inflammation, 
incidence of organ dysfunction and AP severity. These findings reinforce the rationale for investigating early 
phase KMO inhibition as a therapeutic strategy to protect against AP-MODS in human AP.
Methods
Ethics & Regulatory Approvals. This study was approved by the Scotland A Research Ethics Committee 
(REC) (REC reference number: 13/SS/0136, amended REC REF AM01), and NHS Lothian Research & 
Development committee (Project Number: 2013/0098 and SA1). The study sponsor was the Academic and 
Clinical Central Office for Research and Development (ACCORD), a collaboration between the University of 
Edinburgh and NHS Lothian. Permission to access confidential medical records was granted by the NHS Lothian 
Caldicott Guardian. Written informed consent was obtained from all participants or their legal representative. 
Prior to commencing the study, a summary of the study protocol was registered in the public domain on the UK 
Clinical Trials Gateway (former UK Clinical Research Network) (registration number: 16116)26. The study was 
conducted in accordance with the University of Edinburgh and NHS Lothian guidance. Adults without the capac-
ity to give informed consent were recruited in accordance with the Adults with Incapacity (Scotland) Act 2000, 
Part 527. Informed consent was sought when capacity was regained.
Figure 6. Dot-plots of correlations between (a) Plasma concentrations of C-reactive protein and 
3-hydroxykynurenine, for the tAP cohort grouped by AP severity (mild AP n = 25; moderate AP n = 23; severe 
AP n = 9). Data points represent means; error bars show standard deviation on both axes. The dashed red line 
represents mean 3-hydroxykynurenine plasma concentration in healthy volunteers (n = 8). (b) APACHE II  
score and contemporaneous log10 3-hydroxykynurenine plasma concentrations. Due to the non-normal 
distribution of plasma concentrations of of 3-hydroxykynurenine, a logarithmic transformation was used for 
the correlation to provide a better fit. For both correlations, results from samples obtained from T0 up to and 
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Research Sites. Recruitment of participants was undertaken in the Emergency Department (ED), and 
General Surgery wards at the Royal Infirmary of Edinburgh (RIE). The Wellcome Trust Clinical Research Facility 
(WTCRF) provided research nurse support for recruitment and consent, data collection, sample handling and 
storage.
Inclusion and Exclusion Criteria. Any patient over the age of 16 years with a potential or confirmed new 
diagnosis of AP was identified as a potential participant. For the diagnosis of potential AP, two of the following 
three features were required:
(i)   A clinical history of symptoms compatible with AP (i.e. abdominal pain, nausea, and/or vomiting);
(ii)   Serum amylase concentration greater than the upper limit of the reference range (> 100 IU/L). This threshold 
was decided upon in order to capture potential participants with an amylase level below the threshold of the 
revised Atlanta definition for AP, due to a late or atypical presentation. A serum amylase concentration in 
excess of 300 IU/L was required as a feature for the diagnosis of true AP (tAP).
(iii)  Evidence of AP on computerised tomography (CT) and/or abdominal ultrasound scan (AUSS).
Persons under the age of 16 years, prisoners and persons in police custody were excluded from the study.
Recruitment. In order to capture potential participants as early as possible in the course of the disease, an 
automatic alert was initiated from the biochemistry laboratory for any serum sample with a measured elevated 
amylase concentration and transmitted to the WTCRF research nurses on a dedicated study mobile telephone. 
The dedicated study telephone number was also distributed to all ED and surgical team members. Upon each 
alert, the investigator or WTCRF nurse checked the clinical history of each potential study participant via his or 
her electronic records on InterSystems TrakCare®. If the clinical presentation was compatible with AP, the patient 
was visited and suitability for recruitment was confirmed. A member of the direct clinical care team made the 
initial approach to each potential participant, prior to informed consent and recruitment by the WTCRF nurse 
team.
The recruitment phase lasted for 90 calendar days – from 17th September 2013 to 16th December 2013 – and 
was carried out 24 hours per day, 7 days per week with support from 30 WTCRF research nurses on a 12-hour 
shift rota supported by 2 clinical support workers and a clinical technician.
Healthy Volunteers. Healthy volunteers over the age of 18 years were recruited with ethical approval (REC 
reference number: 08/S1103/38, United Kingdom). Volunteers were excluded from participation on the basis of 
the presence of any of the following: renal dysfunction (eGFR < 30 mL/min); hepatic dysfunction (Child-Pugh 
score B or C); pregnancy or breast feeding; blood dyscrasia or anaemia (haemoglobin < 12 g/dL); active malig-
nancy; chronic inflammatory condition; any intercurrent illness; and any recent surgical procedure.
Data Collection and Data Management. Data were collected from individual patient charts, clinical case 
notes and the following electronic sources:
(i)   WardWatcher software (Scottish Intensive Care Society Audit Group - SICSAG).
(ii)   TrakCare Patient Management System (InterSystems, Massachusetts, USA).
(iii)  SCI-Store data repository (SCI NHS National Services Scotland).
(iv)  Picture Archiving and Communication System (PACS).
(v)  Emergency Care Summary (ECS) database (National Information Systems Group).
(vi)  iLaboratory information system (iLab or APEX).
Data were entered into a dedicated, password-protected and software-encrypted study laptop with regular 
back-up. Participant data were link-anonymized and securely stored separately from the identifiers in accordance 
with the secure data protection principles of the sponsor and the WTCRF. A bespoke data collection template 
was created in Java™ with set limits to avoid the potential for mistyping data entry and mandatory completion 
to ensure comprehensive recording. Input from the data collection software was made automatically to a custom 
Microsoft® Access® study database. A diarized alert/reminder system was activated on initiation of a new patient 
at the time of recruitment, that sent email and screen notifications to the study nurses to ensure time points were 
not missed. This was especially important in cases of simultaneously enrolled and overlapping participants to 
ensure all time points were met (Supplementary Figure S5). In addition, WTCRF study nurses kept a hand-written 
log to enter free text, notes and other information pertinent to the study for which there was no appropriate data 
field in the electronic study database. Cross-referencing with the study database was performed at intervals.
Sampling and Sample Handling. Peripheral blood was sampled at recruitment (T0) and 3, 6, 12, 24, 
48, 72 and 168 hours (7 days) afterwards. In addition, the serum sample obtained at presentation to hospital 
(pre-recruitment, Tminus) was retained by the Biochemistry Department and subsequently retrieved by WTCRF 
staff. Blood was sampled into gel clot-activator tubes for serum and into EDTA tubes for plasma and subsequently 
centrifuged at 3200 rpm for 8–10 minutes. All centrifuges were serviced and calibrated prior to the start of the 
study. Serum and plasma were aliquoted and immediately frozen at − 80 °C until transfer on dry ice to long-term 
storage in a monitored, dedicated − 80 °C freezer. A sample history and tracking log was kept for all events. There 
were no breaches of the sample handling/storage protocol. Additionally, routine haematological and biochemical 
analyses were performed in accordance with standard hospital protocols used in clinical care. Serum C-reactive 
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Composite Clinical Scores. For each participant, the APACHE II score was calculated on the day of admis-
sion, by using the most extreme values of the variables of interest (day 1 APACHE II) and on per time-point 
basis28. Similarly, the Marshall multiple organ dysfunction syndrome (MODS) score, modified as per the revised 
Atlanta Classification of AP, was calculated for each patient at each time-point and on a daily basis4,29.
Tryptophan Metabolite Measurement. Kynurenine pathway metabolites were measured in plasma 
by two separate liquid chromatography–tandem mass spectrometry (LC-MS/MS) methods. For the detection 
of tryptophan, kynurenine, kynurenic acid and 3-hydroxyantranilic acid, plasma (5 µ l) was initially diluted in 
phosphate-buffered saline (45 µ l). The diluted plasma was added to 5 mM ammonium formate containing 0.1% 
trifluoroacetic acid (130 µ l). Protein was precipitated by the addition of ice-cold 100% trichloroacetic acid (20 µ l), 
samples were vortexed briefly, incubated for 30 minutes at 4 °C and centrifuged to obtain the supernatant. Separate 
standard curves were used to quantify levels of the individual metabolites. For tryptophan, the standard curve 
consisted of serial dilutions of d5-tryptophan (as surrogate analyte of tryptophan) in 10% pooled human plasma. 
For kynurenine, 1% BSA in phosphate-buffered saline was used. For kynurenic acid and 3-hydroxyanthranilic 
acid, 0.2% BSA in phosphate-buffered saline was used. Samples (10 µ l) were injected onto a Waters Select HSS XP 
column (3 mm × 100 mm, 2.5 µ m, Waters, Elstree, Herts) using a Waters Acquity UHPLC system, coupled to an 
ABSciex QTRAP 5500 mass analyser. The flow rate was 0.35 mL/min at 25 °C. Separation was carried out using a 
water:methanol gradient (both containing 0.1% formic acid). Chromatographic conditions were 50% methanol 
rising to 60% over 60 seconds, then to 65% over 180 seconds; held for 110 seconds, returned to 50% over 10 sec-
onds and re-equilibrated for a further 200 seconds, giving a total run time of 10.2 minutes. The mass spectrometer 
was operated in positive electrospray ionization mode. The multiple reaction monitoring (MRM) transitions for 
the protonated analytes were tryptophan (m/z 205-188), kynurenine (m/z 209-146), kynurenic acid (m/z 190-144) 
and 3-hydroxyanthranilic acid (m/z 154-136). The transitions for d5-tryptophan standard were (m/z 210-122). 
Collision energies were 11, 29, 31, 33 and 37 eV respectively.
For the analysis of 3-hydroxykynurenine, plasma (100 µ l) was added to a 40:60 mixture of acetonitrile in water 
containing 0.1% formic acid (130 µ l) and 50 ng/ml of internal standard. Protein was precipitated by the addition 
of trichloroacetic acid (33 µ l), samples were vortexed briefly, incubated for 30 minutes at 4 °C and centrifuged to 
obtain the supernatant. A standard curve containing serial dilutions of 3-hydroxykynurenine in 10% BSA diluted 
with phosphate-buffered saline enriched with 50 ng/ml internal standard was used. 10 µ L volumes of each sample 
were injected onto a Waters Select HSS XP column (30 mm × 100 mm, 2.5 µ m, Waters Corp, Elstree, Herts) using a 
Waters Acquity UHPLC system, coupled to an ABSciex QTRAP 5500 mass analyser. The flow rate was 0.8 mL/min 
at 30 °C. Separation was carried out using a water:methanol gradient (both containing 0.1% formic acid). 
Conditions were 5% methanol rising to 95% over 150 seconds, returning to 5% over 30 seconds, giving a total run 
time of 4 minutes. The mass spectrometer was operated in positive ion electrospray mode. The transitions for the 
protonated analytes were 3-hydroxykynurenine (m/z 225-208) and internal standard (m/z 228-211). Collision 
energies were 20 and 12 eV respectively.
Data were acquired and processed using Analyst quantitation software 1.3 (ABI Sciex). Results from retrieved 
acute presentation (pre-recruitment) samples were excluded from the time-course analysis since serum-gel acti-
vator tube containers were routinely used by the clinical care teams, a fact that may have led to discrepancy upon 
comparison with results from the dedicated K3-Ethylenediaminetetraacetic acid containers that were used for 
the study.
Four samples obtained from two patients in the severe AP group returned values of kynurenine concentra-
tion that were greater than 20 standard deviations away from the remaining concentration values of the severe 
AP cohort, including temporally adjacent samples from the same patient. These samples were deemed to have 
resulted from contamination during sample analysis, were designated as extreme outliers and were removed from 
further analysis.
Cytokine Analysis. Plasma cytokines were analysed using a custom-designed Human Magnetic Luminex 
Screening Assay according to the manufacturer’s instructions (R&D Systems, MN, USA). Levels of insulin, 
interleukin-1 beta (IL-1B), insulin C-peptide and IFN-γ were measured using kit LXSAHM-4, cancer antigen 
15-3 (CA 15-3) using kit LXSAHM-1 and tumour necrosis factor alpha (TNFα ), B7 homolog 1 (B7-H1), chemok-
ine (C-X-C motif) ligand 12 (CXCL 12), cluster of differentiation 163 (CD163), tumour necrosis factor superfam-
ily member 10 (TNFS10), receptor for advanced glycation endproducts (RAGE), trefoil factor 3 (TFF3), cluster 
of differentiation 40 ligand (CD40 ligand), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10), inter-
leukin 17A (IL-17A), cardiac troponin I and chemerin using kit LXSAHM-15, respectively. The concentrations of 
each cytokine were determined using Bio-Rad Bio-Plex 200 system (BioRad, CA, USA).
Statistical Analysis. A data analysis plan was formulated prospectively and was adhered to. Quantitative 
data are presented as median and interquartile range (IQR) or mean and standard deviation (SD), as appropriate. 
Qualitative data are presented by utilising absolute and/or relative frequencies. Data conformity to the normal 
distribution was analysed by one-sample Kolmogorov-Smirnov testing, and comparisons between patient groups 
were performed by using one-way ANOVA or the independent samples Kruskal-Wallis H test, as appropriate. 
For statistically significant differences, post-hoc pairwise comparisons were performed by using Tukey’s honestly 
significant difference test or Dunn’s test, respectively. Spearman’s rho was used to examine bivariate correlations of 
quantitative variables. Logarithmic transformations of non-normally distributed variables were used to establish 
the best linear regression fit during correlation. For the analysis of serial metabolite measurements, the method 
of summary measures was used30. The area under the curve (AUC) for each metabolite was calculated for each 
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of participation in the study, defined by the ultimate time-point of blood sampling for each participant. For the 
computation of each AUC, any uttermost missing values were omitted, whereas for any middle missing values 
AUCs were calculated between the immediately adjacent available values. The Kaplan-Meier method was used 
to compare time-to peak and time-to-minimum metabolite values between groups, and the log-rank test was 
applied to detect differences; only time-points T0 up to and including T72 were included in the latter analyses.
All statistical tests were based on a two-sided α -value of 0.05. Data were analysed using SPSS® Statistics 
version 22.0 (IBM Corp., Armonk, NY, USA) and graphs drawn using GraphPad Prism® version 6.0 (GraphPad 
Software, Inc., La Jolla, CA, USA).
Achieved statistical power was calculated post-hoc using the G-Power algorithm: F tests - ANOVA: Fixed 
effects, omnibus, one-way31. The effect size was computed from measured 3-hydroxykynurenine concentrations 
in tAP as f = 5.78, with α error probability = 0.05. The noncentrality parameter, λ = 1902.25; Critical F = 3.17; 
numerator df = 2; denominator df = 54; computed power (1− β error probability) = 1.00.
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Genetic Consent (optional) – please initial either “Yes” or “No” box: I agree to 
provide research blood, saliva, urine samples for the genetic analysis.  
 
Use of data and already collected samples after withdrawal (optional) – 
please initial either “Yes” or “No” box: In case I decide to withdraw, I give my 
permission for the ongoing use of already collected data and samples and for the 

































Name of Participant……………………………………….    Signature……………………………….…..        Date…………………… 
 
Name of Investigator……………………………………..     Signature……………………………..……        Date…………………… 



















Original – to Investigator Site File First Copy – to participant Second Copy – To Hospital Notes 
IMOFAP 
Relative/Welfare Guardian Consent Form  
Version 2.0 – 14th of August 2013   Page 1 of 1 
   YES                   NO 
 RELATIVE/WELFARE GUARDIAN CONSENT FORM – V 2.0 – 14.08.2013 
Study Title: Inflammation, Metabolism and Organ Failure in Acute Pancreatitis 
Name of Researcher  
Site  
Patient study identification number  
Please initial each box 
 
1. I confirm that I have read and understand the information leaflet dated 14th August 
2013 (version 2.0) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
2. I understand that my relative’s/ward’s participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without my relative’s/ward’s 
medical care or legal rights being affected. 
3. I understand that relevant sections of my relative’s/ward’s medical notes and data 
collected during the study may be looked at by individuals from the University of 
Edinburgh, from regulatory authorities or from the NHS Board, where it is relevant 
to his/her taking part in this research. I give permission for these individuals to have 
access to my relative’s/ward’s records. 
4. I agree that the samples collected and the information gathered about relative/ward 
can be stored by Mr. Damian Mole at the University of Edinburgh and that the 
surplus samples and information may be used in the future for other ethically 
approved research projects. 
5. I understand that some research may be carried out, using my relative’s/ward’s 
anonymised samples and information, by clinical, academic or commercial 
researchers in the UK and overseas. 
6. I understand that I or my relative/ward will not benefit financially from any 
research that may lead to the development of a new treatment or medical tests in 
the future. 
7. I understand that as part of my relative’s/ward’s standard care he/she may undergo 
tests that will expose him/her to ionizing radiation. These will be decided only by 
the doctors looking after my relative/ward, but the researchers will have access to 
the results of these tests. 
8. I give consent for my relative/ward to take part in the above study. 
 
9. I agree to my relative’s/ward’s GP being informed of my participation in the study. 
 
 
Genetic Consent (optional) – please initial either “Yes” or “No” box: I agree to provide 
research blood, saliva, urine samples for the genetic analysis.  
 
Use of data and already collected samples after withdrawal (optional) – please initial 
either “Yes” or “No” box: In case I decide to withdraw, I give my permission for the ongoing 
use of already collected data and samples and for the future recording and use of routinely 

































I confirm that I am the nearest relative for ……………………………………………………………………….. and that no other nearest 
relative or welfare attorney or guardian exists. 
 
Relationship to patient: ………………………………………………………………….. 
 
I confirm that I am the Welfare Attorney or Guardian for: ……………………………………………………………………….. 
 
Name of Relative/Welfare Guardian……………………………………………………… Signature…………………………… Date…………….. 
 
Name of Investigator………………………………………………………………….. Signature……………………………..………. Date…………….. 


















Original – to Investigator Site File First Copy – to participant Second Copy – To Hospital Notes 
IMOFAP 
Participant with Recovered Capacity Consent Form  
Version 2.0 – 14th of August 2013   Page 1 of 1 
   YES                   NO 
  
PARTICIPANT WITH RECOVERED CAPACITY CONSENT FORM – V 2.0 – 14.08.2013 
Study Title: Inflammation, Metabolism and Organ Failure in Acute Pancreatitis 
Name of Researcher  
Site  
Patient study identification number  
Please initial each box 
 
1. I confirm that I have read and understand the information leaflet dated 14th 
August 2013 (version 2.0) for the above study. I have had the opportunity 
to consider the information, ask questions and have had these answered 
satisfactorily. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected. 
3. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from the University of 
Edinburgh, from regulatory authorities or from the NHS Board, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
4. I agree that the samples I have given and the information gathered about 
me can be stored by Mr. Damian Mole at the University of Edinburgh and 
that the surplus samples and information may be used in the future for 
other ethically approved research projects. 
5. I understand that some research may be carried out, using my anonymised 
samples and information, by clinical, academic or commercial researchers 
in the UK and overseas. 
6. I understand that I will not benefit financially from any research that may 
lead to the development of a new treatment or medical tests in the future. 
7. I understand that as part of my standard care I may undergo tests that will 
expose me to ionizing radiation. These will be decided only by the doctors 
looking after me, but the researchers will have access to the results of these 
tests. 
8. I agree to continue participating in the above study. 
 
9. I agree to my GP being informed of my participation in the study. 
 
 
Genetic Consent (optional) – please initial either “Yes” or “No” box: I agree to 
provide research blood, saliva, urine samples for the genetic analysis.  
 
Use of data and already collected samples after withdrawal (optional) – 
please initial either “Yes” or “No” box: In case I decide to withdraw, I give my 
permission for the ongoing use of already collected data and samples and for the 

































Name of Participant……………………………………….    Signature……………………………….…..        Date…………………… 
 
Name of Investigator……………………………………..     Signature……………………………..……        Date…………………… 
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Study Title: Inflammation, Metabolism and Organ Failure in Acute Pancreatitis 
Participant information sheet – V 2.0 – 14/08/2013 
 We are inviting you to take part in research. Before you decide, it is important that you understand why 
the research is being done and what it will involve. Please read the following information carefully and discuss 
with a member of the research team if you would like any further explanation. 
Purpose of our study 
 You have been invited to participate in this research study because your doctors believe that you may be 
having acute pancreatitis. The aim of this study is to investigate how this disease causes problems with other 
organs, for example lung damage or kidney failure. This study is being conducted by researchers at the University 
of Edinburgh and NHS Lothian University Hospitals. It has been reviewed and has been given a favourable 
opinion by an independent group of health professionals, the Scotland A Research Ethics Committee, in order to 
protect your interests. 
What is involved if I decide to take part? 
 We would like to take some samples of blood, urine and saliva from you, in order to perform some 
specialized tests. All research samples will be in addition to the ones taken by the doctors looking after you, and 
will be collected at specific stages of your admission. We will also perform two ultrasound scans of your lungs, to 
check if they have been affected. These scans will not expose you to any radiation and do not cause any pain, but 
you may have some discomfort when the blood samples are being taken. Furthermore, we will process the first 
samples taken by your doctors on this admission and we will record information about you (for example your 
date of birth, any medical conditions, possible causes of your pancreatitis, information about how you are 
recovering). 
 You don’t have to do anything special and your participation will end after 7 days, or on your discharge, 
whichever comes first. The doctors looking after you may decide to organise some X-Rays, CT scans and/or a 
special camera test called ERCP for you, if this is necessary for your care. These tests will expose you to low doses 
of radiation, but the risk is very small. The researchers will have access to the results of these tests, but you can 
still take part in the study even if none of these tests are required in your case. If your acute pancreatitis was 
discovered during one of these tests, the research team would like to have access to those results. 
Do I have to take part in this research? 
 It is up to you to decide whether you wish to join this research study or not and your care will be the same 
whether you agree to participate or not. If you agree to take part, we will ask you to sign a consent form, but if at 
any time you decide that you no longer wish to participate, you are free to withdraw, without giving a reason and 
without any effect on your care. In case you decide to withdraw, with your permission we may continue using 
any samples and information we have already collected and in the future we may look up information about how 
you have recovered on the hospital computer or in your notes. 
Will my details be kept confidential? 
 All the information you give to the research staff and all the information collected from your records will 
be kept confidential and will be stored in a secure electronic database of the University of Edinburgh. You will be 
allocated a unique study participation number and the samples will be coded. Therefore no names or identifying 
facts about you will be used on any research documentation or samples. You will not be able to be identified by 
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research team hold the link relating your participant number and sample codes to your personal details because 
it is possible that some participants may take part more than once in our studies over a period of time and this 
would enable this important information to be confirmed.  
With your permission, we will inform your GP that you have accepted to participate in this study. It is 
also a requirement that your records in this research are made available for scrutiny by monitors from NHS 
Lothian, whose role is to check that research is properly conducted and the interests of participants are 
protected. 
How might my samples be used? 
 Your samples will be used to measure the levels of substances called “kynurenines” and to perform other 
common tests. These results will be analysed at different stages of your disease, together with your scan results 
and all collected information. With your permission, we will also use your samples for genetic research to see if 
the genes responsible for these substances can tell us how quickly you might recover and if you are more likely 
to get any complications. If you do not wish your samples to undergo genetic analysis, you may still take part in 
the main study. 
 The information, results and samples will be stored for up to 5 years at the University of Edinburgh by 
the Chief Investigator (Mr. Damian Mole) and we ask for your permission to use these in future research, after 
further approval from the Research Ethics Committee. This will provide an invaluable resource which may be 
used by researchers many times in several different studies. Future studies cannot be specified in detail at 
present, but will be in the field of acute pancreatitis and/or organ failure. Some studies may involve 
collaboration(s) with laboratories in other universities or commercial companies in the U.K. or overseas. At the 
end of the 5 year period and if your samples cannot be used for further research, they will be destroyed according 
to the recommendations of the University of Edinburgh. 
Can I benefit from taking part in this research? 
 This is study is non-therapeutic and you cannot expect any benefit. If researchers for example, develop a 
new drug, treatment or test it will not be possible for you to claim any money because you participated. However, 
any new drug, treatment or test would hopefully benefit many people in the future. We do not expect that any of 
the study findings will be of importance to you and your own medical health, however with your permission we 
will inform your GP if any significant information is found unexpectedly. 
 Individual participants will not be personally made aware of the research findings. However, if the overall 
research programme progresses to potential therapies, this will be made public through the media through the 
University of Edinburgh and NHS Lothian Press Offices. 
What if there is a problem? 
 If you have any concerns about this study, the researchers will be glad to discuss with you in person or 
by telephone, on 0131 242 3616. If you would like to discuss with a doctor who is not involved in the study, you 
can contact Dr. Jonathan Fallowfield on 0131 242 6655. If you remain unhappy and wish to complain formally, 
you can contact the NHS Lothian Complaints Team at Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH13EG 
(Tel: 01315363370; Email: complaints.team@nhslothian.scot.nhs.uk). 
Who is organising and funding the research? 
 The University of Edinburgh and NHS Lothian will be co-sponsoring this study, through the established 
joint research and development office (ACCORD). Support staff and running costs will be funded by an industry 
collaborator, GlaxoSmithKline. 
Researcher contact details 
x Mr. Damian Mole – Senior Lecturer in Surgery & Consultant Surgeon 
Tel: 0131 242 3616, Email: damian.mole@ed.ac.uk 
x Mr. Christos Skouras – Clinical/Research Fellow, Clinical Surgery 
Tel: 0131 242 3616, Email: christos.skouras@ed.ac.uk 
 
THANK YOU FOR READING THIS INFORMATION SHEET 
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Study Title: Inflammation, Metabolism and Organ Failure in Acute Pancreatitis 
Relative/welfare guardian information sheet – V 2.0 – 14/08/2013 
 As the relative or welfare guardian of INSERT NAME you are being invited to give your consent for 
INSERT NAME to take part in research, because HE/SHE currently lacks capacity. Before you decide, it is 
important that you understand why the research is being done and what it will involve. Please read the following 
information carefully and discuss with a member of the research team if you would like any further explanation. 
Purpose of our study 
 INSERT NAME has been invited to participate in this research study because HIS/HER doctors believe 
that HE/SHE may be having acute pancreatitis. The aim of this study is to investigate how this disease causes 
problems with other organs, for example lung damage or kidney failure. This study is being conducted by 
researchers at the University of Edinburgh and NHS Lothian University Hospitals. It has been reviewed and has 
been given a favourable opinion by an independent group of health professionals, the Scotland A Research Ethics 
Committee, in order to protect each research participant’s interests. 
What is involved if I decide to permit participation of my relative/ward? 
 We would like to take some samples of blood, urine and saliva from INSERT NAME, in order to perform 
some specialized tests. All research samples will be in addition to the ones taken by the doctors looking after 
HIM/HER, and will be collected at specific stages of HIS/HER admission. We will also perform two ultrasound 
scans of HIS/HER lungs, to check if they have been affected. These scans will not expose HIM/HER to any 
radiation and do not cause any pain, but HE/SHE may have some discomfort when the blood samples are being 
taken. Furthermore, we will process the first samples taken by HIS/HER doctors on this admission and we will 
record information about HIM/HER (for example INSERT NAME’s date of birth, any medical conditions, possible 
causes of HIS/HER pancreatitis, information about how HE/SHE is recovering). 
 You don’t have to do anything special and INSERT NAME’s participation will end after 7 days, or on 
HIS/HER discharge, whichever comes first. The doctors looking after HIM/HER may decide to organise some X-
Rays, CT scans and/or a special camera test called ERCP for HIM/HER, if this is necessary for HIS/HER care. 
These tests will expose HIM/HER to low doses of radiation, but the risk is very small. The researchers will have 
access to the results of these tests, but INSERT NAME can still take part in the study even if none of these tests 
are required in HIS/HER case. If HIS/HER acute pancreatitis was discovered during one of these tests, the 
research team would like to have access to those results. 
Do my relative/ward have to take part in this research? 
 It is up to you to decide whether you wish INSERT NAME to join this research study or not and HIS/HER 
care will be the same whether you agree for HIM/HER to participate or not. If you agree to take part, we will ask 
you to sign a consent form, but if at any time you decide that you no longer wish your relative/ward to participate, 
you are free to withdraw, without giving a reason and without any effect on HIS/HER care. In case you decide to 
withdraw, with your permission we may continue using any samples and information we have already collected 
and in the future we may look up information about how HE/SHE has recovered on the hospital computer or in 
your notes. If INSERT NAME regains capacity during his participation in the study, we will seek HIS/HER consent, 
in order to remain in the study. 
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 All the information collected from HIS/HER records will be kept confidential and will be stored in a 
secure electronic database of the University of Edinburgh. INSERT NAME will be allocated a unique study 
participation number and the samples will be coded. Therefore no names or identifying facts about HIM/HER 
will be used on any research documentation or samples. HE/SHE will not be able to be identified by the 
researchers who will be using the tissue samples in their laboratories. It is however important that the research 
team hold the link relating HIS/HER participant number and sample codes to HIS/HER personal details because 
it is possible that some participants may take part more than once in our studies over a period of time and this 
would enable this important information to be confirmed. 
With your permission, we will inform HIS/HER GP that you have accepted our invitation for INSERT 
NAME to participate in this study. It is also a requirement that HIS/HER records in this research are made 
available for scrutiny by monitors from NHS Lothian, whose role is to check that research is properly conducted 
and the interests of participants are protected. 
How might my relative’s/ward’s samples be used? 
 All samples will be used to measure the levels of substances called “kynurenines” and to perform other 
common tests. These results will be analysed at different stages of INSERT NAME’s disease, together with the 
scan results and all collected information. With your permission, we will also use the samples for genetic research 
to see if the genes responsible for these substances can tell us how quickly HE/SHE might recover and if HE/SHE 
is more likely to get any complications. If you do not wish INSERT NAME’s samples to undergo genetic analysis, 
you may still agree for HIM/HER to take part in the main study. 
 The information, results and samples will be stored for up to 5 years at the University of Edinburgh by 
the Chief Investigator (Mr. Damian Mole) and we ask for your permission to use these in future research, after 
further approval from the Research Ethics Committee. This will provide an invaluable resource which may be 
used by researchers many times in several different studies. Future studies cannot be specified in detail at 
present, but will be in the field of acute pancreatitis and/or organ failure. Some studies may involve 
collaboration(s) with laboratories in other universities or commercial companies in the U.K. or overseas. At the 
end of the 5 year period and if the samples cannot be used for further research, they will be destroyed according 
to the recommendations of the University of Edinburgh. 
Can my relative/ward benefit from taking part in this research? 
 This is study is non-therapeutic and you cannot expect any benefit. If researchers for example, develop a 
new drug, treatment or test it will not be possible for you or your relative/ward to claim any money because you 
participated. However, any new drug, treatment or test would hopefully benefit many people in the future. We 
do not expect that any of the study findings will be of importance to INSERT NAME and HIS/HER own medical 
health, however with your permission we will inform your GP if any significant information is found 
unexpectedly. 
 Individual participants will not be personally made aware of the research findings. However, if the overall 
research programme progresses to potential therapies, this will be made public through the media through the 
University of Edinburgh and NHS Lothian Press Offices. 
What if there is a problem? 
 If you have any concerns about this study, the researchers will be glad to discuss with you in person or 
by telephone, on 0131 242 3616. If you would like to discuss with a doctor who is not involved in the study, you 
can contact Dr. Jonathan Fallowfield on 0131 242 6655. If you remain unhappy and wish to complain formally, 
you can contact the NHS Lothian Complaints Team at Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH13EG 
(Tel: 01315363370; Email: complaints.team@nhslothian.scot.nhs.uk). 
Who is organising and funding the research? 
 The University of Edinburgh and NHS Lothian will be co-sponsoring this study, through the established 
joint research and development office (ACCORD). Support staff and running costs will be funded by an industry 
collaborator, GlaxoSmithKline. 
Researcher contact details 
x Mr. Damian Mole – Senior Lecturer in Surgery & Consultant Surgeon 
Tel: 0131 242 3616, Email: damian.mole@ed.ac.uk 
x Mr. Christos Skouras – Clinical/Research Fellow, Clinical Surgery 
Tel: 0131 242 3616, Email: christos.skouras@ed.ac.uk 
 
THANK YOU FOR READING THIS INFORMATION SHEET 
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Study Title: Inflammation, Metabolism and Organ Failure in Acute Pancreatitis 
Participant information sheet – Recovered Capacity – V 2.0 – 14/08/2013 
 We are inviting you to consider continuing to take part in research. Before you decide, it is important that 
you understand why the research is being done and what it will involve. Please read the following information 
carefully and discuss with a member of the research team if you would like any further explanation. 
Why am I already in this study? 
 During your recent admission to hospital you were unable to give consent for participation in a study; we 
therefore asked your nearest relative or welfare attorney or guardian who gave consent on your behalf. This is 
permissible under the Adults with Incapacity Act (Scotland) 2000. You are now capable of making an informed 
decision about whether you wish to continue in the study or not. 
Purpose of our study 
 You have been invited to participate because your doctors believe that you may be having acute 
pancreatitis. The aim of this study is to investigate how this disease causes problems with other organs, for 
example lung damage or kidney failure. This study is being conducted by researchers at the University of 
Edinburgh and NHS Lothian University Hospitals. It has been reviewed and has been given a favourable opinion 
by an independent group of health professionals, the Scotland A Research Ethics Committee, in order to protect 
your interests. 
What is involved if I decide to continue taking part? 
 We would like to take some samples of blood, urine and saliva from you, in order to perform some 
specialized tests. All research samples will be in addition to the ones taken by the doctors looking after you, and 
will be collected at specific stages of your admission. We will also perform two ultrasound scans of your lungs, to 
check if they have been affected. These scans will not expose you to any radiation and do not cause any pain, but 
you may have some discomfort when the blood samples are being taken. We have already taken X samples 
and performed X scans of your lungs. Furthermore, we will process the first samples taken by your doctors on 
this admission and we will record information about you (for example your date of birth, any medical conditions, 
possible causes of your pancreatitis, information about how you are recovering). 
 You don’t have to do anything special and your participation will end after 7 days, or on your discharge, 
whichever comes first. The doctors looking after you may decide to organise some X-Rays, CT scans and/or a 
special camera test called ERCP for you, if this is necessary for your care. These tests will expose you to low doses 
of radiation, but the risk is very small. The researchers will have access to the results of these tests, but you can 
still take part in the study even if none of these tests are required in your case. If your acute pancreatitis was 
discovered during one of these tests, the research team would like to have access to those results. 
Do I have to take part in this research? 
 It is up to you to decide whether you wish to join this research study or not and your care will be the same 
whether you agree to participate or not. If you agree to take part, we will ask you to sign a consent form, but if at 
any time you decide that you no longer wish to participate, you are free to withdraw, without giving a reason and 
without any effect on your care. In case you decide to withdraw, with your permission we may continue using 
any samples and information we have already collected and in the future we may look up information about how 
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Will my details be kept confidential? 
 All the information you give to the research staff and all the information collected from your records will 
be kept confidential and will be stored in a secure electronic database of the University of Edinburgh. You will be 
allocated a unique study participation number and the samples will be coded. Therefore no names or identifying 
facts about you will be used on any research documentation or samples. You will not be able to be identified by 
the researchers who will be using the tissue samples in their laboratories. It is however important that the 
research team hold the link relating your participant number and sample codes to your personal details because 
it is possible that some participants may take part more than once in our studies over a period of time and this 
would enable this important information to be confirmed.  
With your permission, we will inform your GP that you have accepted to participate in this study. It is 
also a requirement that your records in this research are made available for scrutiny by monitors from NHS 
Lothian, whose role is to check that research is properly conducted and the interests of participants are 
protected. 
How might my samples be used? 
 Your samples will be used to measure the levels of substances called “kynurenines” and to perform other 
common tests. These results will be analysed at different stages of your disease, together with your scan results 
and all collected information. With your permission, we will also use your samples for genetic research to see if 
the genes responsible for these substances can tell us how quickly you might recover and if you are more likely 
to get any complications. If you do not wish your samples to undergo genetic analysis, you may still take part in 
the main study. 
 The information, results and samples will be stored for up to 5 years at the University of Edinburgh by 
the Chief Investigator (Mr. Damian Mole) and we ask for your permission to use these in future research, after 
further approval from the Research Ethics Committee. This will provide an invaluable resource which may be 
used by researchers many times in several different studies. Future studies cannot be specified in detail at 
present, but will be in the field of acute pancreatitis and/or organ failure. Some studies may involve 
collaboration(s) with laboratories in other universities or commercial companies in the U.K. or overseas. At the 
end of the 5 year period and if your samples cannot be used for further research, they will be destroyed according 
to the recommendations of the University of Edinburgh. 
Can I benefit from taking part in this research? 
 This is study is non-therapeutic and you cannot expect any benefit. If researchers for example, develop a 
new drug, treatment or test it will not be possible for you to claim any money because you participated. However, 
any new drug, treatment or test would hopefully benefit many people in the future. We do not expect that any of 
the study findings will be of importance to you and your own medical health, however with your permission we 
will inform your GP if any significant information is found unexpectedly. 
 Individual participants will not be personally made aware of the research findings. However, if the overall 
research programme progresses to potential therapies, this will be made public through the media through the 
University of Edinburgh and NHS Lothian Press Offices. 
What if there is a problem? 
 If you have any concerns about this study, the researchers will be glad to discuss with you in person or 
by telephone, on 0131 242 3616. If you would like to discuss with a doctor who is not involved in the study, you 
can contact Dr. Jonathan Fallowfield on 0131 242 6655. If you remain unhappy and wish to complain formally, 
you can contact the NHS Lothian Complaints Team at Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH13EG 
(Tel: 01315363370; Email: complaints.team@nhslothian.scot.nhs.uk). 
Who is organising and funding the research? 
 The University of Edinburgh and NHS Lothian will be co-sponsoring this study, through the established 
joint research and development office (ACCORD). Support staff and running costs will be funded by an industry 
collaborator, GlaxoSmithKline. 
Researcher contact details 
x Mr. Damian Mole – Senior Lecturer in Surgery & Consultant Surgeon 
Tel: 0131 242 3616, Email: damian.mole@ed.ac.uk 
x Mr. Christos Skouras – Clinical/Research Fellow, Clinical Surgery 
Tel: 0131 242 3616, Email: christos.skouras@ed.ac.uk 
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IMOFAP GP Information Letter – V 1.0 – 03/07/2013 
 
[GP Surgery]  
 
[Recipient's name & address]  
 
MRC Centre for Inflammation Research,  
W2.16, Queen's Medical Research Institute,  
The University of Edinburgh, 
47 Little France Crescent, 
Edinburgh, EH16 4TJ, 
United Kingdom 
 
Date  [date]  
Enquiries to: Mr. Damian J. Mole 
Direct Line  +44 (0)131 242 3616 




Dear Dr. [Recipient]  
 
RE: [Patient's Details]  
 
NOTIFICATION OF RECRUITMENT TO A CLINICAL RESEARCH STUDY – Please note that 
this letter is not intended to be part of direct patient care correspondence and that a 
clinical discharge summary will follow in due course. 
I would like to inform you that your patient has been admitted in the Royal Infirmary of 
Edinburgh with a likely diagnosis of acute pancreatitis. [He/She] has been recruited as a 
participant in a Clinical Study of the Department of Clinical Surgery of the University of 
Edinburgh, entitled: “Inflammation, Metabolism and Organ Failure in Acute Pancreatitis”. This 
study has been approved by the designated Research Ethics Committee. This study is 
observational only and there is no randomisation or intervention or any departure from the 
usual clinical care received by participants. 
A formal discharge summary will follow, and no action is required on your behalf.  
 








Mr. Damian J. Mole, BMedSc, MBChB, PhD, FRCS  
 
Clinician Scientist Fellow and Honorary Consultant Surgeon  
Royal Infirmary of Edinburgh 






 Inflammation, Metabolism, and Organ Failure in Acute Pancreatitis 
One Page Study Summary – V3.0 – 21/08/2013 
Page 1 of 1 
 
What is acute pancreatitis? Acute pancreatitis (AP) is inflammation of the pancreas usually triggered by 
gallstones or drinking excessive alcohol. Most people who have an episode of AP get better without having any 
complications, but approximately 1 out of every 4 people with AP will have problems with the pancreas or with 
other organs, for example the lungs and kidneys, and require treatment in high dependency or intensive care. 
 
Why are we doing this study? We are doing research to try and reduce the harm done during a severe attack 
of AP. We have discovered that a particular aspect of the immune system is involved in AP and we are working 
with a drug company (GSK), to develop better medicines to treat AP. We are not testing any new medicines or 
drugs in this study but we want to see how part of the immune system changes in AP.  
  
Who is regulating this study? This study has been examined and approved by the Scotland A Research Ethics 
Committee, the University of Edinburgh, NHS Lothian ACCORD R&D Office and the Caldicott Guardian (patient 
confidentiality authority). 
 
Where is the study taking place? At the Royal Infirmary of Edinburgh. 
 
Is this a clinical trial? No, we are not testing or comparing any new medicines or treatments. We are gathering 
information and clinical samples. 
 
Will participation affect my treatment? No, participation will not affect the way any person with AP is looked 
after. 
 
How long does the study last? Each participant will be in the study for 1 week, or less if you are discharged 
from hospital before that. We will continue to check routinely collected information (e.g. about any subsequent 
illnesses) relevant to the study for up to 5 years. 
 
Who can participate? Most adults (aged 16 years or over) with AP can be considered for participation. Certain 
individuals belonging to vulnerable groups e.g. prisoners will not be able to participate. 
 
What is involved if I decide to participate? 
x We will collect detailed clinical information about your health and your episode of AP, including 
collecting information from scans done as part of your normal care 
x We will invite you to donate a series of blood, urine and saliva samples, at regular time points over one 
week making a total of 8 blood samples, 8 urine samples and 1 saliva sample. 
x We will invite you to have 2 lung ultrasound scans during the week, in addition to scans organised by 
the team looking after you. 
x If you participate, you will remain in the study for a total of seven days or until hospital discharge, 
whichever comes first, but we will continue to gather relevant  information from your records for a up 
to 5 years. 
x The samples will be analysed for biochemical markers of inflammation and to see how cells change the 
way they use their genes during AP. If you have a specific wish not to have any genetic analysis done on 
your samples, then you can opt out of that part of the study but still participate in the rest of the study. 
 
Can I see my own results from the study? We are not able to disclose any results to individual participants, 
but we will be able to inform you of the outcome of the analysis of the whole study when it is complete.  
 
Where can I get more information? We would be very happy to answer any questions about the study. Please 
get in touch with Mr Christos Skouras, Postgraduate research fellow and Investigator, or Mr Damian Mole, Chief 
Investigator on tel: 0131 242 3616, or by email (christos.skouras@ed.ac.uk or damian.mole@ed.ac.uk) 
 




HEALTHCARE PROFESSIONAL SUMMARY 
 
 
Page 1 of 2 
 
Inflammation, Metabolism, and Organ Failure in Acute Pancreatitis 
Study Summary – V2.0 – 21/08/2013 
PLEASE NOTE THAT THIS DOCUMENT IS NOT A PATIENT INFORMATION SHEET AND DOES 
NOT FORM PART OF THE INFORMED CONSENT PACK. 
 
Introduction 
Acute pancreatitis (AP) is inflammation of the pancreas usually triggered by gallstones 
or drinking excessive alcohol. Most people who have an episode of AP experience a short self-
limiting illness, but approximately 1 out of every 4 will develop dysfunction of one or more 
organ systems and often require treatment in high dependency or intensive care. The overall 
mortality in AP is approximately 7%, but for those who get organ dysfunction, the mortality 
approaches 20%.  
We are investigating ways in which we can reduce the proportion of patients who suffer 
a severe attack and reduce the harm done during a severe attack. We have identified that a 
particular metabolic pathway that also affects the immune system (called the kynurenine 
pathway of tryptophan metabolism) is important in experimental models of AP and in 
preliminary studies involving patients. We are working with GSK, a drug company, to develop 
new ways of altering that metabolic pathway to prevent or reduce organ dysfunction and this 
work is at an early stage. In order to understand this inflammatory process in more detail and 
build a better medicine, we are examining exactly how and when this metabolic pathway is 
altered in patients with AP.  
  
Approvals 
This study will have been reviewed and prior to commencement will have confirmed approval 
from the Scotland A Research Ethics Committee, University of Edinburgh/NHS Lothian ACCORD 
R&D Office and the Office of the Caldicott Guardian for NHS Lothian. 
 
Study design and endpoints: 
1. The present study is an observational, prospective, clinical study, which involves no 
intervention or randomisation. 
2. The study will be performed in the Royal Infirmary of Edinburgh. 
3. No deviation from the usual process of care should occur as a result of 
participation in this study and direct clinical care teams should act as they 
normally would while caring for any patient with AP. 
4. The whole duration of the study is one year. The recruitment period will last three 
months. The estimated start date is 15th September 2013. 
5. We will be recruiting adult (aged 16 years or over) patients with acute pancreatitis, 
regardless of aetiology and as early as possible after their presentation. Patients with 
and without capacity will be included. Prisoners will be excluded. 
6. The recruitment will be performed on 24/7 basis. 
7. We are aiming to recruit up to 70 patients. 
 
Participant Identification: 
In order to i) maximise the number of patients recruited, ii) to recruit as early as possible in the 
disease course and, iii) to capture as many possible potential participants in order to reduce 
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1. An alert for any patient with raised serum amylase result will be given from the 
biochemistry laboratory to the research team member on call for the study (the 
“investigator” – usually a research nurse from the WT CRF). 
2. The investigator will review the clinical notes (electronic and/or hand-written) to 
ascertain eligibility. 
3. If patient is eligible for recruitment, the investigator will liaise with a member of the 
clinical care team and ask them to make the initial approach to the potential participant 
as follows: 
a. For patients with capacity, a member of the clinical care team will approach the 
potential participant and will ask for their permission for a discussion with the 
investigator. 
b. For patients with incapacity (e.g. due to critical illness or significant alcohol 
intoxication), the first point of contact to the relative/welfare guardian will be a 
member of the clinical care team. 
4. After permission has been obtained, the investigator will undertake recruitment and 
informed consent, both for patients with and without capacity. 
 
Participation in the study: 
1. Detailed clinical information for each recruited patient will be collected. 
2. Participants will be subjected to a series of blood, urine and saliva sampling, at pre-
defined time-points (a total of eight blood and urine samples and one saliva sample for 
each participant). 
3. Two lung ultrasound scans will also be performed on each participant at pre-defined 
time-points. 
4. Apart from lung ultrasound scans, all other imaging examinations will be decided by the 
clinical care team based on clinical indications and are not a pre-requisite for 
participation in the study. The research team will however obtain access to the results of 
these tests. 
5. Each participant will remain in the study for a total of seven days or until hospital 
discharge, whichever comes first. 
 
Please do not hesitate to contact the project lead and Co-Investigator, Mr Christos Skouras 
(Postgraduate research fellow), or the Chief Investigator, Mr Damian Mole (Clinician Scientist 
Fellow and Hon Cons Surgeon) if you have any questions, concerns or wish to clarify any aspect 
of this study. 
 
Mr Christos Skouras MBBS MRCS 
Postgraduate Research Fellow 
Clinical Surgery 
College of Medicine and Veterinary Medicine, 
The University of Edinburgh 
49 Little France Crescent 
Edinburgh EH16 4SA 
Tel: 0131 242 3616 
christos.skouras@ed.ac.uk 
Mr Damian J. Mole BMedSc MBChB PhD FRCS 
Clinician Scientist Fellow and Honorary 
Consultant Surgeon RIE 
MRC Centre for Inflammation Research W2.16 
Queen's Medical Research Institute 
The University of Edinburgh 
47 Little France Crescent 
Edinburgh EH16 4TJ 
Mobile: 07775 801868 






















































IMOFAP – Sample handling protocol 
Saliva samples 
V1.0 – 02/09/2013 
 




• BLUE top Sarstedt® Salivette® tubes for cortisol determination (Ref No: 51.1534.500) 
• Nunc™ CryoTubes™ (Thermo Scientific™ – Tube volume 1.8 mL – Ref No: 375418) 
è At least 2 Nunc™ tubes 
 
Method: 
1. Perform only on T0 (for conscious patients only) 
2. Patient or investigator removes synthetic swab from Salivette® tube 
3. Swab is placed in patient’s mouth and is chewed for about 45 seconds to stimulate 
salivation 
4. Return swab with absorbed saliva to the Salivette® tube and replace stopper 
5. Label Salivette® tubes with participant ID and T0 (e.g. #0005, T0) 
6. CENTRIFUGE for 2 minutes at 1000 g 
7. After spinning open Salivette® tube and discard swab 
8. Aliquot collected precipitate from the tip of the Salivette® tube in Nunc™ CryoTubes™ 
9. Mark filled Nunc™ tubes (black dot on lid) 
10. Label Nunc™ tubes with participant ID and time-point (e.g. #0005, T0) 
11. Freeze filled Nunc™ CryoTubes™ in -80oC freezer 
12. Discard Salivette® tube 
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IMOFAP – Sample handling protocol 
Urine samples 
V1.0 – 02/09/2013 
 




• WHITE top urine tubes (Universal container) 
• Nunc™ CryoTubes™ (Thermo Scientific™ – Tube volume 1.8 mL – Ref No: 375418) 
è At least 2 Nunc™ tubes 
 
Method: 
1. Aseptic technique 
2. Collect urine sample from participant, either by directly asking for a sample, or 
by retrieving sample from catheter bag in catheterised participants 
3. Label white top urine tube with patient ID and time-point (e.g. #0005, T24) 
4. NO CENTRIFUGE 
5. Dip urine and record results results to dedicated study laptop 
6. Carefully aliquot 1 mL of urine into each of the 2 Nunc™ CryoTubes™ 
7. Mark filled Nunc™ tubes (black dot on lid) 
8. Label Nunc™ tubes with participant ID and time-point (e.g. #0005, T24) 
9. Freeze filled Nunc™ CryoTubes™ in -80oC freezer 
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